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Smoking during pregnancy is the leading modifiable risk factor for poor 
maternal and infant health outcomes. Pregnancy-related health problems 
associated with smoking during pregnancy include complications during 
labour, increased risk of miscarriage, premature birth, stillbirth and low 
birthweight. Despite this, around 12% of pregnant women in the United 
Kingdom (UK), 13% in the United States and 20% in France continue to 
smoke during pregnancy. A Cochrane review of 136 studies found that 
nicotine replacement Therapy (NRT) is proven to be effective amongst non-
pregnant smokers, however a Cochrane review of eight studies found its 
efficacy in pregnancy to be uncertain. It is unclear whether we can ascertain 
a conclusion from this review as it may be subject to error due to repetitive 
testing, furthermore there may be insufficient power in the meta-analyses. 
Trial Sequential Analysis (TSA) is a method which could overcome these 
issues. This thesis provides an overview of TSA and applies the method to 
a systematic review of NRT use in pregnancy. This thesis also presents an 
alternative use for TSA, where it can be used for trial sample size estimation. 
In most studies investigating NRT use for smoking cessation in pregnancy, 
women are instructed to discontinue use of nicotine patches if they have 
even brief smoking lapses. This is due to concerns that concomitant smoking 
and NRT use could increase exposure to nicotine and potentially more 
tobacco smoke toxins if they smoke heavily when using NRT. In 2014, the 
‘Study of Nicotine Patch in Pregnancy’ (SNIPP) trial, a large randomised 
controlled trial (RCT) investigating NRT used in pregnancy for smoking 
cessation reported that it did not increase either smoking cessation rates or 
birth weights. This study was unique as participants were told that they 
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could continue using nicotine patches during smoking lapses. Using data 
from this trial, this thesis aims to explore whether concurrent smoking and 
NRT use resulted in changes in nicotine intake as well as smoking behaviour. 
This thesis also uses this trial to explore whether NRT use and changes in 
expired air carbon monoxide throughout pregnancy have an impact on 
birthweight. 
Methods 
Systematic review and meta-analysis 
To determine the efficacy and safety of NRT for smoking cessation in later 
pregnancy, systematic review methods were used following standard 
Cochrane methods. The primary outcome was smoking cessation at the 
latest time point in pregnancy at which this was measured, and secondary 
outcomes were safety related. Meta-analyses were conducted where 
appropriate. 
Trial Sequential Analysis 
Trial sequential analysis was used to investigate whether there is sufficient 
evidence available to come to a firm conclusion on the efficacy of nicotine 
replacement therapy in pregnancy. Trial Sequential Analysis is a 
methodology that can be used in systematic reviews and meta-analyses to 
control random errors, and to assess whether further trials need to be 
conducted. We employ this method to the data from the systematic review, 
to assess whether there is sufficient evidence to conclude a clinically 
important treatment effect, no evidence of an effect, or lack of evidence. 
This thesis goes on to explain an alternative use for Trial Sequential 
Analysis, where it can be used to estimate trial sample sizes for one or more 
trials investigating a behavioural smoking cessation intervention. We show 
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how data from a new, planned trial can be combined with data from the 
earlier trials using Trial Sequential Analysis to assess the intervention’s 
effects. Using feasibility and pilot trials of a behavioural smoking cessation 
intervention, data are combined to estimate the sample size that one or 
more future RCTs would need to recruit, to provide a more decisive answer 
regarding intervention benefit. 
Analysis of the SNIPP trial 
The final study in this thesis used data from 402 women recruited to the 
SNIPP trial. Paired t-tests, linear regression, interaction tests, and within-
individual variability analysis techniques were employed to answer the 
following questions: (1) does concurrent smoking and NRT use result in 
changes in nicotine, and other indicators of smoking intensity?; (2) do these 
changes differ between NRT or placebo patch use?.  
Results 
Systematic review and meta-analysis 
Compared to placebo and non‐placebo controls, there was low‐certainty 
evidence that NRT increased the likelihood of smoking abstinence in later 
pregnancy (RR 1.37, 95% CI 1.08 to 1.74; I² = 34%, 9 studies, 2336 
women). There was unclear evidence of an effect in placebo‐controlled RCTs 
(RR 1.21, 95% CI 0.95 to 1.55; I² = 0%, 6 studies, 2063 women), whereas 
non‐placebo‐controlled trials showed clearer evidence of a benefit (RR 8.55, 
95% CI 2.05 to 35.71; I² = 0%, 3 studies, 273 women). 
Trial Sequential Analysis 
The meta-analysis was not adequately powered to provide a strong 
conclusion, and TSA estimates that further placebo-controlled trials with 
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approximately 10,741 participants in total are needed to arrive at a firm 
conclusion. 
Analysis of the SNIPP trial 
(1) In the nicotine patch group, there was no change in saliva cotinine 
concentrations between baseline and 2-weeks post quit date (ratio of 
geometric means = 0.94, 95% CI=0.83 to 1.07; p=0.37, Bayes 
factor=0.15). However, there was a reduction in reported number of daily 
cigarettes smoked (mean difference -6, 95% CI’s -7 to -5, p<0.001) and in 
CO concentrations (mean difference -3.0ppm, 95% CI’s -4.2 to -1.9, 
p<0.001).  (2) These changes were not significantly different from changes 
in the placebo group except for cigarette consumption which reduced more 
in the placebo group (p=0.046).  
Conclusions 
 NRT used for smoking cessation in pregnancy may increase smoking 
cessation rates in late pregnancy. However, this evidence is of low 
certainty, as the effect was not evident when potentially biased, non‐
placebo‐controlled RCTs were excluded from the analysis. 
 According to TSA, there is uncertainty regarding the efficacy of NRT 
use for smoking cessation during pregnancy compared to control, 
and further placebo-controlled trials are needed to arrive at a firm 
conclusion.  
 Although TSA suggests more research is required for a firm 
conclusion, the general trend appears that NRT as it has previously 
been trialled, may not be effective for smoking cessation in pregnant 
women. Further trials should focus on what can be done differently 
in future. For example, using higher dose NRT or encouraging better 
adherence to treatment may produce more positive outcomes. 
V 
 
 Our findings suggest that when pregnant women use nicotine 
patches as part of a quit attempt, but they also smoke, they smoke 
less than they did before the quit attempt started. This means that 
their exposure to the toxic products of burnt tobacco is reduced. 
 Despite having similar cotinine exposure to that from cigarette 
smoking, pregnant women who use nicotine patches and smoke, 
smoke less and exhale less CO, so their exposure to other tobacco 




This thesis was completed under the supervision of Professor Tim Coleman 
(Division of Primary Care, University of Nottingham), Professor Jo Leonardi-
Bee (Division of Epidemiology and Public Health, University of Nottingham) 
and Dr. Ivan Berlin (Department of Pharmacology, Sorbonne Université, 
Faculté de medicine‐Hopital Pitie‐Salpetriere). Ravinder Claire’s PhD is 
funded by the National Institute for Health Research (NIHR) Applied 
Research Collaboration East Midlands (ARC EM). The views expressed in this 
thesis are those of the author and not necessarily those of the National 
Institute for Health Research or the Department of Health and Social Care. 
I am extremely grateful to my supervisors for their invaluable advice and 
patience during my PhD. Their guidance over the past four years has been 
exceptional, and without them I would not be where I am today. I hope one 
day we will be able to have a Skype meeting without any glitches! My sincere 
thanks also goes to Dr. Christian Gluud, for his technical support and his 
ever enthusiastic attitude to our meetings. 
To all the comers and goers from 1502, it has been a pleasure sharing an 
office with you all. And to everyone I met in Paris and Cité Universitaire who 
made me feel at home, thank you for an unforgettable six months. Thank 
you to my friends, who have always been there when I have needed a pick 
me up or a laugh. 
Finally, a very special mention to my family. My mum and dad, and my 
sister, Kiran – thank you for your unconditional love and support. You may 
not still fully understand my research, but none of this would have been 
possible without you. I hope I have made you all proud. 
VII 
 
Table of contents 
 
Abstract .......................................................................................... I 
Acknowledgements ......................................................................... VI 
Table of contents .......................................................................... VII 
List of figures ................................................................................ XV 
List of tables .............................................................................. XVIII 
List of abbreviations ..................................................................... XIX 
List of publications.......................................................................... XX 
Chapter 1: Introduction ................................................................ 21 
1.1 Smoking during pregnancy .................................................. 22 
1.1.1 Epidemiology of smoking during pregnancy ...................... 22 
1.1.2 Harms related to smoking during pregnancy .................... 24 
1.1.3 Benefits of smoking cessation in pregnancy ...................... 26 
1.2 Smoking cessation during pregnancy .................................... 27 
1.2.1 Influences on smoking cessation .................................... 27 
1.2.2 Psychosocial interventions ............................................. 28 
1.2.3 Pharmacological interventions ........................................ 29 
1.3 Nicotine Replacement Therapy ............................................. 30 
VIII 
 
1.3.1 Adherence to NRT ........................................................ 31 
1.3.2 Metabolism of Nicotine .................................................. 32 
Chapter 2: Aim and objectives ....................................................... 34 
2.1 Aims .................................................................................... 35 
2.2 Objectives ............................................................................. 35 
Chapter 3: Trial Sequential Analysis................................................ 37 
3.1 Introduction .......................................................................... 38 
3.2 Aim ...................................................................................... 38 
3.3 Combining sources of evidence ................................................ 38 
3.3.1 Narrative review ............................................................... 39 
3.3.2 Systematic review ............................................................ 40 
3.4 Meta-analysis ........................................................................ 41 
3.4.1 Fixed-effects and random-effects models in meta-analysis ...... 43 
3.4.2 Cumulative meta-analysis .................................................. 44 
3.4.3 Publication bias in meta-analysis ......................................... 45 
3.4.4 Random error in meta-analysis ........................................... 45 
3.4.5 Limitations of meta-analysis ............................................... 48 
3.5 Trial Sequential Analysis ......................................................... 49 
3.5.1 Information size ............................................................... 51 
IX 
 
3.5.2 Significance testing with inadequate information size ............. 53 
3.5.3 Futility testing with inadequate information size .................... 54 
3.5.4 Example results from trial sequential analysis ....................... 56 
3.5.5 Limitations of Trial Sequential Analysis ................................ 61 
3.6 Conclusion ............................................................................ 64 
Chapter 4: Using Trial Sequential Analysis for estimating the sample sizes 
of further trials .............................................................................. 66 
4.1 Introduction .......................................................................... 67 
4.2 Aims .................................................................................... 68 
4.3 Objectives ............................................................................. 68 
4.4 Methods ............................................................................... 68 
4.5 Results ................................................................................. 69 
4.5.1 Previous MiQuit trials ........................................................ 69 
4.5.2 Conventional meta-analysis ............................................... 70 
4.5.3 Conventional sample size estimation ................................... 71 
4.5.4 Trial Sequential Analysis .................................................... 72 
4.5.5 Calculating sample size for a third MiQuit RCT ....................... 75 
4.5.6 Sensitivity analysis ........................................................... 79 
4.6 Discussion ............................................................................. 79 
4.7 Conclusions ........................................................................... 81 
X 
 
Chapter 5: A systematic review of nicotine replacement therapy for 
promoting smoking cessation during pregnancy .................................. 83 
5.1 Introduction .......................................................................... 84 
5.1.1 Why it is important to do this review ................................... 84 
5.2 Objectives ............................................................................. 85 
5.3 Methods ............................................................................... 86 
5.3.1 Criteria for considering studies for this review ....................... 86 
5.3.2 Search methods for identification of studies .......................... 88 
5.3.3 Data collection and analysis ......................................... 90 
5.4 Results ............................................................................... 100 
5.4.1 Results of the search ....................................................... 100 
5.4.2 Included studies ............................................................. 102 
5.4.3 Excluded studies ............................................................. 107 
5.4.4 Risk of bias in included studies ......................................... 107 
5.4.5 Effects of interventions .................................................... 111 
5.5 Discussion ........................................................................... 121 
5.5.1 Summary of main results ................................................. 121 
5.5.2 Overall completeness and applicability of evidence .............. 124 
5.5.3 Certainty of the evidence ................................................. 124 
XI 
 
5.5.4 Potential biases in the review process ................................ 126 
5.5.5 Agreements and disagreements with other studies or reviews 126 
5.6 Authors' conclusions ............................................................. 128 
5.6.1 Implications for practice .................................................. 128 
5.6.2 Implications for research ................................................. 128 
Chapter 6: Trial Sequential Analysis of the efficacy of nicotine 
replacement therapy for smoking cessation during pregnancy ............. 130 
6.1 Introduction ........................................................................ 131 
6.2 Aim .................................................................................... 131 
6.3 Objectives ........................................................................... 131 
6.4 Methods ............................................................................. 132 
6.5 Results ............................................................................... 133 
6.5.1 Trial sequential analysis for efficacy .................................. 133 
6.5.2 Placebo-controlled trials subgroup analysis ......................... 134 
6.5.3 Trial sequential analysis for safety ..................................... 136 
6.6 Discussion ........................................................................... 139 
6.6.1 Conclusions ................................................................... 140 
Chapter 7: Saliva cotinine concentrations in pregnant women who 
smoke and use nicotine patches ..................................................... 141 
7.1 Introduction ........................................................................ 142 
XII 
 
7.2 Aim .................................................................................... 143 
7.3 Objectives ........................................................................... 143 
7.4 Methods ............................................................................. 144 
7.4.1 Design .......................................................................... 144 
7.4.2 Participants .................................................................... 144 
7.4.3 Measures ....................................................................... 145 
7.4.4 Analyses ....................................................................... 147 
7.5 Results ............................................................................... 149 
7.5.1 Descriptive statistics ....................................................... 149 
7.5.2 Comparison of indicators of smoking intensity ..................... 151 
7.5.3 Sensitivity analysis ......................................................... 154 
7.6 Discussion ........................................................................... 157 
7.6.1 Key findings ................................................................... 157 
7.6.2 Strengths and weaknesses ............................................... 157 
7.6.3 Discussion in context of previous literature ......................... 159 
7.6.4 Conclusions ................................................................... 161 
Chapter 8: Conclusions and recommendations ............................... 162 
8.1 Introduction ........................................................................ 163 
8.2 Summary of thesis findings ................................................... 163 
XIII 
 
8.2.1 Objective I: To use conventional systematic review and meta-
analysis to determine the efficacy and safety of NRT used during 
pregnancy for smoking cessation in later pregnancy and after childbirth.
 ............................................................................................ 163 
8.2.2 Objective II: To describe the limitations of meta-analysis and 
demonstrate how trial sequential analysis methodology can be used to 
supplement the findings of meta-analysis. .................................. 164 
8.2.3 Objective III: To determine whether there is sufficient information 
in the meta-analyses presented for objective I above regarding the 
efficacy and safety of NRT for smoking cessation in later pregnancy.
 ............................................................................................ 165 
8.2.4 Objective IV: To demonstrate how trial sequential analysis can 
alternatively be utilised to calculate trial sample size, using results from 
feasibility and pilot studies. ...................................................... 165 
8.2.5 Objective V: To use the SNIPP trial to investigate the differences 
in indicators of smoking intensity in pregnant women when smoking 
before using NRT, and when using NRT and smoking concurrently. 166 
8.3 Policy and practice implications .............................................. 167 
8.4 Possibilities for further research ............................................. 168 
8.5 Overall conclusions ............................................................... 171 
8.6 Personal development and development of research skills .......... 172 
References .................................................................................. 175 
Appendix A: Tables and figures from systematic review (Chapter 5) .... 189 
XIV 
 
Systematic review: characteristics of included studies tables ............ 189 
Systematic review: Table of adherence with NRT regimens .............. 205 
Forest plots .............................................................................. 208 
Appendix B .................................................................................. 210 
Publications .............................................................................. 210 
Appendix C .................................................................................. 291 
Professional Development ........................................................... 291 
Appendix D ................................................................................. 294 




List of figures 
Figure 1 Women known to be smokers at time of delivery by year ......... 23 
Figure 2 Women known to be smokers at time of delivery by CCG, compared 
with the national ambition ............................................................... 24 
Figure 3 Methodology for a systematic review of randomised controlled 
trials. ........................................................................................... 41 
Figure 4 Example forest plot of smoking status and COVID-19 severity .. 43 
Figure 5 Examples of convergence in test statistics as studies are included 
and followed to an outcome measure in two meta-analyses A and B ...... 47 
Figure 6 An example output from a TSA report ................................... 51 
Figure 7 Examples of significance threshold adjustment  ...................... 54 
Figure 8 Examples of futility boundaries where the experimental 
intervention is not superior to the control intervention ......................... 56 
Figure 9 Example TSA showing the cumulative Z-score crossing the 
monitoring boundary, but information size has not been reached .......... 57 
Figure 10 Example TSA showing the cumulative Z-score crossing the 
monitoring boundary, and information size has been reached ............... 58 
Figure 11 Example TSA showing the cumulative Z-score not crossing the 
monitoring boundary or the conventional test boundary, and information 
size has not been reached. .............................................................. 60 
Figure 12 Example TSA showing the cumulative Z-score crossing the futility 
boundary. ..................................................................................... 60 
XVI 
 
Figure 13 Example TSA showing the cumulative Z-score not crossing the 
monitoring boundary, and information size has not been reached. ......... 61 
Figure 14 Trial Sequential Analysis output of both MiQuit trials ............. 74 
Figure 15 Trial Sequential Analysis output of the MiQuit feasibility trial with 
the pilot trial removed  .................................................................... 78 
Figure 16 PRISMA flow diagram for updated review search ................. 102 
Figure 17 Methodological bias summary: review authors' judgements about 
each methodological bias item for each included study ...................... 108 
Figure 18 Forest plot of nicotine replacement therapy versus control, 
outcome: Validated cessation in later pregnancy (subgrouped by 
comparator type) ......................................................................... 111 
Figure 19 Forest plot of nicotine replacement therapy versus control, 
outcome: Validated cessation in later pregnancy (subgrouped by NRT type)
 ................................................................................................. 112 
Figure 20 Forest plot of nicotine replacement therapy versus control, 
outcome: Self-report cessation at 3 or 6 months after childbirth ......... 114 
Figure 21 Forest plot of nicotine replacement therapy versus control, 
outcome: Self-report cessation at 12 months after childbirth .............. 114 
Figure 22 Forest plot of nicotine replacement therapy versus control, 
outcome: Miscarriage and spontaneous abortion ............................... 115 
Figure 23 Forest plot of nicotine replacement therapy versus control, 
outcome: Stillbirth........................................................................ 116 
XVII 
 
Figure 24 Forest plot of nicotine replacement therapy versus control, 
outcome: Mean birthweight (g) ...................................................... 117 
Figure 25 Trial sequential analysis of biochemically validated smoking 
cessation at the latest time point in pregnancy compared to placebo or non-
placebo control  ........................................................................... 134 
Figure 26 Trial sequential analysis of biochemically validated smoking 
cessation at the latest time point in pregnancy compared to placebo control 
only ........................................................................................... 135 
Figure 27 Flow chart to show each planned visit in the ‘Study of Nicotine 
Patch in Pregnancy’ relevant to the current study. ............................. 147 
Figure 28 Graph to show interaction of nicotine patches on cotinine 
concentrations at 2-weeks with increasing baseline cotinine concentrations
 ................................................................................................. 152 
Figure 29 Graph to show interaction of nicotine patches on cigarettes 
smoked at 2-weeks with increasing number of cigarettes smoked at baseline
 ................................................................................................. 156 
XVIII 
 
List of tables 
Table 1 Summary of findings table .................................................. 122 
Table 2 Conventional meta-analysis and trial sequential analysis outcomes.
 ................................................................................................. 138 
Table 3 Participant baseline characteristics ....................................... 150 
Table 4 Baseline to 2-weeks after the quit date ‘within-participant’ 
differences in indicators of smoking intensity in pregnant smokers by 
treatment group, with a significance test for interaction with nicotine patch
 ................................................................................................. 153 
Table 5 Baseline to 8-weeks after the quit date ‘within-participant’ 
differences in indicators of smoking intensity in pregnant smokers by 
treatment group, with a significance test for interaction with nicotine patch
 ................................................................................................. 155 
XIX 
 
List of abbreviations 
3HC trans-3’-hydroxycotinine 
ARC EM Applied Research Collaboration East Midlands 
ASQ Ages and Stages Questionnaire, 3rd edition 
BMI Body Mass Index  
BP Blood Pressure 
CCG Clinical Commissioning Group 
COPD Chronic Obstructive Pulmonary Disease 
CI Confidence Interval 
CINAHL Cumulative Index to Nursing and Allied Health Literature 
CO Carbon Monoxide 
FTCD Fagerström Test for Cigarette Dependence 
FTCQ-12 French Tobacco Craving Questionnaire, 12 items 
ICC Intracluster Correlation Co-efficient 
IQR Interquartile Range 
IS Information Size 
IUGR Intra-Uterine Growth Restriction 
MD Mean Difference 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NIHR National Institute for Health Research 
NMR Nicotine Metabolite Ratio 
NRT Nicotine Replacement Therapy 
OR Odds Ratio 
RCT Randomised Control Trial 
RR Risk Ratio 
RRR Relative Risk Reduction 
SD Standard Deviation 
SGA Small for Gestational Age 
SIDS Sudden Infant Death Syndrome 
SNAP The Smoking, Nicotine and Pregnancy trial 
SNIPP Study of Nicotine Patch in Pregnancy 
TSA Trial Sequential Analysis 
UK United Kingdom 
USA United States of America 
WHO World Health Organisation 
XX 
 
List of publications 
PhD related publications 
Claire R, Coleman T, Leonardi‐Bee J, Berlin I. Saliva cotinine concentrations 
in pregnant women who smoke and use nicotine patches. Addiction. 2019 
Sep;114(9):1651-8. 
Claire  R, Chamberlain  C, Davey  MA, Cooper  SE, Berlin  I, Leonardi‐Bee  
J, Coleman  T. Pharmacological interventions for promoting smoking 
cessation during pregnancy. Cochrane Database of Systematic Reviews 
2020, Issue 3. Art. No.: CD010078. DOI: 
10.1002/14651858.CD010078.pub3. 
Taylor L, Claire R, Campbell K, Coleman‐Haynes T, Leonardi‐Bee J, 
Chamberlain C, Berlin I, Davey MA, Cooper S, Coleman T. Fetal safety of 
nicotine replacement therapy in pregnancy: systematic review and meta‐
analysis. Addiction. 2020 Jul 4. 
Claire R, Gluud C, Berlin I, Coleman T, Leonardi-Bee J. Using Trial 
Sequential Analysis for estimating the sample sizes of further trials: 
example using smoking cessation intervention. (Submitted to BMC Medical 
Research Methodology, revision two currently under review. Pre-print 
available at https://www.researchsquare.com/article/rs-35669/v2) 
Associated publications 
Hickson C, Lewis S, Campbell KA, Cooper S, Berlin I, Claire R, Oncken C, 
Coleman‐Haynes T, Coleman T. Comparison of nicotine exposure during 
pregnancy when smoking and abstinent with nicotine replacement therapy: 
systematic review and meta‐analysis. Addiction. 2019 Mar;114(3):406-24.
21 
 




1.1 Smoking during pregnancy 
The World Health Organisation (WHO) reports that approximately eight 
million deaths annually are caused by tobacco (1), and without further 
intervention tobacco could kill up to one billion people worldwide by the end 
of the century (2). All forms of tobacco are harmful and cigarette smoking 
is the most common form of tobacco use worldwide (1).  
Smoking during pregnancy is a significant public health issue globally and 
is one of the leading preventable causes of poor health outcomes for 
mothers and their babies. Smoking tobacco during pregnancy exposes 
pregnant women to carcinogens, high concentrations of carbon monoxide 
(CO), nicotine and a multitude of other chemicals and heavy metals. The 
significant harms associated with smoking on both the mother and 
developing foetus, mean that smoking cessation and prolonged abstinence 
in pregnancy is critical for improving birth outcomes. In the following 
sections, the prevalence and harms of smoking in pregnancy will be 
discussed.  
1.1.1 Epidemiology of smoking during pregnancy 
It is estimated that 29 of 174 countries worldwide have a prevalence of 
smoking during pregnancy greater than 10%, and 12 countries have a 
prevalence of greater than 20% (3). The three countries with the highest 
prevalence of smoking are Ireland (38%), Uruguay (30%), and Bulgaria 
(29%) (3). Since the 1980’s, high-income countries such as the 
Netherlands, Canada and Scotland have seen a decline in the prevalence of 
smoking in pregnancy from between 20% and 35% in the 1980s to below 
10% in 2010 (4-6). 
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In England, the rates of smoking in pregnancy in England have been on the 
decline over the last 10 years (Figure 1). In 2006/07, smoking at time of 
delivery rates were 15.1%, and in 2011, the Tobacco Control Plan set an 
ambition to reduce smoking rates throughout pregnancy to 11% or less by 
the end of 2015 (7). This ambition was fulfilled in 2015/16 when smoking 
at the time of delivery rates declined to 10.6% (8). Whilst this decline is 
positive, recent data has shown that this rate has stagnated at 10.5% for 
2016/17, with concerning variations by area (8). 
 
Figure 1 Women known to be smokers at time of delivery by year (8). 
 
Smoking in pregnancy rates vary vastly throughout the UK, with NHS West 
London and NHS Richmond the Clinical Commissioning Groups (CCGs) 
having the lowest rates in the UK with rates of 2.3% and 2.5% for 2016/17 
respectively (8). In contrast, the CCGs with the highest proportion of 
pregnant smokers were NHS Blackpool (28.1%) and NHS Hull (22.9%) - 
















met the national ambition of reaching smoking during pregnancy rates of 
11% or less, an increase of one from the previous year (8). Furthermore, 
all CCGs in the London commissioning region achieved the national 
ambition, whereas none of the 11 CCGs in the Cumbria and North-East 
commissioning region achieved this (Figure 2). As a result of the rates of 
smoking during pregnancy remaining stagnant over the last 2 years, and 
the disparity of rates throughout the UK, the latest tobacco control plan has 
made it an ambition to reduce the prevalence of smoking in pregnancy to 
6% or less by the end of 2022 (9). 
 
Figure 2 Women known to be smokers at time of delivery by CCG, 
compared with the national ambition (8). 
1.1.2 Harms related to smoking during pregnancy 
Smoking during pregnancy can cause a number of issues for both expectant 
mothers and their babies. Smoking during pregnancy is the leading 
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preventable cause of stillbirth, and babies that are born to mothers who 
smoke have a greater chance of being born underdeveloped or in poor 
health (9).  
The rate of stillbirths in England and Wales in 2016, was the lowest it had 
been since 1992, at a rate of 4.4 stillbirths per 1000 total births (10). The 
UK’s annual rate of reduction has been approximately 1.4% per year since 
2000, however this is ranked 24th of 49 high income countries, and is small 
compared to the annual rate of reduction in the Netherlands and Poland 
(6.8% and 4.5% respectively) (11). Several studies have shown that 
smoking in pregnancy can increase the risk of stillbirth by approximately 
30-50% (12-14). 
As well as increasing the risk of stillbirth, smoking during pregnancy is also 
associated with increased perinatal and neonatal deaths (13), and a 
systematic review found that smoking increases the risk of miscarriage by 
approximately one quarter (15). A significant reduction in birthweight is also 
associated with smoking during pregnancy, this is most commonly defined 
as babies born <2,500g at ≥37 weeks gestation. Babies that are born to 
women who smoke through pregnancy weigh an average of 250g less than 
those from non-smoking mothers (16). Low birthweight is a risk factor for 
stillbirth, but is also associated to complications in later life, such as an 
increased risk of diabetes and cardiovascular disease (17). Smoking can 
also lead to babies being born small for gestational age (SGA). This is 
defined as a baby being born with a weight less than the standardised 
average for a given gestation. Smoking is considered to have a causal 
relationship with intra-uterine growth restriction (IUGR) and this affects the 
birth weight regardless of gestation (18).  
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Some studies have found that smoking during pregnancy can double the 
risk of preterm birth (19, 20), and is also now the principal risk factor for 
sudden infant death syndrome (SIDS) (21). SIDS is defined as the 
unexplained, sudden death of a child within the first year of life, and a meta-
analysis found that prenatal smoking increased the risk of SIDS by 3 times 
(OR 2.94, 95% CI: 2.58-3.36) (16, 22). Associations have also been found 
with congenital abnormalities (such as orofacial clefts and musculoskeletal 
defects) and behavioural problems in later life (23, 24). 
Smoking during pregnancy not only affects the baby, but also has a direct 
impact on the mother. Smoking is the leading preventable cause of 
morbidity and mortality, where approximately half of all smokers will die 
from a smoking related cause (25). Smoking prevalence amongst younger 
pregnant women and those in disadvantaged groups is considerably higher 
than older, more affluent women. Mothers in routine and manual 
occupations are 5 times more likely to have smoked during pregnancy, than 
women in managerial and professional occupations (26). Due to this 
disparity in prevalence rates, disadvantaged socioeconomic groups have 
higher rates of stillbirth, premature birth and low birthweight (16). Children 
that are born and grow up with a smoking parent, are more likely to become 
a smoker themselves, which continues the cycle of inequality (27). Smoking 
in pregnancy is a leading cause of health inequality and it is estimated to 
account for 38% of the inequality in stillbirth and 31% of the inequality in 
infant deaths (28).  
1.1.3 Benefits of smoking cessation in pregnancy 
Women are more likely to make an attempt at stopping smoking in 
pregnancy than at any other time in their lives. Despite this, 10.5% of 
women continue to smoke during pregnancy (29). It is estimated that 
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between 47% and 63% of women that do manage to quit during pregnancy, 
relapse to smoking within 6 months of delivery (30). 
There are a number of benefits to both mother and child, if the mother quits 
smoking before pregnancy. A large population-based cohort study in Finland 
found that women who quit smoking in the first trimester of pregnancy had 
equal rates of stillbirth and preterm birth as non-smokers, and the 
prevalence of low birthweight and SGA outcomes were close to those of non-
smokers (31). Smokers are approximately 4 times more likely to quit 
smoking if they use a stop smoking service (32). However, the number of 
pregnant women accessing specialist stop smoking services can be poor, 
with rates of engagement to these services as low as 12% of pregnant 
women who smoke (33). 
1.2 Smoking cessation during pregnancy 
Quitting smoking can reduce harm to pregnant mothers, their babies and 
members of their household. The following section will describe influences 
on smoking cessation in pregnancy and effective interventions that can be 
used to help pregnant women to stop smoking. 
1.2.1 Influences on smoking cessation 
An important factor for women to stop smoking is the realisation of their 
pregnancy. Smoking cessation rates are 3 times greater during the year of 
pregnancy (34), though few women quit smoking after the first trimester 
(35). This increase in cessation rate during pregnancy is likely to be because 
pregnant women are more likely to recognise the risks they pose to both 
the foetus and themselves, which can provoke a strong emotional response, 
motivating them to quit (36). 
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Smoking duration and age are both factors that have been associated with 
an increased number of quit attempts in pregnancy (37), whereas 
multiparity, increased nicotine dependence and having a partner that 
smokes are all factors that have been inversely associated with cessation 
(38). In addition, surveys have found that pregnant women with lower 
education and socioeconomic levels have decreased chances of cessation, 
whereas pregnant women who had a partner that did not smoke, started 
smoking when they were older, smoked fewer cigarettes or were 
primiparous were more likely to stop smoking (39). 
1.2.2 Psychosocial interventions 
Psychosocial interventions are defined as non-pharmacological strategies 
that use cognitive-behavioural, motivational and supportive therapies to 
help women to quit smoking, including counselling, health education, 
feedback, financial incentives, social support, and exercise (40). A Cochrane 
review, that included 120 RCTs and quasi-randomised studies, of 
psychosocial interventions for supporting women to stop smoking in 
pregnancy found that counselling interventions had a clear effect on 
cessation compared with usual care (RR: 1.44, 95% Confidence Interval 
[CI]: 1.19-1.73) and financial interventions also appeared to have a clear 
effect compared with an alternative, non-contingent incentive, intervention 
(RR: 2.36,  95% CI: 1.36-4.09) (40). Interventions that provided feedback 
with information about the foetal health status or measurements of by-
products of tobacco smoking, also had a clear effect when compared with 
usual care and when combined with counselling (RR: 4.39,  95% CI: 1.89-
10.21) (40). Health education (RR: 1.59, 95% CI: 0.99-2.55) and social 
support (RR: 1.21, 95% CI: 0.93-1.58) however, do not have a significant 
effect in stopping women from smoking during pregnancy (40). An 
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important factor for the use of psychosocial interventions during pregnancy 
is that there are no adverse outcomes associated with them (40). 
1.2.3 Pharmacological interventions 
Whilst some psychosocial interventions are successful in aiding pregnant 
women from stopping smoking, these interventions do not address nicotine 
addiction directly (41). Heavier smokers may require pharmacological 
treatments that substitute the nicotine delivery from smoking, to address 
addiction and metabolism of nicotine. 
Pharmacological interventions that can help smokers quit include, nicotine 
replacement therapy (NRT), bupropion, varenicline or e-cigarettes (42). 
Whilst varenicline and bupropion have been successfully used for smoking 
cessation in the general population (43), there are currently no trials 
investigating varenicline in pregnancy, and the one trial investigating 
bupropion had recruitment issues and was only able to randomise 11 women 
(44). The lack of trials investigating varenicline and bupropion for smoking 
cessation during pregnancy is because there are currently no clinical 
guidelines that recommend their use, due to limited evidence for their safety 
during pregnancy (45). Additionally, use of bupropion and varenicline could 
expose the foetus to additional toxins found within these drugs, which is 
one reason why the study investigating bupropion struggled with 
recruitment (44).  
A systematic review of electronic cigarettes for smoking cessation in the 
general population found evidence that e-cigarettes may work better than 
NRT (46). As yet, there are no published results investigating e-cigarette 
use to aid smoking cessation during pregnancy. However, both the WHO 
and Centers for Disease Control and Prevention advise that there is 
insufficient evidence to recommend e‐cigarettes for smoking cessation in 
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adults, including pregnant women (47, 48). NRT is the most extensively 
studied pharmacological intervention for smoking cessation during 
pregnancy. 
1.3 Nicotine Replacement Therapy 
NRT is available in a variety of different forms including, transdermal 
patches, gum, spray and lozenges. Nicotine delivered by the gum, spray 
and lozenges offer brief, short-term doses of nicotine, whereas the patch 
acts over a longer-term (49). NRT works by substituting the nicotine inhaled 
in cigarette smoke with a medicinal form of nicotine. By using NRT, the 
toxins inhaled in cigarette smoke are avoided, whilst also relieving the 
withdrawal symptoms experienced when stopping smoking (49).  
A Cochrane review of pharmacological interventions for smoking cessation 
included 9 studies in the review (50). This review identified the bupropion 
study discussed earlier, and 8 trials investigating NRT use for smoking 
cessation during pregnancy. The analysis of NRT in this review included a 
total of 2,199 pregnant smokers from 5 placebo-controlled studies (51-55), 
and 3 non-placebo-controlled studies (56-58), and found a borderline 
significant result for NRT used in pregnancy increasing smoking cessation 
rates by approximately 40% (RR: 1.41,  95% CI: 1.03-1.93) (59). However, 
a sub-group analysis of only placebo-controlled trials found that NRT was 
borderline not significantly effective in stopping women smoking during 
pregnancy (RR 1.28, 95% CI: 0.99-1.66) (50). The results from the 
Cochrane review show a clear disparity between the efficacy of NRT in the 
general population and the efficacy in pregnancy.  
There could be a number of reasons for why there is a disparity between 
the efficacy of NRT in the general population and pregnancy. However, 
limited research about the factors that might influence pregnant women to 
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stop smoking when using NRT for cessation attempts has been conducted. 
One study found that women who were better educated had higher odds of 
stopping smoking at both one month into pregnancy and at delivery (60). 
Conversely, women who had higher baseline cotinine levels were inversely 
associated with cessation at both one month and at delivery (60). 
Adherence to NRT during pregnancy could be a potential factor to account 
for when determining the efficacy of NRT in pregnancy. 
1.3.1 Adherence to NRT 
In the general population, greater adherence with NRT has been found to 
be associated with increased odds of achieving cessation (49). Adherence 
to NRT in non-pregnant smokers appears to be high, with one study finding 
that 94% of smokers in a trial used NRT throughout their treatment period 
(61). By contrast, a Cochrane review found that only 7%-48% of pregnant 
women who received NRT, reported that they had completed a full course 
(50). Non-adherence of NRT for the prescribed period during pregnancy may 
restrict the efficacy of NRT (62). Adherence may affect the assessment of 
the efficacy and safety of NRT. Therefore, it is important to understand the 
causes of non-adherence and account for these in subsequent analyses.  
The reasons for low adherence to NRT amongst pregnant smokers could be 
partially due to women’s perceptions about the use of NRT and concerns 
that there could be potential foetal harms from nicotine (63). Another 
reason for low adherence could be due to an increase in nicotine metabolism 
during pregnancy (64). Pregnant women that smoke may not receive a high 
enough dose of nicotine from NRT to alleviate their cravings, therefore they 
may be unlikely to continue with the prescribed course. 
Evidence suggests that, in the general population, increased adherence with 
NRT is associated with longer term smoking cessation. There is no such 
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evidence from studies in conducted in pregnancy. It is important to 
understand the possible causes of non-adherence with NRT in pregnancy, 
as well as the characteristics of pregnant women who are predominantly 
adherent. Future analyses should also investigate whether adherence to 
NRT in pregnancy is associated with smoking cessation. 
1.3.2 Metabolism of Nicotine 
Low adherence to NRT during pregnancy could be due to an increase in 
nicotine metabolism. Nicotine is primarily metabolized by the hepatic 
cytochrome CYP2A6 enzyme, with approximately 70-80% of nicotine 
metabolised via this pathway (65). The primary metabolite of nicotine is 
cotinine, which is then primarily metabolised to trans-3’-hydroxycotinine 
(3HC) (66). Measuring the ratio of nicotine to cotinine, or cotinine to 3HC is 
a way of measuring CYP2A6 activity, and both measurements are an 
indicator of nicotine metabolic rate (NMR) (66). Nicotine has a short half-
life, whereas cotinine has longer, more stable half-life, meaning the 
measurement of cotinine to 3HC ratio is preferred (66). The cotinine to 3HC 
ratio can be ascertained effectively using saliva, blood or urine samples 
(67). 
Changes in nicotine metabolism during pregnancy is a potential reason for 
non-adherence or reduced adherence to NRT. A combination of increased 
metabolic enzymes such as the CYP2A6 enzyme and increased liver blood 
flow are potential factors responsible for alterations of nicotine metabolism 
in pregnancy (68). One study found that clearance of nicotine and cotinine 
was 60% and 140% higher respectively, during pregnancy (69). This 
increase in NMR in pregnancy may mean that the fixed amount of nicotine 
derived from adhering to NRT might not be enough to suppress craving and 
withdrawal symptoms (69). It is important to ascertain whether current 
doses of NRT prescribed are sufficient enough to alleviate withdrawal 
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symptoms in pregnant women, and future studies should investigate 
differences between cotinine levels before pregnancy when smoking and 
during when using NRT. 
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This thesis investigates the efficacy, safety and impacts on smoking 
intensity of Nicotine Replacement Therapy used for smoking cessation in 
pregnancy. As mentioned in Section 1.3, the last systematic review 
assessing the safety and efficacy of NRT was conducted in 2015 (59). This 
review found that NRT could be effective for smoking cessation in pregnancy 
(RR: 1.41, 95% CI: 1.03-1.93) (59). Since this review, a number of new 
studies may have been performed, therefore an update to this review is 
justified. Furthermore, it is unknown whether this meta-analysis is 
sufficiently powered to arise at a firm conclusion regarding the efficacy and 
safety of NRT for smoking cessation in pregnancy. If the meta-analysis is 
underpowered, it is unknown how many more studies are required to be 
able to come to a strong conclusion. To overcome this, a relatively new 
statistical methodology called Trial Sequential Analysis is introduced in this 
thesis. This method is appraised and there is a demonstration of how this 
can be utilised for planning trials in the context of smoking cessation 
interventions in pregnancy; as well as for supplementing meta-analysis in 
summarising data of existing trials of NRT for smoking cessation in 
pregnancy. 
The overall aim is to investigate ways in which NRT use in pregnancy might 
be changed such that it has greater potential to be effective. These aims 
were investigated through objectives detailed below. 
2.2 Objectives 
I. To use conventional systematic review and meta-analysis to 
determine the efficacy and safety of NRT used during pregnancy for 
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smoking cessation in later pregnancy and after childbirth (Chapter 
5). 
II. To describe the limitations of meta-analysis and demonstrate how 
trial sequential analysis methodology can be used to supplement the 
findings of meta-analysis (Chapter 3). 
III. To determine whether there is sufficient information in the meta-
analyses presented for I above regarding the efficacy and safety of 
NRT for smoking cessation in later pregnancy (Chapter 6). 
IV. To demonstrate how trial sequential analysis can alternatively be 
utilised to calculate trial sample size, using results from feasibility 
and pilot studies (Chapter 4). 
V. To use the SNIPP trial to investigate the differences in indicators of 
smoking intensity in pregnant women when smoking before using 
NRT, and when using NRT and smoking concurrently (Chapter 7).
37 
 




Systematic reviews and meta-analysis of randomised controlled trials 
(RCTs) are considered top of the hierarchy of evidence for decision making 
related to therapeutic interventions. To keep the evidence for decision 
making up to date, then systematic reviews, hence meta-analyses, require 
updating on a regular basis. However, the addition of data from more recent 
trials to the existing meta-analysis leads to significance testing being 
repeated, this increases the risk of random error and false-positive results. 
Trial Sequential Analysis (TSA) is a relatively new statistical method that 
has been developed to address these issues. 
3.2 Aim 
This chapter aims to discuss a background of reviews and meta-analysis, 
addressing biases and potential pitfalls of conducting a meta-analysis. This 
chapter will also discuss TSA and how this method can be used to 
supplement the findings of the meta-analysis. Additionally, criticisms of TSA 
will be addressed and the different types of outcome of TSA will also be 
discussed, using examples.  
3.3 Combining sources of evidence 
Healthcare decisions for both public policy and individual patients ought to 
be informed by the latest and best available research evidence (70). 
However, this can be challenging since there is a plethora of information 
available. In 2006, it is estimated that approximately 1,350,000 articles 
were published in over 24,000 peer-reviewed journals, and this number has 
been increasing year on year since (71, 72). This information can be found 
in both print and electronic media, from different countries and in a diverse 
range of languages. Furthermore the large amounts of information 
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generated by individual studies may be biased, methodologically flawed and 
can achieve conflicting results (73). It is unlikely that healthcare providers 
and policy-makers have the time, skills and resources to search, appraise 
and interpret this evidence, and then incorporate this into healthcare 
decisions (74). 
3.3.1 Narrative review 
Narrative reviews are the more traditional type of review found in medical 
literature, where experts summarise the evidence in their field from a 
theoretical or contextual standpoint (75). Narrative reviews provide readers 
with up-to-date information about a specific topic or theme.  
The goal of a narrative review is to present an argument based on existing 
information aimed at an expert audience (77). Authors of narrative reviews 
must represent the evidence underpinning their argument (including but not 
limited to primary research), and demonstrate how the evidence has been 
collated to inform the reviews conclusions (77). Whilst traditional narrative 
reviews can be useful, the validity of a review depends on its methodological 
quality (75). Authors of narrative reviews may use subjective methods to 
collect and interpret data, and there is potential for authors to be selective 
in citing reports that support their ideas (76).  
Narrative reviews are still commonly found in medical literature, but due to 
narrative reviews’ risk of bias, systematic reviews are preferred for decision 
making (78). Systematic reviews involve the application of scientific 
strategies, in ways that limit bias, to the assembly, critical appraisal, and 




3.3.2 Systematic review 
Systematic reviews are overviews of literature, undertaken by identifying, 
critically appraising and synthesising results of primary research studies 
using a strict, methodological approach, to answer a specific research 
question, thus making the available evidence more accessible to policy 
makers (79). This is done by framing a research question and then collating 
all empirical evidence that matches pre-defined inclusion criteria, which are 
set to answer the specific research question. Systematic reviews are based 
on strict, pre-specified, reproducible methods that aim to minimise bias, 
providing a greater reliability of findings (74). When conducted well, they 
can provide reliable estimates about intervention effects with defensible 
conclusions (80).  
Systematic reviews are considered the pinnacle of evidence in the traditional 
hierarchy of evidence (81). This is because the specific methods in 
systematic reviews (Figure 3), limit bias and improve reliability and 
accuracy of conclusions (79). Systematic reviews can also be used to 
establish whether findings are consistent and generalizable across 
populations, settings and treatment variations (79). Where suitable, 
combining the results of several individual studies in a systematic review 
using statistical methods gives a more reliable and precise estimate of an 
intervention’s effect than results from a single RCT, this is called meta-




Figure 3 Methodology for a systematic review of randomised controlled 
trials. 
3.4 Meta-analysis 
Meta-analysis is the use of statistical methods to summarize the results of 
independent studies (82). A meta-analysis may be conducted following a 
systematic review, by pooling quantitative data from individual studies, and 
reanalysing them using recognised statistical methods (75). By combining 
the data from individual studies in a meta-analysis the overall sample size 
is increased, leading to a greater statistical power as well as more precision 
of the estimates of treatment effects (75). 
Meta-analysis typically involves two stages, where the first stage calculates 
a measure of treatment effect with 95% confidence intervals for individual 
studies (83). The second stage of meta-analysis estimates an overall 
intervention effect as a weighted average of the individual summary 
statistics. When calculating this overall intervention effect, studies are 
weighted based on level of heterogeneity and the standard error of the 
State objectives of the systematic review of RCTs and outline 
eligibility criteria
Search for trials that seem to meet eligibility criteria
Tabulate characteristics of each trial identified and assess its 
methodological quality
Apply eligibility criteria, and justify any exclsuions
Assemble the most complete dataset feasible, with assistance 
from investigators, if possible
Analyse results of eligible RCTs, using statistical synthesis of data 
(meta-analysis) if appropriate and possible
Compare alternative analyses if appropriate and possible
Prepare a critical summary of the review, stating aims, describing 
materials and methods, and reporting results
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study, which takes into account the sample size and for dichotomous 
outcomes, the event rate in the two intervention groups (83). 
Systematic review and meta-analysis are regarded as the most reliable 
sources of evidence as to whether an intervention should implemented into 
practice or further trials should be performed (84). Interventions are often 
recommended in clinical guidelines and implemented in clinical practice 
based on a meta-analysis showing statistical significance (P<0.05) (85). 
Additionally, meta-analyses published in the Cochrane Library are 57% 
more likely to be updated when they do not demonstrate statistical 
significance (P ≥ 0.05) compared to those which do (P < 0.05), indicating 
that meta-analyses with statistically significant findings at the 5% level (P 
< 0.05) contribute to the decision to refrain from the updating of meta-
analyses (86). 
The findings included in a meta-analysis are typically presented in a forest 
plot, where an intervention effect size and 95% confidence interval is given 
for each study included (Figure 4). Each study is presented by a line and a 
solid square, where the lines represent the confidence intervals. The solid 
square represents the effect size for that individual study, and the area of 
the square is proportional to the study’s weight in the meta-analysis. In 
meta-analysis, if all studies included were identical in terms of the methods 
and sample sizes used, one could simply calculate the mean of the effect 
sizes (87). However, it is rare to find all studies in a meta-analysis to be 
identical, therefore more weight is assigned to studies that carry more 
information and a weighted mean of the intervention effect is calculated. 
The pooled intervention effect and its 95% confidence interval are 
represented at the bottom of the forest plot by a diamond, where the lateral 







Figure 4 Example forest plot of smoking status and COVID-19 severity (88) 
 
3.4.1 Fixed-effects and random-effects models in meta-analysis 
The fixed-effect and random-effects models are two commonly used models 
used in meta-analysis. These models make different assumptions about the 
nature of studies included, and thus lead to differing methods for assigning 
weights (87).  
The fixed-effect model assumes that the true intervention effect size is the 
same across all studies, and the pooled estimate of effect is an estimate of 
this common intervention effect size (87). Therefore, it is assumed that the 
sole reason the intervention effect size differs between studies is due to 
sampling error (chance). The weighting typically used in this model is based 
on the inverse variance of the individual studies, thereby assigning less 
weight to smaller studies. A limitation of this model is that a meta-analysis 
which only includes one large study and several relatively small sized studies 
would give the vast majority of the weight to the large study (87); thus the 
result for the meta-analysis would be very similar to the result of the large 
study. The fixed-effect model assumes that studies are identical in design 
and population and hence there is little variation between them; however, 
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this assumption may not be true for many systematic reviews of healthcare 
interventions. When studies are included in a systematic review, the 
inclusion criteria set means that studies are similar enough so that a single 
estimate of the intervention can be determined. However, this does not 
mean that all of these studies have to be identical, in the sense that the 
true intervention effect size is exactly the same for all studies (87). 
Systematic reviews addressing a clinical question draw together several 
studies. Whilst these studies are only included if they match set inclusion 
criteria, it is inevitable that there will be some element of diversity between 
studies. Studies may differ in design, participants, interventions exposures 
or outcomes; this is called heterogeneity (89). The random-effects model 
assumes that the true intervention effect varies between each study, and 
the studies included in the meta-analysis represent a random sample of all 
of the potential intervention effects that could have been observed in 
individual studies, thus the pooled intervention effect is an estimate of the 
mean of the effects (87). In the random-effects model, heterogeneity is 
modelled within the weightings, so that the weights assigned to each study 
is a combination of both the standard error of the individual study and an 
estimate of heterogeneity between studies. The effect of this is that as the 
estimate for heterogeneity increases, the weights will be more evenly 
distributed between the studies – i.e. smaller studies are given more relative 
weight, and larger studies are given less relative weight (87).  
3.4.2 Cumulative meta-analysis 
In 1992, Lau et al. (90) developed a new technique for updating meta-
analyses whenever a new study is published, thus enabling the evaluation 
of the pooled intervention effect as a continuum. This is known as 
cumulative meta-analysis. The advantage of this method over conventional 
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meta-analysis is that by updating a meta-analysis routinely, the benefit or 
harm of an intervention can be identified as early as possible (90). 
Alternatively it can be used to justify commencement of new trials, or to 
question whether further trials should be carried out (91). 
3.4.3 Publication bias in meta-analysis 
The intention of a meta-analysis is to summarise the intervention effects 
from all available studies; however, this may not be possible; for example, 
where some studies are not identified from literature searching. Electronic 
databases such as MEDLINE and PUBMED do not contain all medical journal 
papers, and solely searching these would be insufficient to capture all 
studies addressing a specific research question. Furthermore, studies are 
less likely to be published if the intervention effect was not statistically 
significant, this is known as publication bias (92).  
3.4.4 Random error in meta-analysis 
The result from a meta-analysis is usually deemed positive or negative 
based on a test statistic, communicated with a p-value or confidence interval 
(93). Meta-analyses can sometimes yield false-positive (type I error) or 
false negative (type II error) results (94). Type I errors occur when chance 
(random error) is the cause of a positive meta-analysis result, rather than 
due to a ‘true’ intervention effect. Conversely, some negative meta-analytic 
results may be due to lack of statistical power and precision, yielding a type 
II error (94). 
Meta-analysis methods do not consider the amount of the available evidence 
in relation to the required sample size (86, 95, 96). The reliability of a 
statistically significant intervention effect generated by meta-analysis is 
often overvalued, particularly where sparse data (e.g. number of events and 
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participants) or repetitive analyses (type I errors) are seen (74, 93, 97, 98). 
In  meta-analyses with many study participants and studies with similar 
findings, test statistics and intervention effect estimates will tend to 
converge towards the true intervention effect (93). Figure 5(A) and (B) 
demonstrate examples of convergence in test statistics. In both figures, 
interpretation of statistical significance are inaccurate in early studies, but 
eventually converge toward the ‘true’ side of statistical significance as 





Figure 5 Examples of convergence in test statistics as studies are included 
and followed to an outcome measure in two meta-analyses A and B (93). 
Random error and imprecision only cause problems if statistical tests are 
performed at stages where the extent of the random error is substantial 
enough to yield spurious statistical conclusions (93). For example, in Figure 
5(A), significance testing during the two peaks in early trials would lead to 
a false positive result. Similarly, in Figure 5(B), early significance testing 
would have led to a false-negative conclusion. 
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The likelihood of observing a false-positive or false-negative result is greater 
with an increasing number of statistical tests performed on accumulating 
data. This is known as ‘multiplicity due to repeated significance testing’ (99). 
It is important for meta-analyses to minimise the risk of making a false-
positive or false-negative conclusion. Pooled intervention effects in meta-
analysis are usually assessed using P-values, and meta-analysts must 
decide on the threshold at which a P-value is sufficiently small to justify a 
‘positive’ conclusion or the threshold below which a P-value is considered 
statistically significant (93). Deciding on a threshold involves a trade-off 
between the risk of observing a false-positive and false-negative result.  
When significance tests are performed with few studies in a meta-analysis, 
or performed multiple times, there is an increase in the risk of observing a 
false result. Therefore, interpretations about statistical significance should 
be made in relation to the strength of evidence. That is, the total number of 
participants, observed number of events (for dichotomous outcomes), as 
well as the impact of multiplicity (100). 
3.4.5 Limitations of meta-analysis 
Meta-analyses aim to discover the benefit or harm of an intervention as 
early and as reliably as possible, as a result they tend to be updated when 
new studies are published (101). In previous years, reviewers which 
published their reviews in the Cochrane Library were required to update 
their systematic reviews at least once every two years, however they are 
now updated based on priority (74). When meta-analyses are updated, they 
are subjected to repeated significance testing, which has been shown to 
increase the risk of type I error (102) by between 10% and 30% (99). In 
practice, this means that between 1 and 3 out of 10 treatments 
implemented based on meta-analysis results are likely to be inappropriate. 
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Another limitation of conventional meta-analysis methods is that they do 
not consider the amount of the available evidence, and the reliability of a 
statistically significant intervention effect is often overvalued, irrespective 
of the number of events and participants (74, 93). In addition, intervention 
effects that don’t show statistical significance are seen as unreliable, and it 
is assumed that more evidence is required (103).  
A criticism of cumulative meta-analysis is that there are no guidelines for 
assessing whether statistical evidence is conclusive or not, other than the 
nominal P-value calculated from a meta-analysis after a new trial is added 
(91). This P-value does not fully take into account the amount of information 
or the number of participants included in the analysis (91). Additionally, 
there is an increased risk of random error in cumulative meta-analysis.  
There is no way to differentiate between an underpowered meta-analysis 
and a true finding of an intervention being ‘ineffective’. However, it is 
imperative that a conclusion as to whether an intervention is truly ineffective 
or truly effective is made as soon as possible after studies are completed, 
in order to guide investigators’ decisions as to whether further studies could 
be informative or not (93). TSA is a method that can overcome this issue 
by distinguishing whether meta-analyses provide evidence for either 
beneficial or harmful intervention effects, lack of effect (futility), or 
insufficient evidence for evaluation of the intervention effect (93, 104). 
3.5 Trial Sequential Analysis 
As discussed in Section 3.4, meta-analyses aim to discover the benefit or 
harm of an intervention as early and as reliably as possible. As a result, they 
tend to be updated when new studies are published (101). When 
intervention evaluation has just begun and only few, smaller trials are 
available, meta-analyses may be conducted on sparse amounts of data and 
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their findings are therefore at high risk of random error (105). As meta-
analyses are updated they are subjected to repeated significance testing, 
which increases the risk of type I errors (102). When there are few data 
available, TSA resolves these issues by having stringent thresholds for 
assessing statistical significance, using monitoring boundaries. Monitoring 
boundaries also take into account the volume of significance testing which 
has been undertaken through adjusting the thresholds that are used to 
define whether or not results are considered statistically significant (93).  
TSA is also able to assess when an intervention has an effect smaller than 
what would be considered clinically minimally important (93). Futility 
boundaries, originally developed for interim analysis in RCTs, can be 
estimated and used to provide a threshold below which an intervention 
would be considered to have no clinically important effect (102). Thus, 
performing further trials is considered futile as the intervention does not 
possess the postulated clinically minimally important effect (93).  
In TSA, when neither the monitoring boundaries nor the futility boundaries 
are crossed, further information is required. TSA can also inform how much 
more information is required to provide a conclusive answer regarding the 
effect of the intervention versus its comparator – this is the distance 
between the accrued information and the required information.  
TSA can be used on all meta-analyses, and uses an approach that is 
analogous to the interim analysis of single RCTs developed by Lan and 
DeMets (106). In TSA of meta-analysis, trials are included in chronological 
order, and interim analysis is performed on them relative to the required 
number of participants for conclusive findings regarding intervention 
efficacy (information size). If the studies accrued in the TSA does not reach 
the information size, the uncertainty of the intervention effect will increase 
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(104). The more participants included, the smaller the uncertainty. When 
the required information size has not been reached, the threshold for 
significance is adjusted. The fewer participants in the TSA, the lower the 
significance level is in order to reliably assess the uncertainty of the 
estimated intervention effect (104). Figure 6 shows a labelled example 
output from a TSA report. 
 
Figure 6 An example output from a TSA report. Each individual square 
represents a different study in chronological order. The blue line is the 
cumulative z-line, and represents the significance. The horizontal dotted line 
represents the conventional test boundary (p=0.05). The red line is the 
adjusted monitoring boundary – the cumulative z-line will cross this if there 
is evidence of an effect. The dashed vertical arrow represents the 
information size – this is the required number of patients needed to come 
to a firm conclusion. 
3.5.1 Information size 
If all available studies are included, systematic reviews and meta-analyses 
are considered the best available evidence, because power and precision of 
the estimated intervention effects are increased in meta-analyses compared 
to using a single study alone (74). However, this does not necessarily mean 
that the available evidence is either sufficient or strong enough to be able 
to provide a conclusion.  
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Evidence suggests that intervention effects and P-values based on few 
events and participants are unreliable (107). Approximately one quarter of 
conventional meta-analyses with a small number of participants and events 
may falsely pronounce the estimated intervention effects as statistically 
significant (108). Furthermore, positive large pooled intervention effects 
observed in early meta-analyses, tend to dissipate as more evidence is 
gathered (108-110).  
For individual trials, an estimation of the required sample size is performed 
to ensure the number of participants included is enough to detect or reject 
a minimum clinically important effect size (104). For dichotomous 
outcomes, such as death, the sample size estimation is based on the 
expected proportion of deaths in the comparator group, the expected 
relative risk reduction of the intervention, and the selected maximum risks 
of both type I and type II errors (101). Similarly, for meta-analyses to 
produce adequately powered findings regarding an intervention effect, 
sufficient numbers of participants need to be included. This number is 
referred to as the ‘required information size’ (also known as ‘optimal 
information size’ and ‘meta-analytic sample size’) (102, 105, 111). The 
required information size can be estimated using similar parameters as 
those used in sample size estimation for a single study. If it is applicable to 
consider random-effects model for assessing the intervention effect size, 
then an adjustment for between-study heterogeneity, measured by 
diversity (D2), is needed (104). Heterogeneity between studies is likely to 
be observed in meta-analyses due to the magnitude of the intervention 
effect varying when used in different study populations, in studies with 
different methodological characteristics, or due to variations in the 
intervention itself (96). Thus, sample size estimations need to be increased 
to allow for this between-trial heterogeneity (104).  
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In TSA, studies are chronologically ordered, and interim analyses are 
conducted as each study is added. In a TSA where the ‘required information 
size’ has not been reached, the threshold for statistical significance is 
inflated to account for sparse data and multiple testing of the interim 
analyses using monitoring boundaries; thus, the 95% confidence interval is 
not providing coverage of the real uncertainty and the cut-off for 
determining statistical significance is below the usual nominal figure of 0.05 
(104).  
3.5.2 Significance testing with inadequate information size 
As discussed in Section 3.4.5, meta-analyses are subjected to repeated 
significance testing when they are updated, increasing the risk of type I 
error. A resolution to solve this problem is to adjust the thresholds which 
are used to define whether or not results are considered statistically 
significant (93). Figure 7 demonstrates an example of a meta-analysis 
where false-positive results are avoided using monitoring boundaries 




Figure 7 Examples of significance threshold adjustment (stipulated 
monitoring boundaries) (93). 
3.5.3 Futility testing with inadequate information size 
Meta-analyses often influence future research. Before developing future 
studies, investigators require an accurate summary of the most up to date 
information. If a meta-analysis has found that an intervention has no 
significant effect, it is important to ascertain how valid this finding is and to 
be able to exclude the possibility that the intervention is really effective but 
meta-analysis findings have arisen due to a lack of power (93). Using the 
TSA approach, unless an appropriate information size has been reached, 
when an intervention is found to have no effect, such a finding would be 
considered to be due to lack of power (93). Without using an approach such 
as TSA however, one would be unable to differentiate between an 
underpowered meta-analysis and a true ‘ineffective’ finding. However, it is 
imperative that a conclusion as to whether a treatment effect isn’t as large 
as expected, is made as soon as possible in order to prevent investigators 
spending resources on unnecessary further studies (93). Alternatively, the 
anticipated intervention effect can be re-evaluated, and further research can 
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be designed to investigate whether there is evidence of a smaller, but still 
clinically significant, intervention effect size. 
TSA is able to assess when an intervention has an effect smaller than what 
would be considered minimally important as early as possible (93). Futility 
boundaries, originally developed for interim analysis in RCTs, are created 
and used to provide a threshold which an intervention would be considered 
to have no effect (102). In a sufficiently powered meta-analysis, if an 
intervention is truly an improvement compared to the comparator, the test 
statistic would be expected to fluctuate around an upward sloping straight 
line, eventually yielding statistical significance (93). In a meta-analysis with 
fewer events and participants, obtaining a statistically significant result is 
unlikely due to lack of power. As further studies are introduced, the risk of 
getting a negative finding due to chance is reduced. Futility boundaries are 
a set of thresholds that reflect the uncertainty of obtaining a chance 
negative finding in relation to the number of participants (93). 
If a test statistic is above the futility boundary, the test statistic may not 
have returned statistical significance due to lack of power, however there is 
a chance that that a statistically significant effect will be found before the 
meta-analysis exceeds the information size (93). If a test statistic is below 
the futility threshold, the test statistic is so low that the likelihood of a 
significant effect being found becomes negligible. At this point, performing 
further studies is futile as the intervention does not possess the postulated 
effect (93). Figure 8(A) illustrates an example of a meta-analysis where 
the intervention is not superior to the comparator. The test statistic crosses 
the futility boundary before the required information size is passed. Figure 
8(B) demonstrates an example of a meta-analysis where the intervention 
is statistically significantly superior to the comparator. Here the test statistic 
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stays above the futility boundary and also yields statistical significance by 
crossing the monitoring boundary (93).  
 
Figure 8 Examples of futility boundaries where the experimental 
intervention is not superior to the control intervention (and unnecessary 
trials may have been conducted) (A) and where the experimental 
intervention is statistically significantly superior to the control intervention 
(again where unnecessary trials may have been conducted) (B) (93). 
3.5.4 Example results from trial sequential analysis 
This section aims to illustrate the various results that can be yielded from 
using TSA. Figure 9 shows a TSA of a meta-analysis comparing two 
treatments A and B where the Y-axis signifies the cumulative Z-score and 
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the x-axis signifies the cumulative number of participants included in the 
meta-analysis. In this TSA, the information size required is 855, however 
the cumulative Z-score crosses the monitoring boundary after two studies 
have been included. Even though the required information size has not been 
reached, it can be concluded that intervention B has a greater effect than 
intervention A and perhaps the intervention effect is larger than the 
anticipated effect (112). Thus, there is sufficient evidence to provide a firm 
conclusion and further studies based on this research question are not 
required. Screenshots of the TSA software to demonstrate the inputs 
required can be found in Appendix D. 
 
Figure 9 Example TSA showing the cumulative Z-score crossing the 
monitoring boundary, but information size has not been reached. 
The cumulative Z-score crosses both the monitoring boundary as well as the 
required information size in Figure 10. Again, the conclusion is that 
intervention B is superior to intervention A and that the intervention effect 
is larger than the anticipated effect. Similar, to Figure 9, further studies 
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are not required. However, three studies had been conducted after a firm 
conclusion was already determined; therefore if a TSA had been conducted 
earlier, perhaps these studies could have been avoided and resources been 
better placed elsewhere. 
 
Figure 10 Example TSA showing the cumulative Z-score crossing the 
monitoring boundary, and information size has been reached. 
In meta-analysis, it is important to understand whether a non-significant 
result is truly down to a lack intervention effect, or whether this result is 
due to lack of statistical power. TSA enables this differentiation. In Figure 
11 the Z-curve does not cross either the monitoring boundary or the 
conventional test boundary (P=0.05). However, a sample size of 1143 was 
not sufficient to reach the required information size (2144), therefore more 
studies are required. 
Whereas in Figure 12 the cumulative Z-curve crosses the futility boundary. 
When this occurs it can be inferred that the intervention effect is smaller 
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than what would be considered minimally clinically important to participants 
(93). Figure 12 also demonstrates that the futility boundaries were crossed 
after the fifth study was included in the TSA, suggesting that the sixth study 




Figure 11 Example TSA showing the cumulative Z-score not crossing the 
monitoring boundary or the conventional test boundary, and information 
size has not been reached. 
 




Figure 13 shows the cumulative Z-score crossing the conventional test 
boundary, however the monitoring boundary has not been crossed. Futility 
boundaries have not been crossed, suggesting that there could be a 
significant intervention effect but the required information size has not been 
reached, deeming the meta-analysis inconclusive with more studies being 
required before a firm conclusion can be made. Specifically, further studies 
with a total of approximately 930 participants are required to come to a firm 
conclusion. 
 
Figure 13 Example TSA showing the cumulative Z-score not crossing the 
monitoring boundary, and information size has not been reached. 
 
3.5.5 Limitations of Trial Sequential Analysis 
In the previous section, it has been explained how TSA may overcome the 
risks of type I and II errors when conducting meta-analyses. In recent 
years, TSA has been increasingly utilised by authors, the Cochrane 
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Collaboration and other evidence synthesis groups (108). However, TSA can 
be difficult to perform, may be misused and has its limitations (104, 113).  
A criticism of TSA is that, if a TSA is designed and conducted following data 
collection, the analysis becomes data driven and may not be thorough 
enough to address a predefined alternative hypothesis (113). However, 
Wetterslev et al. (85) argued that many meta-analyses follow data-driven 
hypotheses and analyses. Therefore it is recommended that for each TSA, 
a protocol should be registered which describes the anticipated intervention 
effect, anticipated trial heterogeneity, and the anticipated outcome event 
rate in the comparator group prior to conducting the TSA (85). Alternatively, 
authors should make it explicit they are conducting a post-hoc analysis, and 
should do a sensitivity analysis around the values chosen to inform the TSA.  
Recently, the Cochrane Collaboration evaluated and updated their guidance 
on using sequential approaches in meta-analysis in their systematic reviews 
(49, 50). The authors of the Cochrane Collaboration Handbook for 
Systematic Reviews of Interventions concluded that sequential methods 
should not be used in primary analyses or to draw conclusions, but could be 
used as secondary analyses in systematic reviews if they are prospectively 
planned and the assumptions underlying the design are clearly justified 
(50). In their guidance, they recommend that authors’ interpretations of 
evidence should be based on estimated magnitude of intervention effect and 
its uncertainty rather than drawing binary conclusions from interpretations 
of the P-value from the TSA, and decisions should not be influenced by plans 
for future updates of meta-analyses (50). In the future there may be scope 
to use TSA in conjunction with the GRADE approach used in Cochrane 
reviews, to assess the certainty of the body of evidence relating to the 
outcomes. For example, if a TSA shows that more information is required, 
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this could be used as a reason to downgrade the certainty of an 
interventions effects. 
Higgins et al. (113) questioned the analogy used in TSA between stopping 
trials based on interim analyses and ‘stopping’ further meta-analyses. In 
TSA, if there is sufficient or insufficient evidence to reject or not reject the 
null hypothesis, it is concluded that more studies are needed (113). If the 
null hypothesis is not rejected (the TSA result crosses the futility boundary, 
based on pre-specified power and minimum clinically important effect size) 
or rejected (the TSA result crosses boundaries that represent a harmful or 
beneficial effect), the research question has been answered, and no more 
studies are required (113). If these ideas are applied to a single trial, this 
can lead to the continuation or stopping of the trial. Higgins et al. (113) 
argues that this same notion cannot be applied to TSA since meta-analysts 
are not able to make these decisions about future studies, but should make 
recommendations instead. If new, high quality studies are already underway 
when the decision is made to stop further analyses, these would need to be 
included in updates, and should not be ignored. 
It is argued that TSA relies too heavily on the result of the statistical 
significance test (P-value) rather than the 95% confidence intervals (114). 
In TSA, confidence intervals can be adjusted for the incomplete meta-
analysis information size and for multiple significance testing (104). It has 
been suggested that the traditional 95% confidence intervals are sufficient 
enough to measure whether or not an intervention works (114), however 
these intervals exclusively relate to the null hypothesis and not to an 
alternative hypothesis relating to the type I error risk (115). If the 
unadjusted confidence intervals are used when the information size has not 
been reached, this can lead to false assertions of statistically significant 
events (104). Therefore, the traditional unadjusted 95% confidence interval 
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is only sufficient for statistical significance when the required information 
size has been achieved (104). 
TSA has also been scrutinised for being too conservative as TSA users may 
decide to use a conservative a priori intervention effect and the total 
variance in the meta-analysis to calculate the required information size 
(104). Although using an a priori intervention effect does not consider the 
intervention effect from the collected data, doing so may lead to a greater 
required information size (116). Furthermore, although using the total 
variance for the calculation of information size is seen as the worst-case 
scenario of risk of random error, it is unknown whether this variation is 
produced by systematic differences or by random variations (104). As it 
cannot be deduced where the variation arises from, it must be assumed that 
all of the variance arises from chance (117). 
Kulinskaya and Wood (118) have argued that in an underpowered meta-
analysis, not only is it necessary to assess the gap from the accrued 
information size to the required information size (i.e. the number of 
additional participants you need to randomise), but also the number of 
studies that should be conducted to achieve the required information size 
(118). Using multiple studies to reach the required information size may be 
beneficial in meta-analyses where heterogeneity occurs (118) since smaller 
studies are more likely to have more imprecise estimates of intervention 
effects; hence contribute to the precision of the estimate of the between-
study heterogeneity. However, setting up more than one study can be more 
expensive and this may not be realistic in practice. 
3.6 Conclusion 
TSA overcomes the issues of multiple testing resulting from updating a 
meta-analysis by providing corrected results using monitoring boundaries 
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and a required information size. TSA has the added advantage over 
standard meta-analysis methods, which allows the reader to assess whether 
there is sufficient evidence to conclude a clinically important treatment 
effect, no evidence of an effect, or lack of evidence. By giving an 
approximation for information size based on a minimum clinically important 
treatment effect, future studies can be better informed regarding sample 
size estimations. Furthermore, if information size has been surpassed, this 
can prevent further resources being wasted on more studies. In the 
following chapter an alternative use for TSA is presented, where it is used 




Chapter 4: Using Trial Sequential Analysis for 





The arguments presented in this chapter have been submitted in a 
manuscript to BMC Medical Research Methodology, and a pre-print has been 
published on Research Square (Appendix B) (119). Journal editors have 
requested a revised version which is currently under review. 
Demonstrating that health interventions work requires substantial 
resources. Often feasibility and pilot randomised clinical trials are conducted 
before larger-scale randomised controlled trials (RCTs) are designed to 
determine benefits and harms (120-122). Feasibility trials are used to 
ascertain information such as intervention acceptability, feasibility of 
intervention delivery, and recruitment likelihood to help design more 
decisive RCTs (120). A pilot trial is a smaller version of a large-scale RCT, 
and is used to test whether the main components of the trial, such as 
recruitment, randomisation, treatment, and follow-up assessments can all 
work together (120). Moreover, their data can be used to inform sample 
sizes for large-scale RCTs (121, 122). 
Chapter 3 discusses how TSA is a methodology that can be used in meta-
analyses to control for random errors, and to assess whether further studies 
need to be conducted (123). In a novel approach, here we employ TSA and 
combine data from feasibility and pilot RCTs testing a text message-based 
smoking cessation intervention for pregnant women (‘MiQuit’) (124, 125) to 
estimate the sample size that one or more future RCTs would need to 




The aim of this chapter is to demonstrate an alternative use for TSA by 
calculating the sample size required for an RCT of MiQuit, using results from 
feasibility and pilot studies. 
4.3 Objectives 
The study aim was investigated through the following objectives: 
I. To use parameters from feasibility and pilot trials of MiQuit to 
perform TSA. 
II. To use TSA to calculate the required information size of one or more 
trials of MiQuit. 
4.4 Methods 
As presented in Section 3.5.1, TSA can inform how much more information 
is required to yield a firm conclusion regarding the effect of the intervention 
versus its comparator – the distance between the accrued information and 
the required information. 
In TSA, trials are chronologically ordered, and interim analyses are 
conducted as each trial is added. In a TSA where the ‘required information 
size’ has not been reached, the threshold for statistical significance is 
inflated to account for sparse data and multiple testing of the interim 
analyses using monitoring boundaries; thus, the 95% confidence interval is 
not providing coverage of the real uncertainty and the cut-off for 




In the worked examples below, we show how TSA methods can be used to 
estimate the sample size required for one or more new trials to add further 
data to a meta-analysis to provide more firm evidence for an intervention 
either having or not having the postulated minimally clinically significant 
effect. 
4.5 Results 
In this section, we provide an example of how TSA successfully used data 
from feasibility and pilot RCTs that tested MiQuit, a text-message, self-help 
smoking cessation intervention for pregnant women, to justify research 
funds to undertake a third RCT. 
4.5.1 Previous MiQuit trials 
Smoking during pregnancy increases the risk of miscarriage, stillbirth, low 
birth-weight, premature birth, perinatal morbidity and mortality, sudden 
infant death, as well as adverse infant behavioural outcomes (126, 127). 
Pregnancy is a life event which motivates cessation attempts amongst 
smokers and over 50% of pregnant women who smoker attempt to quit 
during this time (128), consequently pregnancy is an opportune moment to 
offer smoking cessation support. Text message, self-help support, smoking 
cessation programmes developed for non-pregnant smokers are effective, 
but such programmes are inappropriate for use during pregnancy (129-
131). To address the lack of acceptable self-help, support cessation 
programmes for pregnant smokers in the UK, MiQuit was developed (124). 
MiQuit delivers individually-tailored text messages to pregnant smokers, 
with the aim of encouraging them to stop smoking (124). Further details on 
MiQuit can be found elsewhere (124). 
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A MiQuit feasibility RCT was conducted, including 207 women. 
Biochemically-validated, 7-day point prevalence cessation at 12 weeks post 
randomisation (~6 months gestation) was 12.5% in the MiQuit group, 
compared with 7.8% in the control group (odds ratio (OR) 1.68, 95% 
confidence interval (CI) 0.90 to 3.16) (124). Although the trial was relatively 
small in sample size and the cessation period brief, the trial provided an 
estimate suggesting that MiQuit could have a positive impact in addition to 
routine care.  
Next, a pilot RCT was conducted to investigate the feasibility of undertaking 
a fully-powered multi-centre RCT in UK National Health Service (NHS) 
settings (125). The pilot MiQuit RCT recruited 407 pregnant smokers and 
the prolonged abstinence rate from smoking, validated in late pregnancy 
was 5.4% in the MiQuit group versus 2.0% in the control group (OR 2.70, 
95% CI 0.93 to 9.35) (125). This trial also suggested a beneficial effect of 
MiQuit. 
As MiQuit is a cheap intervention and can be disseminated widely, we 
anticipated that even a 1% to 2% absolute effect on smoking cessation in 
pregnancy could be clinically important and cost effective (125). The results 
from the feasibility and pilot trials suggested that an impact of this size was 
attainable; however, an adequately powered RCT would still be needed to 
determine whether MiQuit is effective and guide future routine clinical 
practise. 
4.5.2 Conventional meta-analysis  
The conventional way to determine if an intervention is effective or not is to 
use the naïve alpha of 5% and the naïve 95% confidence interval (74). Since 
both the feasibility and pilot trials used virtually the same design as that 
which would be used in any new RCT, they can be considered as pilots and 
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it would be appropriate to meta-analyse these trials’ findings together. 
Using a random-effects model, a traditional meta-analysis of pilot and 
feasibility studies’ data found, that women randomised to MiQuit were more 
than twice as likely to be abstinent in their pregnancy (pooled OR 2.26, 95% 
CI 1.04 to 4.93; I2=0%, p=0.041). Although, this result can be interpreted 
to be significant according to conventional assessment (P<0.05), it should 
be interpreted with caution because, as described above, findings from 
meta-analyses based on only two small RCTs can produce spurious findings 
due to type I error (86, 95, 132).  
In the next sections, we use conventional sample size estimation methods 
to estimate the sample size for an RCT which, on its own would have enough 
power to show whether MiQuit might be effective, using a plausible 
treatment effect estimate derived from the conventional meta-analysis 
above. We also calculate a second sample size estimate for one or more 
further RCTs, which when pooled with data from feasibility and pilot trials 
using TSA methods, would be similarly decisive. 
4.5.3 Conventional sample size estimation 
As the pilot trial (125) was considered at lower risk of bias compared to the 
feasibility trial (124), a traditional sample size calculation using smoking 
cessation rate estimates derived from the pilot trial suggests a new trial 
would require a total sample size of 1292 participants. This estimate has 
90% power (10% type II error) and 5% significance (2-sided test; type I 
error) to detect a 3.4% absolute difference in prolonged abstinence from 
smoking from 4 weeks after enrolment until 36 weeks’ gestation between 
the MiQuit and control groups (5.4% versus 2.0%) (125). 
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4.5.4 Trial Sequential Analysis 
Figure 14.I illustrates a TSA incorporating findings from the MiQuit 
feasibility (A) (124) and pilot (B) (125) trials. In this TSA output, the x-axis 
represents the number of participants and marked on this are the numbers 
of participants recruited to each trial. The y-axis represents the Z-score, 
where a positive Z-score favours the MiQuit intervention and a negative Z-
score favours the control.  
The Z-score is the test that helps you decide whether to reject or not reject 
the null hypothesis. Very high positive or very low negative Z-scores are 
associated with very small P-values. The critical Z-score values when using 
a 95% confidence level which are known as the ‘conventional test 
boundaries’, are -1.96 and +1.96 and these relate to a two-sided P-value of 
0.05. If the Z-score is between -1.96 and +1.96, the P-value will be larger 
than 0.05, and the null hypothesis of no difference between intervention 
groups is not rejected. The Z-curve represents the cumulative Z-score as 
each RCT is added to the analysis. In Figure 14.I, when trial B is added to 
the analysis, the Z-curve crosses the conventional test boundary (p=0.05). 
This is consistent with the results from the conventional meta-analysis for 
MiQuit, where we found P=0.041. 
The required information size is represented by the vertical red line in 
Figure 14. The required information size was estimated using the same 
parameters as used for the conventional sample size estimation above (90% 
power, 5% significance, to detect a 3.4% absolute difference) (125); 
although this estimate could take into account observed heterogeneity, 
there was none in this meta-analysis due to the similarity of the intervention 
and methodology used within the trials (I2 = 0% and D2 = 0). Consequently, 
the estimated required information size of 1296 participants is only slightly 
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different to that using conventional sample size estimation due to rounding 






Figure 14 Trial Sequential Analysis output of both MiQuit trials using; 90% 
power, 5% significance, to detect a 3.4% absolute difference. Points A and 
B on the Z-curve represent each trial added to the trial sequential analysis. 
A – Feasibility trial n=198 (124); B – Pilot trial n=407 (125). Figure 14.II. 
Point C represents a theoretical trial with a sample size of 630 women, 
where an absolute difference of 3.17% was observed, in favour of the MiQuit 
group, between the control and intervention groups. Figure 14.III. Point 
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D represents a theoretical trial with a sample size of 630 women, with an 
absolute difference of -0.63% in favour of the control group. 
As the cumulative Z-curve does not cross the upper trial sequential 
monitoring boundary which indicates MiQuit being effective, this TSA shows 
that further information is required before any firm conclusion can be 
reached about the efficacy of the MiQuit intervention. Although the 
conventional meta-analysis suggested, with borderline significance, that 
pregnant women randomised to MiQuit were more than twice as likely to be 
abstinent from smoking in late pregnancy, the TSA indicates that this finding 
is not sufficiently robust. The TSA-adjusted 95% confidence intervals for 
cessation using MiQuit (pooled OR 2.26, TSA-adjusted 95% CI 0.66 to 
7.70), are much wider than those of the conventional meta-analysis (pooled 
OR 2.26, unadjusted 95% CI 1.04 to 4.93).  
Without TSA having been undertaken, an interpretation of the conventional 
meta-analysis would have been that MiQuit is effective. However, TSA 
indicates that one cannot be secure in this interpretation and further trial 
data should be collected to eliminate the possibility that this is a false 
positive result, which can occur early in intervention evaluation, particularly 
when small trials are undertaken.  
4.5.5 Calculating sample size for a third MiQuit RCT  
TSA has demonstrated that further RCT data are required before a firm 
conclusion about the efficacy of the MiQuit intervention can be determined. 
As the initial two trials were sufficiently similar to be combined in the TSA, 
we will now demonstrate how TSA methods can be used to estimate the 
sample size for (a) further trial(s) – data from which, when combined with 
the previous two trials in the TSA, would be expected to provide more 
conclusive findings regarding the efficacy of the MiQuit intervention. We will 
also demonstrate how exemplar theoretical findings from future trials which 
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are both in favour and against MiQuit having a positive effect would impact 
the TSA result. 
4.5.5.1 Trial Sequential Analysis sample size estimation  
Estimates derived from the TSA found the required information size as 1296 
participants. From the feasibility and pilot studies, 605 women have already 
been recruited and randomised; therefore, the required sample size for 
further RCTs can be estimated as the difference between the required 
information size minus the number of women already recruited into the 
previous trials; thus a sample size of 691 women (346 per intervention 
group) would be needed, assuming a 1:1 ratio.  
Figure 14.II shows the TSA output after adding a theoretical third trial (C) 
with a sample size of 630 women (315 per trial group), where an absolute 
difference of 3.17% was observed in favour of the MiQuit group versus the 
control group. The TSA shows the cumulative Z-curve line crossing the 
upper trial sequential monitoring boundary which indicates MiQuit being 
effective. As the trial sequential monitoring boundary has been crossed, the 
TSA Z-curve does not need to reach the required information size of 1296. 
In the present scenario, we can firmly conclude that MiQuit is effective for 
smoking cessation compared to control (provided that all trials are valid and 
not influenced by systematic errors (bias) or other errors). 
When a theoretical third trial (D) with a negative outcome is included in the 
TSA (Figure 14.III), we observe a different conclusion. Here, the third trial 
D with a sample size 630 was intentionally given a negative outcome 
(absolute difference of -0.63% in favour of control). Here we observe the 
Z-curve drop below the conventional test boundary, and in a meta-analysis 
we would have concluded that MiQuit was not effective. However, in the 
TSA, the futility boundary is not crossed, so we are unable to decisively say 
77 
 
that MiQuit is not as effective as control for smoking cessation. Due to the 
diversity, the required information size has increased to 1941, meaning 
future trials will need a further 706 participants. 
4.5.5.2 A conservative approach to sample size estimation 
In the above example, the required information size was derived using the 
smoking cessation rate from the pilot trial (125). Therefore, it can be 
postulated that data from the pilot trial should not be included in subsequent 
TSA. Consequently, consistent with this one could exclude the data from the 
pilot trial from the TSA and re-estimate the total number required (Figure 
15.I). Using this approach, to provide a conclusive result, either a single 
trial of 1098 participants (549 per intervention group, assuming a 1:1 ratio) 
or multiple trials cumulating to a total of 1098 participants, would be 
needed. This figure, although conservative, is still less than the estimate 
from the conventional sample size calculation. 
Figure 15.II and Figure 15.III also show the TSA outputs if theoretical 
trials C and D were included in the TSA. In both situations further 
information is needed, despite the Z-curve coming close to the upper trial 
sequential monitoring boundary in Figure 15.II and the futility boundary 




Figure 15.I Trial Sequential Analysis output of the MiQuit feasibility trial 
with the pilot trial removed, using; 90% power, 5% significance, to detect 
a 3.4% absolute difference. Point A on the Z-curve represents the feasibility 
trial. Figure 15.II. Point C represents a theoretical trial with a sample size 
of 630 women, where an absolute difference of 3.17% was observed, in 
favour of the MiQuit group, between the control and intervention groups. 
Figure 15.III. Point D represents a theoretical trial with a sample size of 
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630 women, with an absolute difference of -0.63% in favour of the control 
group. 
 
4.5.6 Sensitivity analysis 
The modelled scenario, in which there is no heterogeneity between trials in 
a meta-analysis is rare; in most situations where the described approach is 
used, some heterogeneity between studies might be expected. TSA provides 
95% confidence intervals for heterogeneity (I2) within meta-analyses. One 
way to fully allow for heterogeneity is to perform a sensitivity analysis using 
the upper boundary for heterogeneity. This would increase the required 
information size. In our example, the program could not calculate the 95% 
confidence interval surrounding the I-square of 0% as there were less than 
three included studies. In this case it is possible to input an estimate for 
heterogeneity into the TSA software. 
4.6 Discussion 
The chapter demonstrates how TSA can be used to determine the required 
sample size for one or more additional RCTs to make the findings from a 
meta-analysis more conclusive. This sample size would be considered 
underpowered in comparison to a traditional single RCT sample size 
calculation. However, by using TSA in such a way, future trials could be 
planned using significantly fewer resources and with less cost than trials 
planned using traditional sample size calculations. 
In the worked example, data from the pilot trial was used in the TSA to 
estimate the required information size. Ignoring that the same data is being 
used twice (for the estimation and for the meta-analysis) could mean that 
the estimate generated is not sufficiently conservative. Thus, we present a 
modification which attempts to overcome this issue. This approach increases 
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the difference between required information size minus the accrued 
information by the sample size of the trial used in the estimation. 
It is important to note that in the example, the meta-analysis of the existing 
two MiQuit trials quantified heterogeneity as 0%, thereby indicating that 
none of the variation in the meta-analysis was due to heterogeneity. 
However, it is unlikely that this will be the case for meta-analyses of other 
interventions aimed at changing addictive behaviours (133, 134); therefore, 
TSA methods have been developed to account for this (132). In TSA, 
estimated information size and monitoring boundaries vary with the level of 
heterogeneity in the meta-analysis, where the greater the level of 
heterogeneity, the larger the sample size needed for firm conclusions to be 
reached.  
In the example presented, odds ratios were also used instead of risk ratios, 
as the feasibility study was powered using an odds ratio from a meta-
analysis investigating mobile phone interventions for smoking cessation in 
the general population (124). Moreover, the quit rates are relatively low, so 
there is very little difference between the odds ratio and relative risk. In 
other TSAs, it may be advisable to use risk ratios instead of odds ratios, to 
avoid overestimating the intervention effect. Additionally, it may be 
inappropriate to use the odds ratio used to power the feasibility trial to 
estimate sample sizes for future MiQuit trials since data now exists from the 
feasibility and pilot trials. In our example, the stipulated intervention effect 
was derived from the pilot trial (‘internal data’), and it could be argued that 
such adaptive data should not be used in meta-analysis (135).  
In Chapter 3.5.5 it was discussed that using multiple trials to reach the 
required information size may be beneficial in meta-analyses where 
heterogeneity occurs (118). Smaller trials tend to have more imprecise 
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estimates of intervention effects; hence contribute to the estimation of 
heterogeneity in the meta-analysis. However, setting up more than one trial 
can be more expensive, and this may not be realistic in practice. 
In Chapter 3.5.5 it was also discussed how authors of the Cochrane 
Collaboration Handbook for Systematic Reviews of Interventions had 
reservations regarding using TSA to draw conclusions regarding the 
effectiveness of an intervention (136, 137). However, these criticisms of 
sequential approaches in meta-analyses apply to the traditional use of TSA, 
whereas this chapter demonstrates an alternative use of the method. 
Furthermore, a further limitation the authors argue is that a meta-analyst 
does not have any control over the future designing of trials that would be 
eligible for inclusion in the meta-analysis (66), thereby making it impossible 
to construct a set of stopping rules (66). However, in our example, the 
opposite is the case, where both the feasibility and pilot trials were 
conducted by the same group of investigators, and any future trials would 
have a consideration for the desired properties of a stopping rule. 
Finally, the authors of the Cochrane Collaboration Handbook for Systematic 
Reviews of Interventions also highlight that there are methodological 
limitations to sequential methods when heterogeneity is present (137). In 
our example described in this chapter, heterogeneity was not present and 
therefore these limitations are not relevant. However, we discuss how the 
presence of heterogeneity could be explored in TSA by performing 
sensitivity analyses. 
4.7 Conclusions 
In conclusion, TSA is a method that can utilise data from feasibility and pilot 
trials as well as other trials, in order to estimate a sample size for one or 
more future RCTs, to provide an adequately powered conclusion regarding 
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an intervention’s benefits and harms. This simple use of expensively 
collected trial data could be usefully exploited by researchers evaluating 
other interventions and could result in cost saving as fewer participants 




Chapter 5: A systematic review of nicotine 
replacement therapy for promoting smoking 




The work presented in this chapter is an update to an existing Cochrane 
review (59), and has been published as part of wider systematic reviews of 
‘Pharmacological interventions for promoting smoking cessation during 
pregnancy’ published in the Cochrane Library (Appendix B); and ‘Fetal 
safety of nicotine replacement therapy in pregnancy: systematic review and 
meta‐analysis’ published in Addiction (Appendix B). 
Chapter 1 outlined the epidemiology of smoking in pregnancy and 
described the risks associated with smoking in pregnancy. There was also a 
description of how NRT is effective for smoking cessation outside of 
pregnancy, but its efficacy in pregnancy is unclear. Chapter 1 also 
discussed some of the safety concerns surrounding NRT use in pregnancy. 
In this chapter a systematic review is performed to assess the efficacy of 
NRT for smoking cessation in pregnancy, and how safe NRT is when used in 
pregnancy.  
5.1.1 Why it is important to do this review   
Guidelines from many countries recommend that NRT be offered for 
smoking cessation in pregnancy to heavy smokers who have been unable 
to quit smoking using behavioural or psychosocial methods (45, 138-141). 
In most high-income countries (e.g. Canada, the USA, Australia, New 
Zealand), guidelines recommend that pregnant women be offered 
intermittent NRT-delivery formulations (e.g. gum, lozenges, spray - 
classified as category C drugs in pregnancy), rather than continuous ones 
(e.g. patches - classified as category D) (142). The theoretical rationale for 
this is that the overall dose of nicotine delivered by intermittent formulations 
may be lower than that delivered by continuous ones (140), and that the 
peaks in blood nicotine concentrations are more extreme, mimicking the 
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action of smoking. However, some experts recommend patches, as the 
lower peak nicotine levels associated with these may induce fewer adverse 
effects, such as throat irritation (45, 140). 
Consensus-based recommendations about using NRT for smoking cessation 
in pregnancy are underpinned by a belief that medicinal NRT is safer than 
smoking (143). However, to date, individual trials have had inconsistent 
findings (55, 58), and there is no conclusive evidence that NRT is either 
effective or safe in pregnancy (144). There are also reports of low adherence 
to NRT regimens, which could reduce efficacy and suggests that the 
acceptability of NRT use in pregnancy may be limited (52, 145). 
Furthermore, it is unclear whether efficacy or safety is improved with 
intermittent NRT administration (fast-acting NRT products) or with 
continuous administration using nicotine patches. 
Given that NRT appears to be widely accepted for cautious use in pregnancy, 
a systematic review investigating the efficacy and safety of this clinical 
practice was warranted. An up-to-date, robust synthesis of research 
evidence on the use of NRT for cessation in pregnancy will help advance 
clinical practice in an area of substantial clinical need. 
5.2 Objectives  
To determine the efficacy and safety of NRT used during pregnancy for 
smoking cessation in later pregnancy and after childbirth, and to determine 
adherence to NRT for smoking cessation during pregnancy. 
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5.3 Methods   
5.3.1 Criteria for considering studies for this review   
5.3.1.1 Types of studies   
Parallel- or cluster-randomised controlled trials (RCTs) were eligible for 
inclusion. Quasi-randomised, cross-over, and within-participant designs 
were not eligible for inclusion due to the potential biases inherent in these 
designs. 
5.3.1.2 Types of participants   
Women who were pregnant and who also smoked tobacco at study baseline. 
5.3.1.3 Types of interventions   
Comparisons of any type of NRT (including chewing gum, transdermal 
patches, nasal and oral spray, inhalators and tablets or lozenges) versus 
placebo or no NRT control. 
Trials could provide behavioural support to participants, however the 
support provided had to be very similar (ideally identical) across the active 
NRT and comparator trial arms. Behavioural support is effective for smoking 
cessation in pregnancy (40), and differences in its provision would be 
expected to affect cessation and birth outcomes, potentially rendering 
findings difficult to interpret. 
5.3.1.4 Types of outcome measures   
5.3.1.4.1 Primary outcomes   
Self-reported abstinence from smoking at the latest time point in pregnancy 
at which this was measured and, where available, validated biochemically 
using measures such as exhaled carbon monoxide, saliva cotinine, or, in 
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those who are not smoking but using nicotine, anabasine. When validated 
abstinence data were available, these were preferred to self-report. Where 
this information was available, we also used prolonged or continuous 
abstinence measures, timed from a quit date set in early pregnancy and 
which allowed temporary lapses to smoking as per the Russell Standard 
criteria for outcome measurement in cessation studies (146). However, 
point prevalence abstinence measures were substituted for these as 
required.  
5.3.1.4.2 Secondary outcomes   
1) Abstinence from smoking after childbirth (with abstinence defined as 
detailed above) 
2) Safety 
a) Miscarriage/spontaneous abortion 
b) Stillbirth 
c) Mean unadjusted birthweight 
d) Low birthweight (less than 2500 g) 
e) Preterm birth (less than 37 weeks' gestation) 
f) Neonatal intensive care unit admissions 
g) Neonatal death 
h) Caesarean section 
i) Congenital anomaly 
j) Maternal hypertension 
k) Infant respiratory symptoms 
l) Infant development 
3) NRT adherence 
4) Non-serious adverse effects (serious adverse event data contributed to 
safety outcomes, as described above) 
5) Any reported long-term effects of NRT on safety 
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We did not carry out a specific literature search for outcomes 3 to 5, but, if 
reported, these data were extracted from the included studies and described 
qualitatively. 
5.3.2 Search methods for identification of studies   
5.3.2.1 Electronic searches   
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register 
by contacting their Information Specialist, who ran the search on 20 May 
2019. 
The Cochrane Pregnancy and Childbirth Group’s Trials Register is 
maintained by their Information Specialist and contains trials identified 
from: 
1) monthly searches of the Cochrane Central Register of Controlled Trials 
(CENTRAL); 
2) weekly searches of MEDLINE (Ovid); 
3) weekly searches of Embase (Ovid); 
4) monthly searches of CINAHL (EBSCO) (Cumulative Index to Nursing and 
Allied Health Literature); 
5) hand-searches of 30 journals and the proceedings of major conferences; 
6) weekly current awareness alerts for a further 44 journals plus monthly 
BioMed Central email alerts; 
7) scoping searches of the US National Institutes of Health Ongoing Trials 
Register ClinicalTrials.gov (clinicaltrials.gov/) and the World Health 
Organization International Clinical Trials Registry Platform 




Based on the intervention described, each trial report is assigned a number 
that corresponds to a specific Pregnancy and Childbirth review topic (or 
topics) and is then added to the Register. The Information Specialist 
searches the Register for each review using this topic number rather than 
keywords. This results in a more specific search set that has been fully 
accounted for in the relevant review sections (Included, Excluded, Awaiting 
Classification, or Ongoing). 
Details of the search strategies for CENTRAL, MEDLINE, Embase, and 
CINAHL; the list of hand searched journals and conference proceedings; and 
the list of journals reviewed via the current awareness service can be found 
in the ‘PCG Trials Register’ section of the Cochrane Pregnancy and Childbirth 
Group's website. 
5.3.2.2 Searching other resources   
We checked relevant cited studies whilst reviewing the trial reports 
identified by the electronic searches, as well as reference lists from any 
directly relevant reviews identified. We also searched the following trials 
registers on 20 May 2019: US National Institutes of Health Ongoing Trials 
Register ClinicalTrials.gov (clinicaltrials.gov/) and the World Health 
Organization International Clinical Trials Registry Platform 
(apps.who.int/trialsearch/), and OpenGrey, "System for Information on 
Grey Literature in Europe” (www.opengrey.eu/). 
We did not apply any language or date restrictions and included studies 
regardless of the publication type (e.g. conference abstract, trial registry 
entry, journal article). 
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5.3.3 Data collection and analysis   
For this update, the following methods were used to assess the newly 
identified studies resulting from the latest search. 
5.3.3.1 Selection of studies   
Two review authors (RC and TC) independently inspected the search results, 
making separate lists of titles and abstracts that were potentially suitable 
for inclusion. We then retrieved the full texts of reports deemed potentially 
relevant, and two review authors (RC and TC) independently assessed these 
for inclusion in the review. At both stages disagreements were resolved by 
discussion without the need to involve a third review author. 
5.3.3.2 Data extraction and management   
We designed a data extraction form based on that used by Lumley et al., 
2009 (147), which two review authors (RC and TC) used to independently 
extract data from eligible studies. Extracted data were compared, with any 
discrepancies being resolved through discussion. RC entered data into 
Review Manager 5 software (148), double checking this for accuracy. 
When information regarding any of the above was unclear, we contacted 
authors of the reports to provide further details. 
We recorded the following information, where available, in a ‘characteristics 
of included studies’ tables (Appendix A). 
1) Methods: study design. 




3) Interventions: description of intervention and control (treatment, 
dosage, regimen, behavioural support, duration of intervention), 
information regarding dose matching if relevant. 
4) Outcomes: primary outcomes, time points reported, biochemical 
validation, and definitions of abstinence. 
5) Notes: we recorded dates of the trial, trial funding, and declarations of 
interest of trial authors where reported. 
We created additional tables for details of twin births and fetal loss in 
pregnancy and for extracted adherence data. Adherence data can be found 
in Appendix A. 
5.3.3.3 Assessment of risk of bias in included studies   
RC and TC independently assessed risk of bias for all studies which they had 
not authored (the one study led by TC was assessed by CC and JLB), using 
criteria adapted from those in the Cochrane Handbook for Systematic 
Reviews of Interventions (137). Any disagreements were resolved by 
discussion with a third review author (JLB). 
We assessed the following 'Risk of bias' domains for all included studies. 
5.3.3.3.1 Random sequence generation (checking for possible 
selection bias) 
We determined whether the method used to generate the allocation 
sequence was sufficiently described to permit an assessment of whether it 
should produce comparable groups. 
We assessed the method as: 
 low risk of bias (any truly random process, e.g. random number table; 
computer random number generator); 
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 high risk of bias (any non-random process, e.g. odd or even date of 
birth; hospital or clinic record number); or 
 unclear risk of bias. 
5.3.3.3.2 Allocation concealment (checking for possible selection 
bias) 
We determined the method used to conceal the allocation sequence and 
whether intervention allocation could have been foreseen in advance of or 
during recruitment, or changed after assignment. 
We assessed the methods as: 
 low risk of bias (e.g. telephone or central randomisation; consecutively 
numbered, sealed, opaque envelopes); 
 high risk of bias (open random allocation; unsealed or non-opaque 
envelopes, alternation; date of birth); or 
 unclear risk of bias.    
5.3.3.3.3 Blinding (checking for possible performance bias and 
detection bias) 
In smoking cessation studies, bias can also occur at outcome ascertainment 
if trial participants report that they have stopped smoking when actually 
they have not. Generally, it is perceived that the broadly negative social 
view of smoking can result in self-perceived pressure on participants in 
smoking cessation studies to be seen as having successfully stopped 
smoking, and this may result in false reporting of abstinence from smoking 
at follow-up. Trialists attempt to minimise this bias (detection bias) through 
use of biochemical validation of self-reported smoking status data which is 
collected for trial outcomes.  
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We determined the methods used, if any, to blind study participants and 
personnel from knowledge of which intervention was received by the 
participant. In the previous version of this review, we categorised studies 
that used placebo as at low risk of bias and those that used a behavioural 
control only as at high risk of bias. Using this categorisation of bias, findings 
with respect to efficacy of NRT were different for placebo (low risk of bias) 
and non-placebo (high risk of bias) RCTs, so we have maintained the same 
classification for this update. In the 'Risk of bias' table we also note whether 
participants, personnel, and outcome assessors were blinded to outcome 
assessment and whether the abstinence outcome was biochemically 
validated. We used cut points derived by expert consensus: 8 parts per 
million where exhaled carbon monoxide was used for validation and 10 
ng/mL for saliva cotinine. 
5.3.3.3.4 Incomplete outcome data (checking for possible attrition 
bias through withdrawals, dropouts, protocol deviations) 
We determined for the primary outcome (i.e. smoking cessation) the 
completeness of data including attrition and exclusions from the analysis 
and whether an intention-to-treat analysis (i.e. reporting trial arm cessation 
rates amongst all participants who were originally randomised to that arm) 
was reported. We assessed whether attrition and exclusions were reported, 
the numbers included in the analysis at each stage (compared with the total 
randomised participants), reasons for attrition or exclusion where reported, 
and whether missing data were balanced across groups or were related to 
outcomes.  
5.3.3.3.5 Selective reporting bias 
We determined the possibility of selective outcome reporting bias and 
assessed methods as: 
94 
 
 low risk of bias (where it was clear that all of the study’s prespecified 
outcomes and all expected outcomes of interest to the review have been 
reported); 
 high risk of bias (where a prespecified outcome is not reported and there 
is evidence that this is due to lack of effect or an effect deemed 
unfavourable); or 
 unclear risk of bias (where not all of the study’s prespecified outcomes 
have been reported; one or more reported primary outcomes were not 
prespecified; outcomes of interest are reported incompletely and so 
cannot be used; or the study fails to include results of a key outcome 
that would have been expected to have been reported, however there is 
no clear evidence that this is a source of bias). 
5.3.3.3.6 Other risk of bias 
We considered whether there were any other additional potential sources of 
bias in the study. 
5.3.3.3.7 Overall risk of bias 
Where a study was judged to be at low risk for all of the above domains, it 
was considered to be at overall low risk of bias; where at least one 
judgement of high risk of bias was made, the study was considered to be at 
overall high risk of bias; and where there was no judgement of high risk, 
but at least one judgement of unclear risk, the study was considered to be 
at overall unclear risk of bias. 
5.3.3.4 Assessment of the certainty of the evidence using the GRADE 
approach 
We used the GRADE approach to assess the certainty of the body of 
evidence relating to the following outcomes for each comparison (NRT 
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versus control) (149), as recommended in the Cochrane Handbook for 
Systematic Reviews of Interventions (137): 
 smoking cessation at the latest point in pregnancy (primary outcome); 
 mean birthweight (safety outcome). We chose mean birthweight 
because it can be used as a marker of multiple infant safety outcomes; 
 miscarriage and spontaneous abortion (safety outcome). We chose this 
alongside mean birthweight because it is an important safety outcome 
that would not be reflected in the above mean birthweight outcome. 
We used GRADEpro GDT to import data from Review Manager 5 in order to 
create a 'Summary of findings' table (Table 1) (148, 150). A summary of 
the intervention effect and a measure of certainty for the above outcomes 
was produced using the GRADE approach. The GRADE approach uses five 
considerations (study limitations, consistency of effect, imprecision, 
indirectness, and publication bias) to assess the certainty of the body of 
evidence for each outcome. The evidence can be downgraded from 'high 
certainty' by one level for serious (or two levels for very serious) limitations, 
depending on each of these considerations. 
5.3.3.5 Measures of treatment effect   
5.3.3.5.1 Dichotomous data 
For dichotomous data (all outcomes except mean birthweight), including 
smoking cessation, we have presented results as summary risk ratios (RR) 
with 95% confidence intervals (CI). A RR > 1 for the smoking cessation 
outcomes indicates benefit of the intervention. For undesirable outcomes, 
such as preterm births, RR < 1 indicates benefit of the intervention. 
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5.3.3.5.2 Continuous data 
For mean birthweight (continuous data), we have presented the mean 
difference (MD) between control and intervention groups with 95% CI.  
5.3.3.6 Unit of analysis issues   
5.3.3.6.1 Multiple pregnancies 
The unit of analysis for smoking cessation was the trial participant, 
regardless of whether she had a singleton or multiple pregnancy. For all 
other outcomes, analyses were conducted amongst singleton births only; 
this approach was undertaken because adverse pregnancy 
events/outcomes, adverse infant birth outcomes, and poorer infant 
development are strongly associated with multiple pregnancy. Hence, 
analysing multiple and singleton pregnancies together for these outcomes 
could render review findings difficult to interpret. Outcome data from 
multiple births were insufficient for these to be analysed separately. 
5.3.3.6.2 Cluster-randomised trials 
This study design was eligible for inclusion, however no cluster-randomised 
trials were identified. If in future updates such trials are identified, we will 
include them in the analyses along with individually randomised trials. We 
will adjust their sample sizes or standard errors using the methods described 
in Sections 16.3.4 and 16.3.6 of the Cochrane Handbook for Systematic 
Reviews of Interventions (137), employing an estimate of the intracluster 
correlation co-efficient (ICC) derived from the trial (if possible), from a 
similar trial, or from a study of a similar population. If we use ICCs from 
other sources, we will report this and conduct sensitivity analyses to 
investigate the effect of variation in the ICC. If we identify both cluster-
randomised trials and individually randomised trials, we will synthesise the 
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relevant information. We will consider it reasonable to combine the results 
from both if there is little heterogeneity between the study designs, and the 
interaction between the effect of intervention and the choice of 
randomisation unit is considered to be unlikely. 
We will also acknowledge heterogeneity in the randomisation unit and 
perform a sensitivity analysis to investigate the effects of the randomisation 
unit. 
5.3.3.7 Dealing with missing data   
For the primary smoking abstinence outcome, we assumed any participants 
lost to follow-up were still smoking or had relapsed to smoking, using the 
Russell Standard criteria (146). At all outcome points, participants whose 
smoking status was unknown were assumed to be smoking. 
We used the following denominators for other outcomes. 
 For the pre-birth outcomes, miscarriage/spontaneous abortion and 
stillbirth, the denominator used was the number of women randomised 
with viable singleton pregnancies at the time of randomisation. Where 
terminations occurred after randomisation, terminated fetuses were 
excluded from the denominator if terminations were performed on a 
presumed viable fetus for non-medical reasons. Similarly, pregnancies 
that were documented as non-viable at the point of randomisation were 
also excluded from this denominator (e.g. missed abortion). Where 
terminations were undertaken for medical reasons and were judged 
incompatible with life, these cases were included in denominators and 
also within numerators; they were counted as miscarriages if performed 
before 24 weeks, and as stillbirths if conducted after this time point. 
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 For mean unadjusted birthweight (i.e. the only birth outcome measured 
on a continuous scale), the denominator used was the number of 
singleton births for which this outcome was recorded. 
 For dichotomous birth outcomes (e.g. low birthweight, preterm birth, 
neonatal intensive care admissions, and neonatal death), the 
denominator used was the number of live births from singleton 
pregnancies. 
 For infant outcomes, the number of live births was used. 
For selected secondary outcomes and where appropriate and feasible, we 
conducted sensitivity analyses to investigate the impact of missing data on 
pooled treatment effect estimates. 
For all outcomes, we carried out analyses, to the greatest degree possible, 
on an intention-to-treat basis (caveats outlined above); we attempted to 
include all participants randomised to each group in analyses, and all 
participants were analysed in the group to which they had been allocated 
regardless of whether or not they received the allocated intervention. 
5.3.3.8 Assessment of heterogeneity   
We assessed statistical heterogeneity in each meta-analysis visually by 
inspecting the overlap of 95% CIs for the individual studies on the forest 
plots. We quantified heterogeneity using the I² statistic (137). We regarded 
heterogeneity as substantial and hence worthy of further investigation (see 
Subgroup analysis and investigation of heterogeneity) if the I² was greater 
than 50%. 
5.3.3.9 Assessment of reporting biases   
As there were fewer than 10 studies in all meta-analyses, we did not draw 
funnel plots to assess the potential for reporting bias. If in future updates 
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of this review there are 10 or more studies, we will investigate reporting 
biases (such as publication bias) using funnel plots. We will assess funnel 
plot asymmetry visually if asymmetry is suggested by a visual assessment, 
and we will perform exploratory analyses to investigate it. 
5.3.3.10 Data synthesis   
We carried out statistical analysis using Review Manager 5 software (148). 
Following the standard methods of the Cochrane Tobacco Addiction Group 
for pharmacological interventions, we elected to use a fixed-effect model for 
meta-analyses of smoking abstinence data. For meta-analyses of safety and 
adverse events data, we used random-effects models, as effects are likely 
to vary across populations due to significant differences in baseline risk.  
5.3.3.11 Subgroup analysis and investigation of heterogeneity   
We performed an exploration of heterogeneity for primary and secondary 
outcomes where the I² was greater than 50%. Additionally, for smoking 
cessation outcomes, we performed subgroup analyses based on the 
following groups. 
1) Placebo-controlled versus non-placebo-controlled RCTs 
2) Studies using different types of NRT, both alone and in combination (i.e. 
fast-acting NRT and nicotine patch) 
3) Low-dose NRT (< 10 mg/24 hours) versus high-dose NRT (> 10 mg/24 
hours) 
For secondary outcomes, where the I² was greater than 50% (indicating 
substantial heterogeneity), we also performed these subgroup analyses as 
an exploration of heterogeneity; however, they were not conducted 




We assessed differences between subgroups statistically using subgroup 
interaction tests, and have presented the P values from these tests. 
If in future updates of the review more than 10 studies are included in a 
meta-analysis, we may consider performing meta-regression to further 
explore reasons for heterogeneity or to analyse adherence data. A caveat 
to using this method for adherence data is that there is currently no 
standard method for reporting adherence; however, for meta-regression to 
be undertaken, studies must report adherence data similarly. 
5.3.3.12 Sensitivity analysis   
We planned two sensitivity analyses using smoking cessation outcomes, 
depending on the availability of data. 
1) Excluding studies rated at high risk of bias overall. 
2) Excluding any studies that reported substantially lower treatment 
adherence than others. As there is no consensus on what constitutes 
good or acceptable adherence to NRT in pregnancy, we anticipated 
defining 'low adherence' after consideration of adherence data reported 
within the included studies. 
We were unable to carry out these analyses for the current review 
(explanations follow in the Results section); they will be undertaken in 
future review updates, data permitting. 
5.4 Results 
5.4.1 Results of the search   
We carried out an updated search of the Cochrane Pregnancy and Childbirth 
Group’s Trials Register on 20 May 2019 and identified 14 trial reports for 
potential inclusion. We also deemed a further study, which had recently 
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been published and so was not identified by searches, as potentially relevant 
(151). We identified a total of 15 trial reports for title and abstract 
screening, of which eight studies were clearly not RCTs and were excluded. 
We obtained the full text of the seven remaining records for screening. We 
excluded one article (152), assessed four articles as ongoing studies (see 
below), and included one article in this update (151). Details of the flow of 
studies for this update are recorded in a PRISMA diagram in Figure 16. 
Eight trials included in previous versions of this review are also included in 
this update (51-58).  
This updated review therefore includes a total of 9 trials (30 reports). It 
contains data from one additional trial published since the previous version 
(151), and involves a total of 2336 pregnant women who smoked at study 
baseline. We added two newly identified follow-up reports for each of two 





Figure 16 PRISMA flow diagram for updated review search. 
 
5.4.2 Included studies   
5.4.2.1 Interventions 
Nine studies investigated the efficacy of different forms of NRT (51-58, 151). 
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5.4.2.2 Nicotine replacement therapy studies 
All included studies investigated the efficacy of NRT provided with 
behavioural support and compared this with either behavioural support 
alone or support plus a placebo, therefore studies measured the effect of 
NRT provided as an adjunct to behavioural support. Six papers described 
placebo-controlled RCTs (51-55, 151). Three trials compared NRT plus 
behavioural support with behavioural support alone (56-58); thus, 
participants in these studies could not be blinded to treatment. Two studies 
used fast-acting NRT, one using nicotine gum (53), and the other nicotine 
inhalers (151); six trials used nicotine patches (51, 52, 54-57); and one 
offered a choice of NRT formulations: approximately two-thirds of 
participants chose patches, whilst the remainder elected to use gum and 
lozenges (58). 
Oncken et al., 2008 (53) used 2 mg nicotine gum, and Oncken et al., 2019 
(151) used 4 mg nicotine inhalers. Four studies used 15 mg/16-hour 
nicotine patches (52, 55, 57, 58); one of these used a higher nicotine dose 
(21 mg/24 hours removed at night) for participants who reported smoking 
more than 15 daily cigarettes (58). Two studies attempted to match nicotine 
doses prescribed with either saliva,(51), or urinary cotinine levels (56), 
obtained at earlier appointments. Depending on cotinine levels, women in 
one study were treated with combinations of 10 mg and 15 mg 16-hour 
patches (51), and in the other study with 21 mg, 14 mg, or 7 mg 24-hour 
patches, with instructions to remove these at night (56). One trial advised 
women to use trial treatments from randomisation until childbirth, 
irrespective of whether or not they had relapsed to smoking (51), and 
another trial encouraged continued use of treatment for six weeks as long 
as the woman was actively trying to quit smoking (151). Other trials advised 
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women to stop using NRT if they restarted smoking and had a defined period 
for use of NRT. 
5.4.2.3 Setting 
Studies were conducted in the USA (n = 4) (53, 56, 58, 151), Australia (n 
= 1) (57), Canada (n = 1) (54), Denmark (n = 1) (55), France (n = 1) (51), 
and England (n = 1) (52). All trials were conducted in public hospitals or 
antenatal clinics. 
5.4.2.4 Outcomes 
In one study, smoking cessation was ascertained between 20 and 28 weeks' 
gestation (54); however, in all other studies this was ascertained at 32 
weeks or later. In all of the included studies, biological samples were 
obtained from participants, and after any required clarification from the 
authors we determined that all used such samples to validate reported 
cessation at the primary endpoint: four studies used exhaled carbon 
monoxide (53, 56, 57, 151); three saliva cotinine (51, 55, 58); and one 
used both exhaled carbon monoxide and saliva cotinine (52). One study 
reported both thiocyanate and cotinine concentrations (54). For two studies, 
cut points were obtained from the trial authors (55, 58), and we obtained 
further data on biochemical validation from the authors of a trial that used 
a higher-than-standard cut point for saliva cotinine (26 ng/mL) (55). This 
revealed that the cotinine assay used had a lower limit of 20 ng/mL, which 
was also above the currently accepted cut point of 10 ng/mL, so some 
women who smoke may have been wrongly categorised as abstinent in this 
study.   
The periods of abstinence from smoking that participants were required to 
demonstrate varied across studies. For smoking outcomes measured at 
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delivery, three studies reported both seven-day point prevalence abstinence 
from smoking and a measure of continuous abstinence simultaneously (51, 
52, 58); however, definitions varied. One study (52), permitted a small 
number of temporary lapses to smoking as recommended by the Russell 
Standard criteria for outcome measurement in smoking cessation studies 
(146). The remaining two studies did not permit temporary lapses and 
defined continuous abstinence as seven-day point prevalence abstinence 
recorded on three (58), or up to seven occasions (51). Four studies reported 
only seven-day point prevalence abstinence (53, 55, 58, 151), and three 
reported point prevalence abstinence for an unstated period (54, 56, 57). 
Four studies reported seven-day point prevalence abstinence data at time 
points after childbirth: Wisborg et al., 2000 (55) provided data at three and 
12 months postnatally; Coleman et al., 2012 (52) at six, 12, and 24 months; 
Oncken et al., 2008 (53) at six to 12 weeks (biochemically validated data); 
and Pollak et al., 2007 (58) at three months. Additionally, Coleman et al., 
2012 (52) reported continuous abstinence between a quit date and each 
time point, allowing for temporary lapses too. Two studies reported self-
reported maternal smoking at 12 months after childbirth (52, 55). 
Infant and fetal safety outcomes were reported in seven studies (51-53, 55, 
56, 58, 151). All seven of these studies reported mean birthweight and 
mean gestation age at delivery, and all reported the incidences of low 
birthweight births (defined as below 2500 g). Six of these studies reported 
rates of preterm birth defined as born before 37 weeks' gestation (51-53, 
55, 58, 151). Six studies reported rates of miscarriage/spontaneous 
abortion and stillbirth (51-53, 55, 58, 151), and four trials also reported 
infants’ rates of special care admission and neonatal death (51-53, 58). Two 
trials reported data on maternal hypertension in pregnancy or measured 
arterial blood pressure at each visit (51, 52), three trials reported rates of 
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congenital malformation (51, 52, 151); and two of these three trials 
reported rates of caesarean section (51, 52). Two trials reported single and 
multiple pregnancy data together, but authors supplied data for singleton 
pregnancies separately (51, 58). 
With regard to the pre-birth fetal outcomes of miscarriage/spontaneous 
abortion and stillbirth, Oncken et al., 2008 (53) reported that, within 
singleton pregnancies, three control group participants had terminations 
that were performed for social reasons (presumed healthy fetus), so these 
fetuses were removed from the denominator for control group analyses 
(control group n = 91). Also, Pollak et al., 2007 (58) reported one fetal 
death prior to randomisation that was documented by ultrasound scanning 
(i.e. a 'missed abortion') in the NRT group, so this fetus was removed from 
the denominator for the NRT group (NRT group n = 121). Coleman et al., 
2012 (52) reported one termination and one fetal death prior to 
randomisation in women allocated to NRT, so these two cases were removed 
from the NRT group denominator (NRT group n = 515). Berlin et al., 2014 
(51) reported one termination in each trial group, both of which were 
conducted for fetal abnormalities that were assessed as not being 
compatible with survival at birth. Consequently, as these terminations were 
undertaken at 25 (placebo group) and 32 weeks, they have been counted 
as stillbirths in the analysis and remained in the denominator as well. 
Coleman et al., 2012 (52) additionally reported infants' "survival without 
developmental impairment" and respiratory symptoms at two years of age 
and self-reported maternal smoking at six and 24 months after childbirth. 
5.4.2.5 Ongoing studies 
One study reported as ongoing in the previous review has now completed, 
with results published, and is now an included study in this review (151). 
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Two further NRT studies were identified as ongoing (153, 154). One study 
appears to offer NRT as part of a multicomponent intervention (153), which 
would likely not be included in this review; however, we will wait for further 
information to become available before making a decision to exclude. The 
other study, based in Iran, is currently aiming to recruit 1050 pregnant 
women to a RCT testing 15mg/16-hour nicotine patches versus a placebo 
control (154). This study appears to be eligible for inclusion in any future 
updates of this review. 
5.4.3 Excluded studies   
We excluded one trial following full-text screening in this update (152). This 
was a pilot cluster-randomised step-wedge trial, where NRT was part of a 
multimodal intervention that provided educational resources to health 
providers at aboriginal medical services. We judged that due to the study 
design and the multimodal intervention strategy, it was not possible to 
identify the independent effect of NRT on smoking cessation from this study.  
5.4.4 Risk of bias in included studies   
We judged four of the nine included studies to be at low overall risk of bias 
(51-53, 55), three as at high risk of bias (56-58), and the remainder unclear 




Figure 17 Methodological bias summary: review authors' judgements about 
each methodological bias item for each included study. 
5.4.4.1 Allocation (selection bias)   
Computer-generated random number sequences were used to generate 
randomisation in most studies. One study used urn randomisation (a 
method that is systematically based in favour of balancing of covariates, 
preserving randomization as the primary basis for assignment to treatment 
(155))  and was judged to be at low risk of bias for random sequence 
generation, but was unclear for allocation concealment due to insufficient 
detail (151). One study used sealed envelopes after random numbers had 
been generated, but it was not clear if these were opaque and sequentially 
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numbered (57); we therefore judged this study to be at unclear risk of bias 
for allocation, whilst the others were rated as satisfactory (low risk of bias). 
5.4.4.2 Blinding (performance bias and detection bias)   
We judged studies that had no placebo control to be at a high risk of bias, 
which was the principal difference between studies that was likely to cause 
bias. Six trials were placebo-controlled RCTs (51-55, 151), and three studies 
compared behavioural support alone with NRT and behavioural support (56-
58). 
As all included trials biochemically validated self-reported smoking 
outcomes, detection bias is not a major issue for this review. However, one 
included study used a cut point for saliva cotinine (26 ng/mL) that was 
substantially higher than the currently accepted level (10 ng/mL) and, 
additionally, used an assay with a lower limit of measurement of 20 ng/mL 
(i.e. samples in the 0 to 20 ng/mL range were reported as 20 ng/mL) (55). 
This means that some of the participants who may have falsely reported 
themselves as not smoking in this study might have had their false reports 
of abstinence validated as true (i.e. some participants who were actually 
smoking might not have had this detected by the validation process). Of 
course, no validation process is perfect, and, using any cut point, some false 
reports of cessation would be accepted to be true, but with a known high 
cut point as in Wisborg et al., 2000 (55), this would be expected to occur 
more frequently. However, the use of biochemical validation in this study 
would still be expected to detect heavier smoking in those who made false 
reports of abstinence, so validated data from this study were still used in 
preference to self-report data. 
110 
 
5.4.4.3 Incomplete outcome data (attrition bias)   
We judged all studies to be at low risk of bias for smoking abstinence 
outcomes; all studies carried out an intention-to-treat analysis, so that 
those participants who could not be contacted at follow-up were assumed 
to have returned to smoking. It should be noted that this assumption is 
conservative and is the standard approach taken when assessing the 
efficacy of smoking cessation interventions. Follow-up for birth outcomes 
was generally high with one exception: the treatment group allocation for 
seven women who experienced miscarriage after being randomised within 
one study could not be ascertained (55); as this was not the primary 
outcome, we assessed this trial as at low risk of attrition bias. 
5.4.4.4 Selective reporting (reporting bias)   
We judged three studies as at unclear risk of reporting bias. Hotham et al., 
2006 (57) collected data on a number of outcomes that were not reported 
in the trial manuscript; however, it is unclear whether this was a source of 
bias. We requested birthweight information from Hotham et al., 2006 (57) 
for our meta-analysis but were unable to obtain it. El-Mohandes et al., 2013 
(56) informed us that within their trial, some data on secondary smoking 
cessation outcomes were collected, but this information was not reported in 
the trial manuscript; however, primary outcomes were reported. Kapur et 
al., 2001 (54) did not report any birth outcomes. We judged the remaining 
six studies to be at low risk of reporting bias. 
5.4.4.5 Other potential sources of bias   
We identified an unanticipated potential source of bias in one study (56): 
two participants were screened and randomised on two separate occasions, 
with each pregnancy counted as a discrete study participation, and both 
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women included in the trial analysis twice. We considered this as potentially 
introducing bias into what was a relatively small study, and so judged this 
study as at high risk of bias. 
5.4.5 Effects of interventions   
Data were not identified for all pre-specified outcomes. Where data were 
available this is summarised below. 
5.4.5.1 Primary outcomes (efficacy) 
In a pooled analysis of nine included studies and 2336 participants, we found 
evidence that the use of NRT, as an adjunct to behavioural support, may 
result in a clinically significant improvement in smoking cessation rates in 
later pregnancy relative to control (risk ratio (RR) 1.37, 95% confidence 
interval (CI 1.08 to 1.74; I² = 34%; Figure 18). 
 
Figure 18 Forest plot of nicotine replacement therapy versus control, 





We carried out a subgroup analysis splitting the studies by comparator type 
- placebo or no placebo- and found evidence of a subgroup difference (P = 
0.008; Figure 18). In the subgroup that compared active NRT with placebo, 
heterogeneity between studies was substantially reduced (I² = 0%), 
however the CIs incorporated the potential for both no effect and a benefit 
of NRT for smoking cessation (RR 1.21, 95% CI 0.95 to 1.55; 6 studies, 
2063 women; Figure 18), whereas the estimate derived from non-placebo-
controlled trials indicated only benefit (RR 8.55, 95% CI 2.05 to 35.71; I² 
= 0%, 3 studies; 273 women), but was limited by substantial imprecision. 
When analysing the data split into fast-acting and nicotine patch subgroups, 
the test for subgroup differences provided no evidence that the effect of 
NRT differed by type (P = 0.08; Figure 19). 
 
Figure 19 Forest plot of nicotine replacement therapy versus control, 
outcome: Validated cessation in later pregnancy (subgrouped by NRT type). 
 
We planned to carry out a sensitivity analysis removing all studies judged 
to be at high risk of bias. The six studies that did not have a high risk of 
bias for any domain were the same six studies in the placebo-controlled 
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trials subgroup. This analysis and resulting 95% CI found evidence of 
potentially no clear effect of NRT, as well as the potential for benefit, 
therefore its interpretation does differ very slightly from that of the overall 
pooled analysis (Figure 18). We were unable to conduct the planned 
sensitivity analysis relating to adherence to treatment as trials reported 
adherence so differently that it was not possible to categorise one or more 
trials as having substantially worse or better treatment adherence than 
others. 
We investigated the impact of NRT as an adjunct to behavioural support on 
cessation at time points after childbirth by pooling data from studies that 
provided postnatal follow-up data on smoking behaviour. In a pooled 
analysis of studies that reported non-validated seven-day point prevalence 
smoking abstinence up to six months after childbirth (predominantly at or 
around three months), there was no clear evidence that NRT compared to 
control was effective for smoking cessation, as CIs incorporated both 
potential benefit and harm of the intervention (RR 1.22, 95% CI 0.84 to 
1.78; I² = 0%, 3 studies, 625 women; Figure 20). There was no statistical 
difference when comparing studies that were placebo controlled to the one 
study that was not (P = 0.59). Similarly, the pooled estimate for non-
validated seven-day point prevalence smoking abstinence when comparing 
NRT to placebo at one year after childbirth resulted in CIs that incorporated 
both a small potentially negative effect of NRT, as well as a potentially 
positive effect at this time point (RR 1.35, 95% CI 0.97 to 1.88; I² = 5%, 




Figure 20 Forest plot of nicotine replacement therapy versus control, 
outcome: Self-report cessation at 3 or 6 months after childbirth 
 
Figure 21 Forest plot of nicotine replacement therapy versus control, 
outcome: Self-report cessation at 12 months after childbirth 
 
The one study that monitored continuous cessation from a quit date set in 
pregnancy to postnatal time points alongside seven-day point prevalence 
abstinence data collected at the same time points reported higher point 
prevalence than continuous cessation rates at each time point, and rates of 
continuous cessation until two years after childbirth were low (2.9% in the 
NRT group versus 1.7% in the placebo group, P = 0.20) (156). 
5.4.5.2  Secondary safety outcomes 
Two study papers reported birth outcomes from single- and multiple-birth 
infants together (51, 58); the authors kindly provided data on birth 
115 
 
outcomes within singleton pregnancies only to enable data from those 
studies to be included in the meta-analyses.  
5.4.5.2.1 Miscarriage/spontaneous abortion 
There was no evidence of a difference in risk of miscarriage/spontaneous 
abortion between the NRT and control group, and CIs incorporated the 
possibility of both potential benefit and harm of the intervention (RR 1.60, 
95% CI 0.53 to 4.83; I² = 0%, 5 studies, 1916 women; Figure 22). 
However, despite contacting the study authors, we could not determine the 
treatment allocation for seven miscarriages from one study, which is not 
included in this comparison (55). If we assume that all miscarriages from 
this study occurred in either the NRT or the control group (i.e. the extremes 
of how these could actually be distributed), this results in the following effect 
estimates: all assumed in the NRT group: RR 2.15, 95% CI 0.77 to 6.02; 
all assumed in the control group: RR 1.06, 95% CI 0.38 to 2.97. This has 
no effect on the interpretation of the results.  
 
Figure 22 Forest plot of nicotine replacement therapy versus control, 





Similarly, there was no evidence of a difference between the numbers of 
stillbirths in the NRT and control groups (RR 1.24, 95% CI 0.54 to 2.84; I² 
= 0%, 4 studies, 1777 women; Figure 23). 
 
Figure 23 Forest plot of nicotine replacement therapy versus control, 
outcome: Stillbirth 
 
5.4.5.2.3 Mean unadjusted birthweight 
Despite the pooled estimate for birthweight being higher for the NRT group 
than for the control group, there was no evidence of a difference of mean 
birthweight between the NRT and control groups (mean difference (MD) 
99.73 g, 95% CI −6.65 to 206.10; I² = 70%, 7 studies, 2202 women; 
Figure 24). Heterogeneity was high; the result for this comparison must 
therefore be interpreted with caution. The reasons for this heterogeneity are 
unclear; it is not easily explained by study design as one large placebo-
controlled RCT (52), and a smaller non-placebo-controlled one (58), both 
reported non-significantly lower birthweight in NRT group infants, in 




Figure 24 Forest plot of nicotine replacement therapy versus control, 
outcome: Mean birthweight (g) 
 
5.4.5.2.4 Low birthweight (less than 2500g) 
There was a lower incidence of low birthweight births in women in the NRT 
group, but again this was not significant and was found in the context of 
much heterogeneity, so caution is again warranted (RR 0.69, 95% CI 0.39 
to 1.20; I² = 69%, 7 studies, 2171 women; Figure S1). The pattern of 
heterogeneity was once again difficult to understand: the same two studies 
reported non-significantly higher rates of low-birthweight infants in the NRT 
arm (52, 58).  
5.4.5.2.5 Preterm birth (less than 37 weeks’ gestation) 
Analyses of rates of preterm births (RR 0.81, 95% CI 0.59 to 1.11; I² = 
21%, 7 studies, 2182 women; Figure S2) resulted in CIs spanning one, 
incorporating the potential for both benefit and harm. 
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5.4.5.2.6 Neonatal intensive care unit admissions 
There was no evidence of a difference in risk of neonatal intensive care unit 
admissions between the NRT and control groups (RR 0.90, 95% CI 0.64 to 
1.27; I² = 0%, 4 studies, 1756 women; Figure S3). 
5.4.5.2.7 Neonatal death 
Similarly, there was no evidence of a difference in risk of neonatal deaths 
between the NRT and control groups (RR 0.66, 95% CI 0.17 to 2.62; I² = 
0%, 4 studies, 1746 women; Figure S4).  
5.4.5.2.8 Caesarean section 
A meta-analysis of rates of caesarean birth suggested no clear evidence for 
a benefit or harm of NRT (RR 1.18, 95% CI 0.83 to 1.69, I² = 46%, 2 studies 
(51, 52), 1401 women; Figure S5). 
5.4.5.2.9 Congenital anomaly 
The same two studies that reported caesarean section, also reported 
congenital anomalies. The meta-analysis found no clear evidence for a 
benefit or harm of NRT (RR 0.73, 95% CI 0.36 to 1.48, I² = 0%, 2 studies 
(51, 52), 1401 women; Figure S6).  
5.4.5.2.10 Maternal hypertension 
The three studies that provided data on blood pressure (BP) reported these 
in different formats: Coleman et al., 2012 (52) reported that 24 (4.6%) in 
the NRT group compared to 25 (4.7%) in placebo were noted to have 
hypertension in pregnancy (i.e. BP of greater than 140/90 mmHg) on at 
least two occasions (no statistical comparison presented). Berlin et al., 2014 
(51) reported significantly higher median diastolic BP in the NRT group 
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(median BP = 70, interquartile range (IQR) = 60 to 80 mmHg) compared 
to placebo (median BP = 62, IQR = 60 to 80 mmHg) (P = 0.02). Berlin et 
al., 2014 (51) also reported an interaction between treatment group and 
time (i.e. during pregnancy) for increases in diastolic BP, though absolute 
increases in BP were small. 
5.4.5.2.11 Infant respiratory symptoms 
Coleman et al., 2012 (52) and Berlin et al., 2014 (51) also reported the 
distribution of mechanical ventilation of infants between NRT and placebo 
groups; no statistically significant differences were noted.  
5.4.5.2.12 Infant development 
Coleman et al., 2012 (52) was the only included study that reported infant 
outcomes after the neonatal period. Using a composite, self-report outcome 
based on the Ages and Stages Questionnaire, 3rd edition (ASQ-3) 
instrument (157), significantly better infant developmental outcomes were 
observed in infants born to women who had been randomised to NRT 
compared to those in the placebo group. The odds ratio (OR) for infants 
reaching two years of age 'without developmental impairment' (i.e. normal 
development) was 1.40 (95% CI 1.05 to 1.86).  
5.4.5.3 Adherence and adverse effects 
Where adherence was reported, this was generally low, as the majority of 
participants in all studies did not use complete courses of the NRT offered 
(Appendix A). Berlin et al., 2014 (51) differed from other studies in that 
transdermal patches were offered to women at 3 time points between their 
quit dates and delivery, whereas other studies offered NRT once. Much 
higher self-reported adherence rates were noted in this study; however, it 
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is difficult to reconcile these with reported rates of intervention 
discontinuation, and direct comparison with other studies was not possible. 
5.4.5.4 Non-serious adverse effects 
Only a narrative reporting of non-serious adverse effect data was possible 
due to wide ranging effects. Six NRT trials reported non-serious adverse 
effects (51-53, 55, 57, 151). One trial reported their frequency within 
women using NRT, noting that five (25%) women in the NRT group 
experienced minor symptoms, and two women stopped using patches after 
unpleasant effects (57); however, non-serious adverse effects were not 
monitored in the control group, so this figure is difficult to interpret. Oncken 
et al., 2008 (53) reported that at least 10% of participants experienced 
headache, dizziness, fatigue, heartburn, nausea or vomiting, with 14 (15%) 
in the NRT and 12 (12%) in the control groups discontinuing treatment due 
to adverse effects. Wisborg et al., 2000 (55) noted that 11 women stated 
that adverse effects (e.g. skin irritations and headache) made them 
discontinue patches, but did not report treatment allocations; this trial also 
reported that five women experienced palpitations and two nausea. 
Coleman et al., 2012 (52) noted 535 non-serious adverse events reported 
by 521 NRT group participants and 450 reported by 529 placebo group 
participants. Berlin et al., 2014 (51) reported a range of non-serious 
adverse events, noting that more non-gynaecological ones occurred in the 
NRT group, but this was principally due to skin reactions. In this study, 11% 
of participants in the NRT group suffered a skin reaction at the patch site 
compared with 4% in the placebo group. Oncken et al., 2019 (151) reported 
a significantly higher number of adverse effects in women using the nicotine 
inhaler (11%) than the placebo inhaler (0%) (P = 0.008). These adverse 
events included throat irritation, cough, and nausea. Furthermore, two 
women in this study were discontinued from the nicotine inhaler group due 
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to repeated elevations in cotinine concentrations exceeding more than 40% 
of their baseline cotinine concentration. 
5.5 Discussion   
5.5.1 Summary of main results   
Overall there is low-certainty evidence that NRT used alongside behavioural 
support by pregnant women for smoking cessation may increase smoking 
abstinence in late pregnancy (Table 1). Caution is required when 
interpreting this pooled estimate, as subgroup analyses revealed potentially 
different treatment effects when comparing NRT to placebo-controlled 
versus non-placebo-controlled studies. These findings may be due to 
unexplained biases potentially within the less robust, non-placebo-
controlled trials. The actual efficacy of NRT used for smoking cessation in 
pregnancy is uncertain and may be lower than the pooled summary estimate 
(Figure 18). Further subgroup analysis found no evidence that the effect 
of NRT on abstinence is moderated by the type of NRT used, that is patches 
versus fast-acting NRT, and there was no consistent evidence of NRT having 
either a positive or negative impact on birth outcomes.
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Table 1 Summary of findings table 
Nicotine replacement therapy compared to control for smoking cessation during pregnancy 
Patient or population: pregnant women who smoke 
Setting: public hospitals and antenatal clinics (Australia, Canada, Denmark, France, the UK, the USA)                                            
Intervention: nicotine replacement therapy 
Comparison: placebo plus similar/matched behavioural support or similar/matched behavioural support only 
Outcomes 
Anticipated absolute 














Biochemically validated smoking cessation 
at the latest point in pregnancy (20 weeks' 
gestation or more) 
Study population RR 1.37 




LOW 1 2 
 
9 per 100 12 per 100 
(10 to 16) 
Mean birthweight (g) Study population MD 99.73 g 





LOW 4 5 
 
3139 g 3 3239 g 
(3132 g to 
3345 g) 







0 per 100 1 per 100 (0 
to 2) 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the 
relative effect of the intervention (and its 95% CI). 
 




GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the 
effect. 
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the 
estimate of effect. 
Footnotes 
1Downgraded one level due to serious risk of bias: in the subgroup of studies at low or unclear risk of bias the effect was no longer statistically significant, and there were 
significant subgroup differences when comparing these studies to the three studies judged to be at high risk of bias (P = 0.008). 
2Downgraded one level due to serious imprecision: there were only 253 events in total (300 to 400 recommended for dichotomous outcomes), and confidence intervals 
span both minimal clinical benefit and considerable clinical benefit. 
3Control risk based on observed birthweights in the control arms. 
4Downgraded one level due to serious inconsistency: I² = 70%, not explained by subgroup differences. 
5Downgraded one level due to serious imprecision: confidence intervals encompass no difference as well as a clinically significant benefit. 
6Downgraded two levels due to very serious imprecision: there were only 12 events in total (300 to 400 recommended for dichotomous outcomes), and confidence intervals 
encompass both no difference and potential harm. 
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5.5.2 Overall completeness and applicability of evidence   
All of the included studies were conducted in high-income countries, with 
only one study specifically recruiting women from ethnic minority 
backgrounds. These findings may therefore not be applicable to low-middle-
income countries if smoking patterns of women or beliefs about using 
medication in pregnancy differ, and more evidence is needed from these 
populations. 
An exclusion criterion for this review was unmatched additional intervention 
components in the intervention or comparator arms. This means that we 
can be confident that we have isolated the independent effects of the 
interventions of interest to our review question. 
It has been mandatory since July 2005 for clinical trials to be recorded on a 
trials register. In this update we searched trials registers from inception, 
therefore we are confident that we have identified all reported ongoing 
trials. 
The findings reported in this review are based on currently accepted, 
evidence-based, biochemical verification cut points for determining 
abstinence from smoking (158), rather than ones that might have been 
acceptable in the past, enhancing the validity of our findings. 
5.5.3 Certainty of the evidence 
The included trials had varied 'Risk of bias' ratings (Figure 17). We 
assessed four of the nine included studies to be at low risk of bias, three at 
high risk of bias, and the remainder at unclear risk of bias. We judged the 
principal difference in studies' propensity to bias to be due to the use/non-
use of placebo controls. The reduction in heterogeneity observed after 
grouping trials according to this criterion seemed to validate this judgement. 
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Trials that were judged to be at an unclear risk of bias lacked information 
regarding allocation concealment or did not report prespecified outcomes. 
It is possible, but relatively unlikely, that the lack of information regarding 
allocation concealment indicates bias. 
We assessed the certainty of the evidence using the GRADE approach for 
critical and important outcome measures. The GRADE assessment of pooled 
data indicated that the evidence for the smoking cessation outcome in NRT 
trials was of low certainty (Table 1), meaning that the true effect might be 
markedly different from the estimated effect. The current evidence was 
downgraded twice, once due to risk of bias: in the subgroup of studies at 
low or unclear risk of bias the effect was no longer statistically significant, 
and there were significant subgroup differences when comparing these 
studies to the three studies judged to be at high risk of bias. We downgraded 
the evidence further due to serious imprecision, as there were few events, 
and confidence intervals spanned both minimal clinical benefit and 
considerable clinical benefit. Both of these downgrades are subjective and 
could be considered marginal, however after discussion with other reviewers 
it was decided that these downgrades were justified. We assessed the 
evidence for the safety outcomes in NRT trials, mean birthweight and 
miscarriage, to be of low certainty. The mean birthweight outcome was 
downgraded due to inconsistency where heterogeneity was high and not 
explained by subgroup differences, and was further downgraded due to 
imprecision, as the pooled confidence interval encompassed no difference 
as well as a clinically significant benefit. Additionally, standard deviations 
were relatively large for most studies. The miscarriage and spontaneous 
abortion outcome was downgraded two levels to low certainty due to 
imprecision, as there were too few events, and confidence intervals 
encompassed both no difference and potential harm. 
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The downgrading of the evidence for all outcomes due to imprecision 
suggests that further research will be beneficial in increasing the reliability 
and precision of effect estimates and the certainty we are able to place in 
them. 
5.5.4 Potential biases in the review process   
We performed the search for studies in this area using the Cochrane 
Pregnancy and Childbirth Group’s Trials Register. It is unlikely that studies 
that have been conducted have been missed, however it is possible that 
unpublished studies, or ongoing studies not registered in clinical trial 
registries, could be missing. Should we identify any such studies, we will 
include them in future updates of the review. Secondly, we were unable to 
produce a funnel plot as there were too few studies, and it is possible there 
was publication bias. In future updates where there are sufficient trials we 
will be able to assess publication bias more rigorously. Finally, we aimed to 
reduce bias wherever possible by having at least two review authors 
independently conduct study selection, data extraction, and 'Risk of bias' 
assessment. 
5.5.5 Agreements and disagreements with other studies or reviews   
This review explicitly assesses the efficacy and safety of pharmacological 
therapies used for smoking cessation in pregnancy. Some trials of smoking 
cessation in pregnancy test NRT as part of multimodal intervention 
strategies, and these are included in an associated review (40). However, 
this review was concerned with the efficacy and safety of NRT when used 
for smoking cessation in pregnancy, and examines the independent safety 
and efficacy of NRT. 
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We have been unable to identify any other systematic reviews that 
investigate the efficacy of smoking cessation medications in pregnancy since 
the previous version of this review was published (144). A systematic review 
of trials conducted in non-pregnant women has shown that NRT is effective 
outside of pregnancy (159). The reasons why NRT may not be as effective 
in pregnancy are not known; however, variations in adherence to NRT or 
nicotine metabolism compared to the general population may play a part. 
Women in trials included in the current review made relatively little use of 
offered NRT. If this low adherence explains the difference in findings 
between this and the 'non-pregnancy' NRT review (159), then 
understanding the phenomenon of low adherence could be important. Lack 
of efficacy could also be explained by the increased metabolism of nicotine 
in pregnancy (160). This may result in NRT generating lower blood nicotine 
concentration in pregnancy, and this reduced nicotine substitution could, in 
turn, increase women's experience of withdrawal symptoms, causing them 
to stop NRT early. A recent systematic review found that pregnant women 
using NRT were exposed to significantly lower concentrations of nicotine 
compared to those who continued to smoke tobacco (161). Furthermore, a 
secondary analysis of a trial included in our review found that pregnant 
women who both smoke and use nicotine patches had similar cotinine 
concentrations, smoke less, and exhale less carbon monoxide, therefore 
they are likely to be exposed to fewer tobacco smoke toxins (162). An 
increased metabolism of nicotine during pregnancy results in lower 
exposure, and coupled with the likelihood that nicotine is unlikely to be 
responsible for the majority of fetal harms caused by tobacco smoke, it is 
likely that NRT is safer for the fetus than smoking (163). Logically, if in trials 
to date, increased metabolism underpinned women's low adherence to NRT, 
higher doses of NRT could be needed for this to be effective in pregnancy. 
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5.6 Authors' conclusions   
5.6.1 Implications for practice   
The evidence suggests that nicotine replacement therapy (NRT) may be 
effective for smoking cessation in pregnancy, however there is uncertainty 
surrounding this evidence. It is also unclear whether NRT affects the risk of 
adverse pregnancy and infant outcomes, but there is no evidence that it is 
harmful. One study suggests that NRT improves child development 
outcomes at two years. 
5.6.2 Implications for research   
As adherence to NRT in pregnant women is low, further research should 
seek to understand why this is and improve it and use an appropriate 
behavioural strategy to enhance adherence in future trials of NRT. 
Qualitative studies could add further context as to why adherence to NRT in 
pregnancy is low. 
In the general population, there is evidence that 25 mg/16-hour patches 
are more effective than 15 mg/16-hour patches (164); most studies in this 
review used 15 mg patches. Consequently, trials are needed in pregnant 
women using either higher-dose nicotine patches or combination of patch 
plus rapid-acting forms of NRT, which are also more effective (164). 
There is a strong case for further trials to examine the effectiveness and 
safety of NRT against placebo. NRT leads to lower blood nicotine 
concentrations than when smoking and is effective in the general population 
(159), however there are also reasons why it may be less effective for 
pregnant women than for the general population, and the evidence in 
pregnant women is uncertain. The following chapter discusses whether 
conducting more trials is futile, and if not, how many more participants 
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would be needed in further trials to ascertain whether NRT is an effective 
treatment for smoking cessation in pregnancy. 
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Chapter 6: Trial Sequential Analysis of the 
efficacy of nicotine replacement therapy for 




In Chapter 5 a systematic review and meta-analysis was performed to 
assess the efficacy of NRT used during pregnancy for smoking cessation. 
This review found that NRT use, together with behavioural support, is 37% 
more effective for smoking cessation in pregnancy relative to control (RR 
1.37, 95% CI 1.08 to 1.74). However, subgroup analysis of only placebo-
controlled studies found a more conservative estimate of effect, which is 
deemed not significant by traditional measures of statistical significance (RR 
1.21, 95% CI 0.95 to 1.55). From these traditional meta-analyses, it is 
unknown whether the intervention effects are spuriously overestimated 
(type I error) or spuriously underestimated (type II error) due to insufficient 
randomised participants (165).  Chapter 3 introduces a method called trial 
sequential analysis which may overcome these issues. In this chapter we 
apply trial sequential analysis methods to the meta-analyses conducted in 
Chapter 5, for the primary outcomes in the Summary of findings table 
(biochemically validated smoking cessation at the latest point in pregnancy; 
mean birthweight; and miscarriage and spontaneous abortion). 
6.2 Aim 
The aim of this chapter is to determine whether there is sufficient 
information in meta-analyses regarding the efficacy and safety of NRT for 
smoking cessation in later pregnancy in Chapter 5. 
6.3 Objectives 
The study aim was investigated through the following objectives: 
I. To use trial sequential analysis to assess whether NRT is effective for 
smoking cessation in pregnancy. 
132 
 
II. To use trial sequential analysis to assess whether NRT is safe for 
smoking cessation in pregnancy. 
III. If unclear, to use TSA to discover whether conducting future trials is  
futile, or how many participants would be required in future studies 
to arrive at a firm conclusion. 
6.4 Methods 
TSA of a meta-analysis of RCTs in an analogous approach to interim analysis 
of a single RCT (166). TSA increases the uncertainty of an intervention effect 
if the cumulative information in the meta-analysis unsuccessfully achieves 
the minimum number of randomised participants to detect or reject a pre-
specified clinically important effect size (104). This uncertainty is reduced if 
the proportion of randomised participants is higher in relation to the 
required information size. When the required information size has not been 
reached, the results from the TSA are adjusted to reflect the uncertainty 
through using TSA-adjusted CIs. Thus, the further the number of 
randomised participants included in the meta-analysis are from the required 
information size, the wider the TSA-adjusted confidence intervals. This 
means that the significance level is lower to assess the uncertainty of the 
point estimate (104). The required information size is calculated using the 
anticipated event proportion in the control group, a pre-specified plausible 
relative risk reduction or increase in the intervention group, and the 
anticipated heterogeneity variance (D2) of the meta-analysis. 
In this study, TSA was applied to the primary outcome of biochemically 
validated smoking cessation at the latest point in pregnancy, and the 
subgroup analysis by comparator. Trials were included sequentially based 
on date of publication according to the year of publication, and if more than 
one trial had been published in a year, we added these trials alphabetically 
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according to the last name of the first author. The required information size 
was estimated based on the control event proportion from the meta-
analysis; D2 as suggested by the meta-analysis; an alpha (type I error) of 
5%; and beta (type II error) of 90%; and an anticipated relative risk 
reduction of that observed in trials with a low risk of bias. These parameters 
were decided a priori, as reported in the PROSPERO record (Appendix B). 
Sensitivity TSA were conducted using the same parameters as above, but 
instead using a D2 of the upper bound of the 95% confidence interval for 
heterogeneity calculated by the TSA software.  
6.5 Results 
6.5.1 Trial sequential analysis for efficacy 
Nine studies, including 2336 participants, reported data on smoking 
cessation at the latest time-point in pregnancy. The meta-analysis found 
evidence that the use of NRT, as an adjunct to behavioural support, may 
result in a clinically significant improvement in smoking cessation rates in 
later pregnancy relative to control (RR 1.37, 95% CI 1.08 to 1.74; I² = 
34%; Figure 18). However, this result was not confirmed by TSA (TSA 
adjusted CI 0.52 to 3.64; Figure 25, Table 2). TSA analysis found that 
although the Z-curve crossed the conventional significance boundary 
(P=0.05) indicating a significant result for NRT, the curve did not cross TSA 
monitoring boundaries, demonstrating potentially early spurious results. 
The TSA reported that a further 18,708 participants from at least one 
additional trial would be needed to reach a firm conclusion regarding the 
effectiveness of NRT for smoking cessation in late pregnancy.  
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6.5.1.1 Sensitivity analysis 
Sensitivity analysis, performing TSA using the upper bound of the 95% CI 
for D2 (54%), was consistent with the primary analysis (TSA adjusted CI 
0.52 to 3.64; Table 2). The required information size increased to 22,860, 
meaning that a further 20,524 participants from at least one additional trial 
would be needed to reach a firm conclusion regarding the effectiveness of 
NRT for smoking cessation in late pregnancy. 
 
Figure 25 Trial sequential analysis of biochemically validated smoking 
cessation at the latest time point in pregnancy compared to placebo or non-
placebo control. The required information size was calculated using α = 
0.05, β = 0.90, relative risk reduction = based on low biased trials, diversity 
(D2) as suggested by trials, and a control event rate of 9.09%. The 
cumulative Z-curve was constructed using a fixed-effects model, and each 
cumulative Z-value was calculated after inclusion of a new trial (represented 
by black dots). The horizontal green lines represent the conventional naïve 
boundaries for benefit. The etched lines represent the trial sequential 
boundaries for benefit, harm, or futility (middle triangular area). The 
cumulative Z-curve does not cross the TSA boundary for benefit, indicating 
future trials are required. The estimated information size is 21,044, meaning 
future trials would need approximately 18,708 participants in total for a firm 
conclusion. 
6.5.2 Placebo-controlled trials subgroup analysis 
Six studies with 2063 participants reported data on smoking cessation in 
pregnancy with a placebo comparator. These studies were deemed at lower 
risk of bias. However, in the conventional meta-analysis, the CIs 
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incorporated the potential for both no effect and a benefit of NRT for 
smoking cessation (RR 1.21, 95% CI 0.95 to 1.55; Figure 18). This result 
was confirmed by TSA (TSA adjusted CI 0.66 to 2.22; Figure 26, Table 2). 
In this scenario, TSA analysis found that the Z-curve did not cross either 
the conventional significance boundary or the TSA monitoring boundaries. 
However, futility boundaries were not crossed, meaning performing further 
trials would not be futile. Therefore, a further 8,453 participants from at 
least one additional placebo-controlled trial would be needed before a firm 
conclusion regarding the effectiveness of NRT for smoking cessation in 
pregnancy can be determined. 
6.5.2.1 Sensitivity analysis 
Sensitivity analysis, performing trial sequential analysis using the upper 
bound of the 95% CI for D2 (49%), was consistent with the primary analysis 
(TSA adjusted CI 0.44 to 3.30; Table 2). The required information size 
increased to 20,619, meaning that a further 18,556 participants from at 
least one additional trial would be needed to reach a firm conclusion 
regarding the effectiveness of NRT for smoking cessation in late pregnancy. 
 
Figure 26 Trial sequential analysis of biochemically validated smoking 
cessation at the latest time point in pregnancy compared to placebo control 
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only. The required information size was calculated using α = 0.05, β = 0.90, 
relative risk reduction = based on low biased trials, diversity (D2) as 
suggested by trials, and a control event rate of 9.09%. The cumulative Z-
curve was constructed using a fixed-effects model, and each cumulative Z-
value was calculated after inclusion of a new trial (represented by black 
dots). The horizontal green lines represent the conventional naïve 
boundaries for benefit. The etched lines represent the trial sequential 
boundaries for benefit, harm, or futility (middle triangular area). The 
cumulative Z-curve does not cross the TSA boundary for benefit, indicating 
future trials are required. The estimated information size is 10,516, meaning 
future trials would need approximately 8,453 participants in total for a firm 
conclusion. 
6.5.3 Trial sequential analysis for safety 
6.5.3.1 Miscarriage and spontaneous abortion 
Five studies with a total of 1916 participants reported miscarriage and 
spontaneous abortion as an outcome measure. Traditional meta-analysis 
found no evidence of a difference in risk of miscarriage/spontaneous 
abortion between the NRT and control group, and CIs incorporated the 
possibility of both potential benefit and harm of the intervention (RR 1.60, 
95% CI 0.53 to 4.83; Figure 22). This result was confirmed by TSA 
analysis, however the adjusted confidence intervals were very wide (TSA 
adjusted CI 0.02 to 145.85; Table 2). In this TSA analysis the z-curve again 
did not cross either the conventional significance boundary or the TSA 
monitoring boundaries. However, futility boundaries were not crossed, 
meaning performing further trials would not be futile. In this circumstance 
sensitivity analysis was not possible, as using the upper bound of the 95% 
CI for D2 (54%) meant that less than 5% of the required information size 
was accrued. 
6.5.3.2 Mean birthweight 
Seven studies incorporating 2202 participants reported mean birthweight as 
an outcome measure. In traditional meta-analysis, the pooled estimate for 
birthweight was higher for the NRT group than for the control group, but 
the CIs incorporated a small decrease in birthweight as well as a more 
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substantial increase (MD 99.73g, 95% CI −6.65 to 206.10; Figure 24). 
Trial sequential analysis widen the CIs further (TSA adjusted CI -64.65 to 
264.11; Table 2). Like the output for miscarriage and spontaneous 
abortion, futility boundaries were not crossed, so further trials would not be 
futile in this instance. Sensitivity analysis using the upper bound of the 95% 
CI for D2 (80%), further widen the confidence intervals (TSA adjusted CI -




Table 2 Conventional meta-analysis and trial sequential analysis outcomes. 
   Primary TSA
















RR 1.37  
(95% CI  






RR 1.21  
(95% CI  





RR 1.60  
(95% CI  
0.53 to 4.83) 0.02 to 145.85 34623 
Insufficient data 
(<5% of IS) 
Insufficient data 




MD 99.73g  
(95% CI  
−6.65 to 206.10) -64.65 to 264.11 9669 -74.73 to 274.18 10970 
1For dichotomous outcomes: α 5%; ß 90%; RRR low risk of bias based; D2 model variance based. For continuous outcomes: α 5%; 
ß 90%; RRR low risk of bias based; D2 upper confidence interval based.  
α: two-sided significance level, ß: power; D2: diversity; CI: confidence interval; IS: information size; RR: relative risk; MD: mean 




According to the findings from the TSA, the current evidence from nine trials 
on the use of NRT during pregnancy is not sufficient to assess whether it 
aids smoking cessation during pregnancy compared to control. To reach a 
firm conclusion, a further 8,453 participants from at least one additional 
placebo-controlled trial is required. 
As discussed in Section 3.5.5, the Cochrane Collaboration evaluated and 
updated their guidance on using TSA approaches in meta-analysis in their 
reviews (136, 137). The authors from the Cochrane Handbook for 
Systematic Review of Interventions concluded that TSA methods should not 
be used in primary analyses or to draw conclusions, but could be used as 
secondary analyses in reviews if they are prospectively planned and the 
assumptions underlying the design are clearly justified (137). In this case, 
all TSA analyses were prospectively planned, and parameters for the TSA 
were decided a priori. Additionally, the results from the TSA have been 
written up to avoid drawing binary conclusions and have not been influenced 
by plans for future updates (137).  
To overcome methodological limitations of TSA methods when 
heterogeneity is present, a sensitivity analysis was performed using D2 of 
the upper bound of the 95% confidence interval for heterogeneity calculated 
by the TSA. The findings of this sensitivity analysis show that the numbers 
increase substantially when substantial heterogeneity is present and 
therefore the estimate of heterogeneity (tau) needs to be robust. As there 
were only few studies included in the meta-analyses the estimate of tau is 
imprecise, which lead to the large increase in required information size. 
Although very impractical in the scenario above, it is important to consider 
whether to conduct one large multicentre trial or a number of smaller trials 
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to reach information size. It may be more insightful to conduct a series of 
smaller trials, as with more studies included in the meta-analysis, the 
estimate of tau will be more precise. 
6.6.1 Conclusions 
The results from the TSA suggest that further placebo-controlled trials 
comprising of a total of around 8,500 participants may be required to arrive 
at a stronger conclusion surrounding NRT use for smoking cessation in 
pregnancy. However, this figure may be impractical. In a period of over 18 
years, only 2,083 women have been recruited to placebo-controlled trials. 
Thus, substantial time and resources would be necessary to recruit four 
times that amount. Furthermore, funders are unlikely to want to pay for 
such large studies to be conducted, especially if the traditional meta-
analysis suggests that the intervention is likely to be effective. 
Instead of focussing on NRT and how it is trialled currently, resources may 
be better spent understanding why NRT does not work as effectively during 
pregnancy. Chapter 7 explores one such reason – by investigating 
concomitant smoking and NRT use and how this affects indicators of 




Chapter 7: Saliva cotinine concentrations in 





The arguments presented in this chapter have been published in Addiction 
(Appendix B). 
Smoking during pregnancy is the leading modifiable risk factor for poor 
maternal and infant health outcomes. Pregnancy-related health problems 
associated with smoking during pregnancy include complications during 
labour, increased risk of miscarriage, premature birth, stillbirth and low 
birth-weight (9, 11, 15). Despite this, around 12% of pregnant women in 
the UK, 13% in the United States and 20% in France continue to smoke 
during pregnancy (128, 167, 168). Several national guidelines have adopted 
using nicotine replacement therapy (NRT) for supporting pregnant smokers 
to quit, based on the idea that NRT is probably safer than smoking as it does 
not contain the toxins present in tobacco smoke (138, 169).  
Whilst NRT has been proven to be effective in non-pregnant smokers (49), 
its efficacy in pregnancy is uncertain (59). It is unclear why the evidence 
for efficacy is uncertain, however it is hypothesised that physiological 
changes in pregnancy could affect nicotine’s metabolism (170). Potential 
factors for the increased metabolism rate include a higher level or activity 
of metabolic enzymes involved and increased blood flow through the liver 
during pregnancy (68). Cotinine is the principal metabolite of nicotine, and 
the clearance of nicotine and cotinine is 60% and 140% higher respectively, 
during pregnancy (69). An increase in metabolic rate could signify that 
nicotine supplied through standard dose NRT may be insufficient to alleviate 
smoking withdrawal symptoms in pregnancy and to provide therapeutic 
effects.  
A systematic review and meta-analysis comparing nicotine exposure in 
pregnant women when smoking, and their nicotine exposure when abstinent 
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and using NRT, found that NRT exposes women to lower doses of nicotine 
than smoking does (161). Generally, in studies included in this review, such 
as the Smoking, Nicotine and Pregnancy (SNAP) trial, women were 
instructed to discontinue use of nicotine patches if they had even brief 
smoking lapses (52). This mimics routine health care, where pregnant 
women are usually advised to stop using NRT if they lapse to smoking, even 
for short periods.  There is concern that concomitant smoking and NRT use 
could increase exposure to nicotine and potentially more tobacco smoke 
toxins if they smoked heavily when using NRT.  However, in pregnancy this 
assumption is untested, and we know little about women’s smoking 
behaviour when they use NRT concurrently. This is important as women who 
lapse to smoking, may still want to quit.  In a non-pregnant population 
continued use of nicotine patches has been found to promote recovery from 
lapses (171), if this is the case during pregnancy, women may have better 
chances of cessation if NRT is continued. 
7.2 Aim 
The aim of this chapter is to investigate the differences in indicators of 
smoking intensity in pregnant women when smoking before using NRT, and 
when using NRT and smoking concurrently. 
7.3 Objectives 
This study aim was investigated through the following objectives: 
I. To investigate ‘within-participant’ differences in indicators of 
smoking intensity at two different time points in pregnancy, in 
women using patches and smoking concurrently, compared with 
those when they only smoked 
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II. To investigate if these changes differed between nicotine and placebo 
patch use. 
III. To investigate whether an interaction between indicators of smoking 
intensity and nicotine patch assignment exist. 
7.4 Methods 
7.4.1 Design 
This is a secondary analysis of data from the ‘Study of Nicotine Patch in 
Pregnancy’ (SNIPP) (51). SNIPP was a multi-centre, double-blind, 
randomised, placebo-controlled study conducted in France using 16-hour 
nicotine patches. The trial randomised 402 women to either nicotine 
(n=203) or placebo patches (n=199). The study was approved by the Ethics 
Committee of the Pitié-Salpêtrière Hospital, Paris, France. 
7.4.2 Participants 
Participants were eligible for inclusion in the SNIPP trial if they smoked at 
least 5 cigarettes per day, were aged over 18 years, of 12-20 weeks 
gestation and scored at least 5 on a scale measuring motivation to stop 
smoking (range 0-10) (51). Prior to enrolment, participants attended a 
baseline visit, where demographic, obstetric, physiological characteristics 
and smoking behaviour data were collected, and saliva cotinine 
concentrations were determined. At this stage, participants were given two 
weeks to quit smoking or reduce the number of cigarettes to fewer than five 
a day. If after this two-week period they were unable to do either of these, 
they could be randomised, receive the study drug, and set a quit date when 
treatment began. Participants were asked to stop smoking on a predefined 
quit date and were randomised to either placebo or nicotine patches. 
Participants were told that they could continue using nicotine patches during 
smoking lapses. Moreover, patch doses were adjusted according to the pre-
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quit saliva cotinine determination to optimize the nicotine substitution; this 
resulted in participants receiving a mean nicotine dose of 18 mg/day 
(SD=6.8) in the nicotine patch arm. 
7.4.3 Measures 
In the SNIPP trial, abstinence was defined as self-reported abstinence, 
confirmed by expired air carbon monoxide concentration ≤8 parts per 
million (ppm) (Smokeanalyzer®, Bedfont Scientific Ltd, Rochester, Kent, 
UK) (172). Saliva cotinine samples were collected by placing a cotton roll in 
the gingival cleft for 1 minute, which was then placed immediately into a 
Salivette tube (Sarstedt, Nümbrecht, Germany) (172). Samples were kept 
at 4 °C and were sent to the central biochemistry laboratory (Hôpital Pitié-
Salpêtrière, Laboratoire de Biochimie, Dr. N. Jacob) within 24 hours for 
determination (172). The quantification limit for cotinine was 7.5 µg/L and 
the between-run coefficient of variation 5–8% (172). 
Figure 27 shows when trial visits occurred and when measurements were 
made. Saliva cotinine concentrations were determined at baseline, 2 weeks 
after quit date and 8 weeks after quit date, with nicotine doses adjusted 
after each of these visits at 4 weeks and 12 weeks after quit date 
respectively. Nicotine doses were adjusted using a conversion factor of 0.1. 
For example, a saliva cotinine concentration of 100 µg/L equated to a 
prescription of one 10mg patch (51).  At baseline, body mass index (BMI), 
gestational age, ethnicity and Fagerström Test for Cigarette Dependence 
(FTCD) scores were recorded. As well as at baseline; at each visit, women 
reported any smoking in the previous week validated by expired air carbon 
monoxide. Additionally, intensity of craving for tobacco via the French 
Tobacco Craving Questionnaire, 12 items (FTCQ-12) and the number of 
cigarettes smoked by the participant in the last week were assessed. The 
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SNIPP trial recorded cigarette consumption in the past week, rather than 
cigarettes per day, due to large day to day fluctuations in cigarette 
consumption (173, 174). Partner smoking in the previous week was also 
assessed, as the second hand smoke exposure is likely to increase cotinine 
measures. Women were permitted to use nicotine patches from quit date 
up until delivery. A more extensive description is available elsewhere (51). 
In this study we used data from women collected at 2-weeks after the quit 
date and who had been allocated nicotine or placebo patches but who 
reported any smoking in the previous week. A second sample of data 
collected at 8-weeks after the quit date from women who had smoked in 
the previous week were used as a sensitivity analysis. Not all women that 
had cotinine measured at 2-weeks returned for the 8-week visit, and 8-
week data also included women who did not return at 2-weeks. We selected 
women from 2-weeks after the quit date rather than 8-weeks after the quit 
date for the main analysis, as this time point was earlier in gestation, and 
so nicotine metabolism changes since the baseline visit would likely be small 




Figure 27 Flow chart to show each planned visit in the ‘Study of Nicotine 
Patch in Pregnancy’ relevant to the current study. 
 
7.4.4 Analyses 
For baseline data, continuous measures were reported as means with 
standard deviations (SD), and categorical measures were reported using 
frequencies and percentages. Participant and partner’s smoking in the 
previous week were divided by seven, to achieve cigarettes smoked per day. 
T-tests were used to assess whether there were any systematic differences 
in baseline characteristics between women who were included and those 
Baseline – cotinine 
measured 
Quit date after 2-week 
period if cigarettes per 
day ≥5 
2 weeks after quit date 
– cotinine measured 
4 weeks after quit date 
– nicotine dose 
adjustment 
8 weeks after quit date 
– cotinine measured 
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excluded from this study. We used a natural log transformation of salivary 
cotinine concentrations to achieve a normal distribution.  
For both nicotine and placebo patch groups we used paired t-tests to assess 
‘within-participant’ differences between cotinine, carbon monoxide, 
cravings, number of cigarettes smoked by the participant, and number of 
cigarettes smoked by their partner, measured at baseline and at 2-weeks. 
The same analyses were conducted using data from 8-weeks. For saliva 
cotinine, we present the back-transformed estimates of treatment 
differences, which is the ratio of the geometric means. Next, we used linear 
regression analysis to test for an interaction between the measures 
mentioned above and nicotine patch assignment. We then performed an 
exploratory analysis to identify whether the interactions were significant at 
increasing increments of baseline values in cotinine, carbon monoxide, 
cravings, number of cigarettes smoked by the participant, and number of 
cigarettes smoked by their partner.  Findings are presented graphically. P-
values less than 0.05 were deemed statistically significant. All analyses were 
conducted using STATA 15. 
After undertaking the planned analyses, we generated a Bayes factor from 
the difference in saliva cotinine, using an online calculator (175). Bayes 
factors enable differentiation between whether there is no evidence of an 
effect, or whether it can be concluded that there is no effect. We were unable 
to identify any studies that investigated nicotine intake of concurrent 
smokers and NRT users in pregnancy, so an expected difference of 139.3 
µg/L was taken from a study of nicotine intake outside of pregnancy (176). 
We used a conservative approach for estimation using a half-normal 





7.5.1 Descriptive statistics 
In the SNIPP trial, 203 women were assigned to the nicotine patch arm and 
199 women were assigned to the placebo patch arm. At 2-weeks after the 
quit-date, 167 (82.3%) and 148 (74.4%) women returned for the visit in 
the nicotine patch and placebo patch arms, respectively. In the nicotine 
patch arm, 149 (73.4%) had smoked in the week prior to the visit and 18 
(8.9%) were abstinent, whereas, in the placebo group 131 (65.8%) had 
smoked in the week prior to the visit and 17 (8.5%) were abstinent. Overall, 
12 women had missing cotinine data at this point and were excluded from 
the study, leaving a sample of 268 for analysis (146 in the nicotine group 
and 122 in the placebo group).  
When comparing SNIPP trial participants excluded from this study with 
those included, it was found that more women in this study had a partner 
that smoked. Table 3 gives baseline characteristics of women in both study 
groups and, using these descriptors, both groups were broadly similar. From 
the participants who provided 2-week data, those assigned nicotine patch 
had a mean age of 30 years and gestational age at baseline of 12.8 weeks; 
therefore, their mean gestational age at 2 weeks post quit date would be 
between 16 and 17 weeks.  
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Table 3 Participant baseline characteristics. n (%) or mean (standard 
deviation)   
  
Characteristic 
Women on Nicotine 
Patch (n=146)  
Women on Placebo 
Patch (n=122) 
Age (years) 29.70 (6.00) 28.88 (5.03) 
BMI (kg/m2) 25.52 (5.40) 25.21 (5.33) 
Gestational age at baseline 
(weeks) 
12.75 (3.24) 12.59 (5.42) 
Ethnicity   
   European 139 (95) 115 (94) 
   African 4 (3) 4 (3) 
   Asian 1 (1) 1 (1) 
   Other 2 (1) 2 (2) 
Current cigarettes smoking per 
day  
 
   5-10 66 (45) 55 (45) 
   11-20 69 (47) 50 (41) 
   21-30 7 (5) 16 (13) 
   >30 4 (3) 1 (1) 
Fagerström Test for Cigarette 
Dependence1  
 
   Very Low 32 (22) 20 (16) 
   Low 34 (23) 42 (34) 
   Medium 29 (20) 18 (15) 
   High 43 (29) 33 (27) 
   Very High 8 (6) 9 (7) 
Partner smoking   
   Yes 99 (69) 90 (75) 
Saliva cotinine (ng/ml) 143.86 (82.81) 144.36 (74.33) 
Expired air carbon monoxide 
(ppm) 11.81 (6.70) 
 
12.22 (7.33) 
French Tobacco Craving 
Questionnaire score 33.64 (8.60) 
 
35.55 (9.53) 
1 FTCD is a 6-item test where answers are summed to yield a total score of 0-10. 
The higher the total score, the more intense is the patient's physical dependence 
on cigarettes. I.e. A score between 0-2 indicates a very low level of dependence on 
cigarettes, and 8-10 indicates a very high-level dependence on cigarettes (23). 
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7.5.2 Comparison of indicators of smoking intensity 
Table 4 compares indicators of smoking intensity between baseline and 2 
weeks after the quit date for pregnant smokers in both the placebo and 
nicotine patch groups. In the nicotine group, there was no significant 
difference between cotinine concentrations (ratio of geometric means = 
0.94ng/ml, 95% CI’s 0.83 to 1.07ng/ml; p=0.37, Bayes Factor=0.15), but 
CO concentrations significantly decreased from baseline to 2-weeks after 
the quit date (mean difference -3.03ppm, 95% CI’s -4.17 to -1.89ppm; 
p<0.001). Whereas the placebo group exhibited a significant reduction in 
cotinine (ratio of geometric means = 0.68ng/ml, 95% CI’s 0.59 to 
0.78ng/ml; p<0.001) as well as a reduction in CO concentration (mean 
difference -2.02ppm, 95% CI’s -3.81 to -0.22ppm, p<0.028). There were 
also significantly lower levels of craving, lower numbers of cigarettes 
smoked in the previous week and women’s partners were reported to have 
smoked fewer cigarettes in both nicotine and placebo patch groups.  
Table 4 also reports results for interaction tests between the indicators of 
smoking intensity and nicotine patch assignment. There was a significant 
interaction between nicotine patch assignment and a reduction in number 
of cigarettes smoked (p=0.046). This means that women assigned nicotine 
patches smoked less at week-2 compared to women assigned placebo 
patches. Interactions between the remaining indicators of smoking intensity 
and nicotine patch assignment were not significant. Upon further exploration 
it was discovered that there was an interaction between nicotine patch 
assignment and women with higher baseline cotinine concentrations 
(Figure 28). Women assigned nicotine patches with baseline saliva cotinine 
concentrations of approximately 90ng/ml and above had higher cotinine 




Figure 28 Graph to show interaction of nicotine patches on cotinine 
concentrations at 2-weeks with increasing baseline cotinine concentrations. 
The shaded area represents the 95% confidence intervals. As the shaded 
area for log cotinine >4.5 is above 0, there is a significant interaction of 
nicotine patches for an increase in cotinine at 2-weeks in women with log 




Table 4 Baseline to 2-weeks after the quit date ‘within-participant’ differences in indicators of smoking intensity in pregnant 
smokers by treatment group, with a significance test for interaction with nicotine patch. 






























(0.83 to 1.07) 
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(0.59 to 0.78) 
<0.001 0.148 
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(-3 to -1) 
0.003 0.168 
Paired t-tests were used to compare differences at baseline and 2-weeks after the quit date. A linear model was used to test for an interaction of nicotine patch 
between baseline and 2-weeks. 
1P-value for the difference between indicators of smoking intensity between baseline and 2-weeks, in the nicotine patch group 
2P-value for the difference between indicators of smoking intensity between baseline and 2-weeks, in the placebo patch group 
3P-value for interaction of nicotine patch with indicators of smoking intensity at baseline compared with at 2-weeks after the quit date 
4FTCQ -12– French Tobacco Craving Questionnaire score 




7.5.3 Sensitivity analysis 
In the sensitivity analysis, the 8-week data showed a similar pattern to the 
2-week data (Table 5). There was no significant difference between cotinine 
concentrations at baseline and 8-weeks in the nicotine patch group (ratio of 
geometric means = 0.85ng/ml, 95% CI’s 0.71 to 1.00ng/ml; p=0.055, 
Bayes Factor=0.12), however there were significant reductions for all other 
indicators of smoking intensity aside from craving score (mean difference = 
-1.69, 95% CI’s -3.58 to 0.20 p=0.079). In women assigned placebo 
patches, there were significant reductions for all indicators of smoking 
intensity aside from expired CO concentration (mean difference -2.38ppm, 
95% CI’s -5.03 to 0.27ppm, p<0.077). The interaction tests found no 
significant interaction for nicotine patch assignment, however graphical 
exploration found that there was a significant interaction for nicotine patch 
assignment and participants that reported smoking between 100-250 
cigarettes a week at baseline (Figure 29); in these women, assignment to 




Table 5 Baseline to 8-weeks after the quit date ‘within-participant’ differences in indicators of smoking intensity in pregnant smokers by 
treatment group, with a significance test for interaction with nicotine patch. 





















Saliva cotinineᶧ            
(ng/ml) 
116.35 98.24 
0.85            
(0.71 to 1.00) 
0.055 118.13 87.11 
0.74 
(0.61 to 0.89) 
0.002 0.874 































































(-3 to 0) 
0.039 0.671 
Paired t-tests were used to compare differences at baseline and 8-weeks after the quit date. A linear model was used to test for an interaction of nicotine patch between 
baseline and 8-weeks. 
1P-value for the difference between indicators of smoking intensity between baseline and 8-weeks, in the nicotine patch group 
2P-value for the difference between indicators of smoking intensity between baseline and 8-weeks, in the placebo patch group 
3P-value for interaction of nicotine patch with indicators of smoking intensity at baseline compared with at 8-weeks after the quit date 
4FTCQ -12– French Tobacco Craving Questionnaire score 




Figure 29 Graph to show interaction of nicotine patches on cigarettes 
smoked at 2-weeks with increasing number of cigarettes smoked at 
baseline. The shaded area represents the 95% confidence intervals. As the 
shaded area for number of cigarettes smoked between 100-250, is below 0, 
there is a significant interaction of nicotine patches for a reduction of 
cigarettes smoked at 8-weeks in women that smoked between 100-250 





7.6.1 Key findings 
Our findings show that, women prescribed nicotine patches but also 
admitted smoking had similar cotinine concentrations to those generated 
when they only smoked. These women also reported smoking less and had 
lower expired air carbon monoxide readings than when they smoked prior 
to their quit attempt. In comparison, smokers issued with placebo patches 
had lower cotinine concentrations than when smoking, they also showed 
reductions in numbers of cigarettes smoked and expired CO concentrations. 
Our results also indicate that women who smoke and use nicotine patches, 
smoke less later in pregnancy.  
7.6.2 Strengths and weaknesses 
A limitation to our study is that, whilst we know that women included in this 
study were prescribed nicotine patches, we have very limited information 
about how much they used these. However, as study measurements at 2- 
and 8-week follow up were taken with the intention of personalising the 
nicotine doses which women received from patches, it seems very likely that 
women who attended these appointments were still using these. 
Furthermore, the SNIPP trial also reports (where adherence data exists) the 
median self-reported adherence rate was 85% (51).   
Another possible limitation concerns the validity of women’s reports of 
smoking or not smoking in the week prior to having 2- and 8-week 
measurements taken. In SNIPP, women were defined as smokers if they 
had reported any smoking in the week prior to a study visit and this was 
validated by an expired CO reading. However, expired air CO can only 
reliably validate smoking status over the previous 6 hours and (177), 
although some women may have over-or under estimated the number of 
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cigarettes smoked in the previous week, we could only accurately quantify 
tobacco smoke exposure in the 6 hours prior to CO measurement.  
Nevertheless, this could only have had a major impact on findings if women 
generally under-reported their smoking in the week prior to follow up 
appointments and, in the 6 hours before follow-up appointments tried to 
smoke less than they had reported they were doing. It seems unlikely that 
trial participants would do this before attending a nicotine patch dose-
titration appointment.    
A strength of this study is that the data were obtained as part of a well-
conducted randomized controlled trial and included reported smoking 
behaviour with concurrent CO and cotinine estimation at several time points. 
To the authors’ knowledge, there has been no previous study that has 
investigated smoking behaviour and CO exposure from concurrent use of 
nicotine patches and smoking in pregnancy. Hence, we believe it makes an 
original contribution to the field. Another strength is that comparisons are 
based on ‘within-participant’ measurements; this means that inter-
participant variations are very unlikely to explain study findings.  Indeed, 
with this study design one would only expect findings to be affected by 
characteristics of women which were prone to change between baseline and 
follow up. Women’s nicotine metabolic rates (NMR) increase as pregnancy 
progresses and these would be expected to affect their plasma nicotine 
concentrations and so potentially their cravings and intensity of smoking too 
(64, 69).  However, any effect would seem to be marginal as, even in the 
placebo group, women reported smoking fewer cigarettes. Also, as 
pregnancy-related NMR (nicotine metabolic ratio) acceleration is generally 
complete by the end of the first trimester and women’s mean gestation at 
baseline was ~ 13 weeks, there may have been little scope for this factor 
to have any influence.  It seems likely, therefore that differences reported 
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reflect differences in smoking behaviour and not changes in women’s 
physiology during pregnancy. 
7.6.3 Discussion in context of previous literature 
Our study informs about cotinine concentrations in pregnant women who 
use nicotine patches but are not abstinent from smoking. Our findings show 
that cotinine concentrations in such women were no higher than when they 
were smoking. Additionally, women included in this study had simultaneous 
and statistically significant reductions in their cigarette use, validated by a 
reduction in expired carbon monoxide. This suggests that when pregnant 
women use nicotine patches and smoke, they smoke less than they would 
without if they were not using nicotine patches. This is important, as it could 
influence how women are advised to use NRT in pregnancy, i.e. encouraged 
to continue using NRT despite a relapse.  
We are unaware of any previous studies measuring cotinine or CO in 
smokers who concurrently use NRT during pregnancy. A systematic review 
and meta-analysis that aimed to identify and describe studies which report 
nicotine or cotinine concentrations in pregnant women when smoking and 
subsequently when abstinent from smoking and using NRT, concluded that 
amongst pregnant women who quit smoking, standard-dose NRT generates 
lower nicotine exposure than smoking (161). The meta-analysis compared 
cotinine exposures when pregnant women smoke with those when they use 
NRT and found that concentrations were on average 75.3 ng/ml lower when 
abstinent and using NRT than when the same women smoked (161). In 
SNIPP, salivary cotinine concentrations at baseline (when smoking) were 
compared to cotinine concentrations at 1 month in women that had stopped 
smoking but were using nicotine patches. Cotinine concentrations were 
98.5ng/ml while smoking, but only 62.8ng/ml while using nicotine patches 
(51). In our study we found that women that were assigned the placebo 
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patch but also admitted to smoking, also exhibited reduced cotinine 
concentrations compared to those when smoking alone. 
Most studies in the above review, used lower nicotine doses than were used 
by participants in this manuscripts’ analyses; other than SNIPP, studies used 
standard rather than higher doses of nicotine and these delivered no more 
than 15mg cotinine in 16 hours or the 24-hour equivalent (161). Thus, when 
pregnant smokers become abstinent and adhere with such ‘standard’ doses 
of NRT, they are on average exposed to less nicotine than from smoking 
(161). In SNIPP, patch doses were adjusted according to the previous saliva 
cotinine determination to optimize the nicotine substitution leading to 
somewhat higher mean nicotine doses than usual (18 mg/day, SD=6.8). It 
is expected that the dose adjustment would improve nicotine substitution, 
thus it is possible that women assigned nicotine patches in the 8-week 
sample would have higher cotinine concentrations than they did at baseline. 
Despite this adjustment, there was no significant difference in cotinine 
concentrations in women that were assigned nicotine patches and admitted 
to smoking to those when smoking alone. This also suggests that smoking 
and using nicotine patches of ‘standard’ doses, may lead to lower cotinine 
concentrations during pregnancy than smoking alone, prior to pregnancy. 
Our findings provide the first data we are aware of which quantifies pregnant 
women’s smoking behaviour when using nicotine patches and this suggests 
that when pregnant women use nicotine patches as part of a quit attempt, 
but they also smoke, they smoke less than they did before the quit attempt 
started. This means that their exposure to the toxic products of burnt 
tobacco is reduced. A possible reason for this is that women who continue 
to smoke when using nicotine patches obtain nicotine from both patches 
and tobacco and nicotine delivered from patches reduces women’s cravings 
such that they feel less need to ‘top up’ concentrations of nicotine in their 
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body fluids through smoking. This suggests that clinicians can reassure 
women that it is ok to smoke and use nicotine patches if, ultimately, they 
are trying for abstinence. 
7.6.4 Conclusions 
In conclusion, despite having similar cotinine exposure to that from 
cigarette smoking, pregnant women who use nicotine patches and smoke, 
smoke less and exhale less CO, so their exposure to other tobacco smoke 
toxins is likely to be lower too. 
162 
 





The overall aim is to raise hypotheses regarding ways in which NRT use in 
pregnancy might be changed such that it has greater potential to be 
effective. This aim was achieved through investigating the efficacy, safety 
and impacts on smoking intensity of Nicotine Replacement Therapy used for 
smoking cessation in pregnancy, and was facilitated by the use of TSA.  
This chapter summarises results from this thesis in context to each of the 
objectives detailed in Chapter 2. This chapter also describes how the 
results have been disseminated, their potential implications for policy and 
practice, and provides suggestions for possibilities of future research that 
could be undertaken relating to the use of NRT for smoking cessation in 
pregnancy. Re-prints of published papers from this thesis are included in 
Appendix B, and a full list of courses attended, training, and publications 
produced from and during the writing of this thesis are detailed in Appendix 
C.  
8.2  Summary of thesis findings 
8.2.1 Objective I: To use conventional systematic review and meta-
analysis to determine the efficacy and safety of NRT used during 
pregnancy for smoking cessation in later pregnancy and after 
childbirth.  
A systematic review with meta-analysis was conducted to assess the 
efficacy and safety of NRT for smoking cessation in pregnancy. There was 
low certainty evidence that NRT used alongside usual care may increase 
smoking abstinence in later pregnancy. However, subgroup analysis of the 
more robust placebo-controlled trials suggest that there may not be an 
effect of NRT on smoking abstinence. Evidence was inconsistent regarding 
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the evidence of NRT having either a positive or negative impact on birth 
outcomes.  
This systematic review was conducted as part of a broader Cochrane review 
assessing the efficacy of pharmacological interventions, including 
bupropion, for smoking cessation in pregnancy. This review has been 
published and is available from the Cochrane Library (178). The results of 
this review have been discussed at the NICE Public Health Advisory 
Committee tobacco meeting for preventing uptake, promoting quitting and 
treating dependence. The purpose of this meeting was to utilise findings 
from the review to update the current NICE guidelines for stopping smoking 
in pregnancy. 
8.2.2 Objective II: To describe the limitations of meta-analysis and 
demonstrate how trial sequential analysis methodology can be used 
to supplement the findings of meta-analysis. 
This thesis provides an overview of how TSA can be used alongside meta-
analysis to assess whether there is sufficient evidence to conclude a 
clinically important treatment effect, no evidence of an effect, or absence of 
evidence. Using example outputs from TSA, this thesis demonstrates how 
TSA can be interpreted, and how they are affected when new studies are 
included. As a worked example, TSA is then applied to a systematic review 
of NRT for smoking cessation in pregnancy (Objective III).  
Whilst TSA methodology and software has been described in depth 
previously (93), and the methodology has been utilised increasingly in 
recent years (179, 180), this thesis attempts to explain TSA in a way that 
is accessible to a broader range of researchers. 
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8.2.3 Objective III: To determine whether there is sufficient 
information in the meta-analyses presented for objective I above 
regarding the efficacy and safety of NRT for smoking cessation in 
later pregnancy. 
Using the meta-analyses conducted in the systematic review for Objective 
I, TSA was applied to the primary outcomes of biochemically validated 
smoking cessation at the latest point in pregnancy; mean birthweight; and 
miscarriage and spontaneous abortion. TSA methods were able to ascertain 
whether there was sufficient information in the meta-analyses regarding the 
efficacy and safety of NRT for smoking cessation in later pregnancy. 
According to TSA, over 8,000 participants to placebo-controlled trials may 
be needed in order to arrive at a firm conclusion regarding the efficacy of 
NRT for smoking cessation in pregnancy. Additionally, an excess of 9,000 
and 30,000 participants respectively would be needed for a strong 
conclusion surrounding the positive or negative impact of NRT on mean 
birthweight; and miscarriage and spontaneous abortion. 
8.2.4 Objective IV: To demonstrate how trial sequential analysis can 
alternatively be utilised to calculate trial sample size, using results 
from feasibility and pilot studies. 
Using data from feasibility and pilot RCT’s testing MiQuit, a text message-
based smoking cessation intervention for pregnant women, TSA was used 
to estimate the sample size of future RCTs for a more conclusive decision 
regarding intervention benefit. The TSA estimated sample size required just 
over half the participants than that calculated by the traditional sample size 
calculation methodology.  
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Prior to this study, no paper has described utilising TSA in this way. This 
relatively simple use of feasibility and pilot trial data with TSA, could save 
researchers significant resources, thus leading to more efficient utilisation 
of funds. A paper describing this methodology has been submitted to BMC 
Medical Research Methodology. This paper has been peer reviewed and a 
response alongside amendments has been submitted, and I now await a 
decision. A pre-print of this paper is available on Research Square (119). 
8.2.5 Objective V: To use the SNIPP trial to investigate the 
differences in indicators of smoking intensity in pregnant women 
when smoking before using NRT, and when using NRT and smoking 
concurrently. 
Using a cohort of participants from the SNIPP trial, within-participant 
differences in indicators of smoking intensity were compared in women who 
both smoked and used nicotine or placebo patches. Women who both 
smoked and used nicotine patches concurrently had similar cotinine 
concentrations as those when they were only smoking. These women also 
reported smoking fewer cigarettes when using nicotine patches, ultimately 
reducing their exposure to toxins in tobacco smoke. 
Prior to this research, no other studies had measured pregnant women’s 
smoking behaviour when using nicotine patches as part of a quit attempt. 
This is mainly because in practice, pregnant women are usually advised to 
stop using NRT if they relapse to smoking. The SNIPP trial was different, as 
it allowed women to continue using NRT despite relapse. This research was 
shared through publication in Addiction Journal (162). 
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8.3 Policy and practice implications 
The most recent UK guidelines and recommendations for stopping smoking 
in pregnancy and in the first year of childbirth were published in 2010 (181). 
These guidelines were reviewed in 2015, and are currently being updated. 
Research from this thesis adds to the current knowledge on smoking in 
pregnancy, and will inform the next update of guidelines. 
The current recommendations surrounding the use of NRT for smoking 
cessation during pregnancy are based on ‘mixed evidence on the 
effectiveness of NRT in helping women to stop smoking during pregnancy’ 
(181). The evidence from the systematic review performed in Chapter 5 
suggests that NRT may be effective for smoking cessation in pregnancy, 
however there is uncertainty surrounding this evidence. It is also unclear 
whether NRT affects the risk of adverse pregnancy and infant outcomes, but 
there is no evidence that it is harmful. One study suggests that NRT 
improves child development outcomes at two years (156). Nevertheless, 
the 2010 guidelines state that NHS Stop Smoking Services should only 
suggest using NRT if smoking cessation attempted without this first (181). 
Findings from the systematic review, conducted as part of a comprehensive 
Cochrane Review, are to be used in the latest update of NICE guidelines. In 
late 2019, I was invited and attended the NICE Public Health Advisory 
Committee tobacco meeting for preventing uptake, promoting quitting and 
treating dependence. Here, the Cochrane review was discussed in detail in 
the context of updating the guidelines. 
Current NICE guidelines state that women should only be prescribed NRT 
once they have stopped smoking, and should only be prescribed two weeks 
of NRT from an agreed quit-date (181). Furthermore, subsequent 
prescriptions of NRT should only be provided when women have 
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demonstrated that they are still abstinent (181). This cautious approach to 
prescribing NRT is to prevent a possible increase of nicotine intake, in case 
women continue to smoke whilst using NRT. Findings from Chapter 7 
provide evidence to suggest that women who smoke and use NRT 
concurrently do not have higher nicotine concentrations compared to when 
they are only smoking. These women also smoked fewer cigarettes. These 
findings could allay some fears regarding higher nicotine concentrations with 
continued use of NRT despite relapse, and suggest that policy could be 
adapted such that, as long as women continue trying to stop smoking, if 
they have a brief relapse to smoking, they should continue using NRT.  
This thesis has provided some potential recommendations for updates of 
policy and practice for the use of NRT for smoking cessation in pregnancy 
however, further research is also required. Possibilities for future research 
are detailed in the following section. 
8.4 Possibilities for further research 
TSA appears to be growing in popularity and there is a developing 
knowledge base of NRT use during pregnancy. The research summarised in 
Section 8.2 adds to the current understanding on this subject. However, 
this thesis has opened up potential avenues for future research and these 
are explored in the following section.  
In Chapter 5 a systematic review was performed to determine the efficacy 
and safety of NRT used during pregnancy for smoking cessation in 
pregnancy. Although overall evidence pointed towards a positive effect of 
NRT on smoking abstinence in pregnancy, a subgroup of low-bias trials 
suggests the effect is smaller or that there may be no effect at all. These 
findings coupled with results from the TSA in Chapter 6, suggest that 
further placebo-controlled trials are needed, for greater certainty regarding 
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the efficacy and safety of NRT for smoking cessation in pregnancy. The TSA 
performed in Chapter 6 recommended that a further 8,500 participants 
would need to be recruited in placebo-controlled trials. This would require 
substantial time and resources, and may not be practical over a short period 
of time.  
Instead, focus could be spent understanding why NRT apparently works less 
well in pregnancy than it does in the general population. For example, the 
systematic review in Chapter 5 found that patch adherence was low. Future 
research should seek to understand why this is and improve it and use an 
appropriate behavioural strategy to enhance adherence in future trials of 
NRT. Additionally, the majority of studies in the systematic review in 
Chapter 5 used 15mg nicotine patches, whereas in the general population 
there is evidence that 25 mg/16-hour patches are more effective than 15 
mg/16-hour patches (164). Consequently, trials are needed in pregnant 
women using either higher-dose nicotine patches or combination of patch 
plus rapid-acting forms of NRT, which are also more effective (164). As of 
yet, there are no complete trials of electronic cigarettes in pregnancy. In a 
non-pregnant population, a recent living systematic review found that 
electronic cigarettes are not only effective for quitting smoking, but they are 
more effective than NRT (46). There is currently one ongoing trial of 
electronic cigarettes for smoking cessation in pregnancy, however further 
research should be conducted.  
With regards to safety, Chapter 5 found no consistent evidence of NRT 
having either a positive or adverse impact on birth outcomes. Coupled with 
the TSA performed in Chapter 6, nearly 10,000 participants would need to 
be recruited for greater certainty over the effects of NRT on mean 
birthweight, and in excess of 30,000 participants would need to be recruited 
for greater certainty over the effects of NRT on miscarriage and spontaneous 
170 
 
abortion. As detailed above, recruiting this number of participants is highly 
unlikely, thus alternative methodology may be required. A possible way to 
investigate this further, would be to perform an individual patient data 
meta-analysis, by combining participants with reported NRT use and 
outcome data from all NRT trials in pregnancy.  
The study in Chapter 7 provides data quantifying concurrent smoking and 
NRT use during pregnancy and as it is the first study of its kind in pregnancy, 
the findings are important. However, this study was limited by insufficient 
data regarding adherence to patches. Future trials should aim to collect 
comprehensive adherence data; where possible, this will facilitate a more 
accurate analysis to see whether greater adherence to NRT leads to fewer 
cigarettes smoked.  
In previous studies investigating the efficacy and safety of NRT during 
pregnancy, women were told not to use NRT if they had relapsed to 
smoking. Findings from the study in Chapter 7 suggest that in future trials 
of NRT in pregnancy, women should be encouraged to continue using NRT 
despite relapse if their ultimate goal is still abstinence. Indeed, safety is of 
paramount importance and so if a decline in cigarette consumption is not 
observed, prescription of NRT should be reviewed in those individual cases. 
The latest RCT of nicotine inhaler in pregnancy advised participants to 
continue the use of the inhaler as long as they were actively trying to quit 
smoking. Although the inhaler group did not have a higher quit rate than 
the placebo group, they did have significantly decreased risks of delivering 
a preterm or a low birth weight infant (151). Data permitting, a secondary 
analysis of this trial similar to that conducted in Chapter 7 could help 
corroborate the findings. 
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In Chapter 4, an alternate use for TSA, to estimate the sample size(s) for 
future trial(s) based on pilot and feasibility trial data, is presented. This 
method could be utilised in the future in trials of NRT in pregnancy. Running 
large scale trials is expensive and resource intensive. Where funding is 
highly competitive or limited, it may be beneficial to use TSA to estimate an 
alternative sample size. For example, if feasibility and pilot studies 
investigating a combination of nicotine patch and fast-acting forms of NRT 
in pregnancy are successful, using TSA to estimate the sample size for a 
more definitive trial could save on costs, which could be more attractive to 
potential funders. If the resulting definitive trial is unsuccessful, recruiting 
fewer participants means that excess resources were not wasted on a much 
larger trial if a traditional sample size calculation was performed. 
Chapter 3 describes the more traditional use of TSA, and as mentioned 
above, Chapter 6 applies TSA to the meta-analysis in Chapter 5. The more 
traditional use of TSA has grown in popularity in recent years and has been 
used in a number of systematic reviews (179, 180, 182), including smoking 
cessation reviews (183, 184). Despite the limitations of TSA, discussed in 
Section 3.5.5, as long as it is used appropriately, i.e. planned prospectively 
with the assumptions underlying the design well planned and justified, then 
TSA should continue to be used to provide additional context to a meta-
analysis.  
8.5 Overall conclusions 
This thesis has demonstrated two possible uses of TSA in the context of 
smoking cessation in pregnancy, and has also provided evidence to illustrate 
some ways in which the use of NRT in pregnancy might be changed, such 
that it has greater potential to be found effective, as it is in non-pregnant 
smokers. NRT used for smoking cessation in pregnancy may increase 
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smoking cessation rates in late pregnancy. According to TSA, there is 
uncertainty regarding the efficacy of NRT use for smoking cessation during 
pregnancy compared to control, and further placebo-controlled trials are 
needed to arrive at a firm conclusion. Although TSA suggests more research 
is required for a firm conclusion, the general trend appears that NRT as it 
has previously been trialled, may not be effective for smoking cessation in 
pregnant women. Further trials should focus on what can be done differently 
in future. Following successful feasibility and pilot trials, these future trials 
could make use of TSA for sample size estimation, to reduce costs and 
resources required. When pregnant women use nicotine patches as part of 
a quit attempt, but they also smoke, they smoke less than they did before 
the quit attempt started. This means that their exposure to the toxic 
products of burnt tobacco is reduced. Despite having similar cotinine 
exposure to that from cigarette smoking, pregnant women who use nicotine 
patches and smoke, smoke less and exhale less CO, so their exposure to 
other tobacco smoke toxins is likely to be lower too. Overall this thesis 
should encourage further investigation of new techniques to trial NRT in 
pregnant women, and reassure policy makers to encourage NRT use despite 
relapse. 
8.6 Personal development and development of research 
skills 
Throughout the duration of this PhD I have improved and developed my 
research skills, and I have learned a number of new methods and techniques 
that will benefit me in the future as an independent researcher. Attending 
the ‘Joanna Briggs Institute (JBI) Comprehensive Systematic Review 
Training Program’, further increased my ability and efficiency to locate 
journal articles and other relevant resources to include throughout the 
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thesis. The JBI program, alongside the two Master’s in Public Health (MPH) 
statistics modules I undertook, gave me a solid foundation for much of the 
statistical analysis performed in the thesis. The analysis in Chapter 7 was 
performed using STATA, and involved performing t-tests and regression 
analysis – which these modules were particularly useful for. Furthermore, 
lectures and practical sessions on meta-analysis and forest-plots in both the 
MPH modules and the JBI program, provided me the basis to better 
understand trial sequential analysis methodology. A large part of this thesis 
discusses and utilises TSA methodology and software, which was an entirely 
new concept to me prior to this PhD. I was able to develop a thorough 
understanding of TSA through independent research of literature, with 
support from my PhD supervisors and external collaboration.  
During the second year of my PhD I spent 6 months in Paris, France on a 
placement to work alongside my supervisor, Ivan Berlin. This enabled me 
to experience a research environment outside of the UK. Through this 
experience I was able to twice present my TSA work to a French audience 
that had not previously heard of TSA. Through dissemination of my research 
via poster and oral presentations at both national and international 
conferences, as well as writing papers as a first author (Appendix C), I 
have been able to develop my capability as an independent researcher. 
Additionally, during the fourth year of my PhD, I have been working as a 
Research Assistant on a National Institute for Health Research - School for 
Primary Care Research (NIHR SPCR) funded programme investigating infant 
and child primary and secondary health care costs associated with mode of 
childbirth and prematurity. As part of this project I have developed an 
understanding for costing of primary and secondary healthcare episodes. 
This project has also exposed me to the use and management of large 
datasets through Clinical Practice Research Datalink (CPRD) data. Finally, 
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as lead applicant, I was able to secure NIHR SPCR funding for a systematic 
review comparing nicotine concentrations generated by concurrent smoking 
and nicotine replacement therapy. This successful application has given me 
experience in writing grant applications, which will benefit me greatly for a 
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Methods Double-blind, placebo-controlled, parallel-group RCT 
Participants 476 pregnant women aged ≥ 18 years, between 9 and 20 weeks' gestation who smoked at least 5 
daily cigarettes and scored at least 5 on a scale measuring motivation for quitting smoking (range 0 
to 10) 
Interventions Intervention and control differed only in the provision of active or visually identical placebo 
transdermal patches. The intervention patch delivered nicotine as nicotine replacement therapy over 
a 16-hour period. Both 10 mg and 15 mg patches were used, and women's doses ranged from 10 
mg to 30 mg per day. A saliva sample was collected at the woman's first trial visit/contact with the 
research team. Between this and a second visit/contact, which occurred 2 weeks later, women were 
instructed to either stop smoking or to reduce this to less than 5 daily cigarettes. Women who 
managed to reduce or stop smoking in this way were, at their second visit, randomised to either 
placebo or active patch in a 1:1 ratio. The nicotine dose used for women's first prescription of NRT 
(made at this 2nd trial visit) was based on their saliva cotinine level obtained from the sample given 
at visit 1 with the aim being to attempt 100% substitution of nicotine obtained from smoking for that 
obtained via patches. 
Women were instructed to use NRT from their quit date until delivery. Smoking and using patches 
was not encouraged (this is described as a "safety concern"). However, if women did have a 
temporary lapse to smoking, they were allowed to remain on NRT afterwards. Both groups received 
counselling on how to use patches. 
Outcomes There were 2 primary outcomes, 1 maternal and 1 relating to infants: complete, continuous 
abstinence from smoking since the quit date and infant birthweight. A positive abstinence outcome 
was recorded where women self-reported 7 days abstinence from smoking at each study visit, and 
this was confirmed by an exhaled CO reading of 8 ppm or less. There were up to 7 study visits with 
the final visit intended for 1 month prior to delivery; no lapses to smoking were permitted. 
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Notes The cessation outcome used was more stringent than in many studies; often some allowance for 
temporary lapses to smoking is permitted, and many studies assess smoking status as a smaller 
number of time points in pregnancy. 
Dates of study: October 2007 to January 2013 
Funding sources: "This study was funded by the Ministry of Health, France (grant No MA05 00150) 
and co-sponsored by Assistance publique-Hôpitaux de Paris (P060604).The Ministry of Health and 
Assistance publique-Hôpitaux de Paris had no role in the design and conduct of the study; the 
collection, conduct, analysis, and interpretation of the data; or the preparation, review, or approval 
of the manuscript." Gunnar Gustavsson and McNeil-Johnson & Johnson provided the nicotine and 
placebo patches free of charge. 
Declarations of interest: "All authors have completed the ICMJE uniform disclosure form at 
www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare 
that: none had support of any kind for the submitted work; IB has served as a paid consultant for 
Pfizer, Novartis, and Ethypharm in the past three years; none of the authors’ spouses, partners, or 
children has financial relationships that may be relevant to the submitted work; and none of the 







Methods Double-blind, placebo-controlled RCT – stratified by trial centre only 
Participants Pregnant women (n = 1050) who agreed to set a quit date, were 16 to 50 years of age, were at 12 
to 24 weeks of gestation, smoked 10 or more cigarettes daily before pregnancy, currently smoked 5 
or more cigarettes daily, and had an exhaled CO concentration of at least 8 ppm 
Interventions Intervention and control conditions differed only in the provision of transdermal patches; the 
intervention group received active patches and the control group received placebo patches. Research 
midwives were trained to provide behavioural support according to national standards, with the use 
of a manual that included guidance from a British expert trainer of smoking-cessation professionals 
and behavioural approaches from the Smoking Cessation or Reduction in Pregnancy Treatment trials 
that were believed to be relevant to British people who smoke. At enrolment, research midwives 
provided behavioural support lasting up to 1 h, and participants agreed to a quit date within the 
following 2 weeks; follow-up was timed from the quit date. Subsequently, participants were randomly 
assigned to receive a 4-week supply of transdermal patches for NRT (at a dose of 15 mg per 16 h) 
or visually identical placebos, which were started on the quit date (all study treatment was purchased 
at market rates from United Pharmaceuticals). 1 month after the quit date, women who were not 
smoking, as validated by an exhaled CO concentration of less than 8 ppm, were issued another 4-
week supply of patches.  
In addition to behavioural support at enrolment, research midwives provided 3 sessions of 
behavioural support by telephone to participants: 1 session on the quit date, 1 session 3 days 
afterward, and 1 session at 4 weeks. The women who collected a 2nd month’s supply of nicotine-
replacement or placebo patches also received face-to-face support from the research midwife at the 
time of collection. Women were offered additional support from local National Health Service smoking 
cessation services and were encouraged to ask for support from the research midwives or smoking 
cessation service staff; support was provided according to the manual. 
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Outcomes Prolonged smoking cessation between a quit date soon after enrolment and delivery, validated by 
both exhaled CO monitoring and saliva cotinine estimation. Cut points: exhaled CO, smoking was 
defined as > 7 ppm; saliva cotinine, smoking defined as > 9 ng/dL. Birth outcomes including Apgar 
score at 5 min after birth, cord arterial blood pH, intraventricular haemorrhage, neonatal convulsions, 
congenital abnormalities, necrotising enterocolitis, mechanical ventilation of infant, assisted vaginal 
delivery, maternal death, and caesarean section. 
For infants: survival to 2 years of age without developmental impairment, reported respiratory 
symptoms. Maternal: self-reported abstinence from smoking for at least 7 days reported at 6, 12, 
and 24 months after childbirth, prolonged abstinence from smoking since a quit date set in pregnancy 
and until 24-month follow-up (defined as having validate abstinence at delivery followed by reported 
abstinence at all outcome points listed above). 
Notes Dates of study: May 2007 to February 2010 
Funding sources: "Supported by a grant from the NIHR Health Technology Assessment Programme 
(06/07/01)" 






Methods Non-placebo, parallel-design RCT 
Participants 52 English-speaking pregnant women who smoked and were residents of Washington, DC in the 
USA, of ethnic minority backgrounds, aged at least 18 years, and less than 30 weeks' gestation. 
Women needed to express a desire to quit and have an expired-air CO reading of 8 ppm or less and 
a salivary cotinine of 20 ng/mL or less (NB: ClinicalTrials.gov website says 30 ng/mL or less) or a 
urinary cotinine of 100 ng/mL or less. 
Interventions 1:1 ratio randomisation, stratified by site and initial salivary cotinine levels to either 1) cognitive 
behavioural therapy (CBT) and NRT transdermal patches or 2) CBT alone. 
NRT: a 10-week course of 24-hour patches was offered, with initial dosing varying with baseline 
salivary cotinine measurements. Women with levels of ≥ 100 ng/mL were issued 21 mg patches for 
2 weeks, 14 mg patches for 4 weeks, and finally 7 mg patches for 4 weeks. Women with levels of ≥ 
20 ng/mL and ≤ 100 ng/mL were issued 14 mg patches for 6 weeks and 7 mg patches for 4 weeks. 
The first batch of patches was issued at the 2nd study visit at which salivary cotinine levels were 
available. 
Participants were given clear verbal and written instructions on patch use. They were advised never 
to smoke whilst using the patch, to remove the patch before going to sleep, and not to use other 
NRT concurrently. 
CBT: this was the same for both groups. 
Outcomes Smoking cessation outcome: during the study participants made 6 visits to the study team in the 
antenatal period. At visit 2 (V2), trial interventions were initiated, and at each of visits V3 to V6 (the 
last before childbirth), women were asked if they had smoked since their previous clinic visit (e.g. 
at V3, they were asked if they had smoked since V2). Participants who reported smoking cessation 
had this validated using exhaled CO, with abstinence viewed as confirmed by a reading of < 8 ppm. 
The trial manuscript reports point prevalence of abstinence from smoking at each time point, and 
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data from V6 are used in analyses. All data were validated (self-report not available), but the period 
of abstinence that was validated is unclear and varied with the interval between clinic visits. 
Secondary outcomes reported in the trial manuscript: premature birth (i.e. at < 37 weeks' 
gestation); gestational age at birth; mean birthweight and low birthweight < 2500 g. 
The following outcomes were also collected, as clarified by the authors: ability to not smoke for 24 
h or more; longest number of days that the woman was able to go without even a puff of smoking; 
frequency of smoking at least puff during the last 7 days; number of cigarettes smoked each day; 
number of cigarettes smoked during the past 24 h; and frequency of use of other forms of tobacco. 
Notes Title of paper states that it was conducted in "African-American smokers", but in manuscript 
participants are described as "ethnic minority women", and inclusion criteria on ClinicalTrials.gov 
includes Hispanic women. 
Dates of study: July 2006 to May 2010 
Funding sources: "This study was supported by the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development (U10 HD036104 and U18 HD031206-07). This research was 
supported, in part, by the intramural program of the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development." 






Methods Non-placebo, parallel-design RCT 
Participants 40 healthy Australian women between 12 and 28 weeks' pregnant and smoking >= 15 cigarettes 
daily with an exhaled breath CO reading of > 8 ppm 
Interventions Control group: 5-minute counselling at baseline and further brief counselling (< 2 minutes' 
duration) at follow-up visits. 
Intervention: counselling as above plus an element concerning correct use of NRT plus 15 mg/16-
hour patches for a maximum of 12 weeks. 
Outcomes Smoking cessation (point prevalence) at final antenatal visit. 
Women seen "at least monthly during gestation"; also seen within 48 h of delivery when exhaled CO 
and saliva sample (for cotinine) taken and by telephone at 6 weeks and 3 months. 
Notes Exhaled CO readings used to validate point prevalence cessation at final antenatal visit. Cut point = 
8 ppm CO.  Author clarification used to obtain this information as not clear in research report. No 
data on smoking outcomes after childbirth are reported in the manuscript. 
Dates of study: not reported 
Funding sources: "This pilot study was supported by the Health Promotion Branch of the (then) South 
Australian Health Commission, now the Department of Health (SA). The WCH Perinatal Pathology 
Fund funded cotinine tests, performed using a competitive micro-plate immuno-assay (COTININE 
MICRO-PLATE EIA)." 






Methods Parallel-design RCT with active and placebo patches and clinicians/researchers and participants 
unaware of allocation 
Participants 30 healthy Canadian women between 12 and 24 weeks' pregnant and smoking >= 15 cigarettes 
daily who want to quit smoking and could not do so in 1st trimester 
Interventions 12-week course of NRT or identical placebo patches: 15 mg/18-hour patch for 8 weeks, then 10 
mg/18-hour patch for 2 weeks, and finally 5 mg/18-hour patch for 2 weeks. Behavioural counselling 
at baseline and at all follow-up points. Counselling at baseline included a video explaining how to 
use patch; also counselling at all follow-ups. Weekly telephone contact with women. 
Intervention = active patch, control = placebo 
Outcomes Smoking cessation (unclear if point prevalence or continuous cessation measured) 8 weeks into 
programme (20 to 32 weeks into pregnancy). 
Follow-up also at weeks 1 and 4 into programme with saliva and serum cotinine measured at all time 
points. 
Notes Primary outcome validated at 8 weeks into programme. Cotinine cut point not reported, but paper 
states that "in no case was smoking cessation associate with thiocyanate levels of > 1 ug/ml". 
Dates of study: not reported 
Funding sources: "This study was supported by a grant from the Canadian lnstitutes of Health 
Research (CIHR)." 






Methods Parallel-design RCT with active and placebo NRT gum and clinicians/researchers and participants 
unaware of allocation 
Participants 194 healthy, US English-/Spanish-speaking women <= 26 weeks' pregnant, smoking >= 1 cigarette 
daily and aged >= 16 years 
Interventions 12 weeks treatment with either 2 mg NRT gum or identical placebo. 6 weeks full treatment was 
followed by 6 weeks tapering of treatment. Instructed not to chew > 20 pieces daily and to use 1 
piece of gum for each substituted cigarette. Additionally, all participants received individual 
counselling at baseline and at all 8 follow-ups: 2, 35-minute counselling sessions at baseline and 
within 1 week of quit date and shorter sessions at other follow-ups. 
Intervention = active gum, control = placebo 
Outcomes Self-reported 7-day point prevalence abstinence at 6 weeks after treatment commenced, at 32 to 
35 weeks of pregnancy, and at 6 to 12 weeks after delivery. Exhaled CO of less than 8 ppm used for 
validation all time points. 
Notes Dates of study: July 2003 to April 2007 
Funding sources: "Supported by NIH grants R01 DA15167, GCRC grant M01 RR006192, P50 
DA013334, P50 AA015632. Nicotine Gum was provided free of charge from Glaxo-Smith Kline." 
Declarations of interest: "Dr. Oncken has received consulting fees and honoraria from Pfizer (New 
York, NY) for advisory board meetings. She has received at no cost nicotine and/or placebo products 
from Glaxo-SmithKline (Philadelphia, PA) for smoking cessation studies (i.e., for pregnant women, 
postmenopausal women). She has received grant funding from Pfizer for smoking cessation studies 
and from Nabi Biopharmaceuticals (Boca Raton, FL) for a nicotine vaccine study. Dr. Kranzler has 
received consulting fees from Ortho-McNeil Pharmaceuticals (Raritan, NJ), H. Lundbeck A/S 
(Copenhagen, Denmark), Forest Pharmaceuticals (St. Louis, MO), elbion NV (Leuven, Belgium), 
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Sanofi-Aventis (Bridgewater, NJ), Solvay Pharmaceuticals (Bruxelles, Belgium), and Alkermes, Inc. 
(Cambridge, MA). He has received research support from Ortho-McNeil Pharmaceuticals and Bristol-
Myers Squibb Company (New York, NY), and honoraria from Forest Pharmaceuticals and Alkermes, 






Methods Parallel-design RCT with active and placebo NRT inhaler and clinicians/researchers and participants 
unaware of allocation 
Participants 137 healthy US English-/Spanish-speaking women smoking at least 5 cigarettes per day, 13 to 26 
weeks’ gestation, ≥ 16 years of age, intending to carry their pregnancy to term, and living in a stable 
residence 
Interventions 6 weeks' treatment using NICOTROL inhaler (nicotine inhalation system) delivering 4 mg of nicotine 
from a porous plug containing 10 mg nicotine. Participants were encouraged to continue the use of 
the inhaler as long as they were actively trying to quit smoking. Participants instructed to puff on 
the inhaler 3 to 4 times per minute for up to 20 minutes and to inhale deeply in short breaths as 
they would normally smoke a cigarette. Participants who smoked ≥ 10 CPD were instructed to begin 
with 4 to 12 cartridge inhalers per day; women who smoked 5 to 9 CPD were instructed to begin 
with 1 to 4 cartridge inhalers per day, based on an estimated 1 to 2 mg of nicotine delivery per 
cigarette, with each cartridge inhaler estimated to release 4 mg of nicotine. At baseline and 1 week 
after quit date, participants received 35 minutes of individual smoking cessation counselling by a 
study nurse trained to deliver the counselling using a motivational interviewing approach. 
Intervention = nicotine inhaler, control = placebo 
Outcomes Self-reported 7-day point prevalence abstinence at 6 weeks after quit date, at 32 to 36 weeks of 
pregnancy, and at 1 and 6 months after delivery. Exhaled CO of less than 4 ppm used for validation 
at all time-points. 
Notes Study planned to recruit 360 women, but the trial was stopped after a recommendation from the 
Data and Safety Monitoring Board due to futility in detecting differences in the primary outcome. 
Dates of study: August 2012 to January 2017 
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Funding sources: "This study was supported by National Institutes of Health (NIH) of United States 
grant R01HD069314 and the Lowell P. Weicker Clinical Research at the University of Connecticut 
School of Medicine. The study medication was donated by Pfizer Pharmaceuticals." 
Declarations of interest: "Dr Kranzler is a member of the American Society of Clinical 
Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by 
AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala 
Neurosciences and is named as an inventor on Patent Cooperation Treaty patent application 
15/878,640 entitled genotype-guided dosing of opioid agonists, filed Jan. 24, 2018. The other 






Methods Non-placebo, parallel-design RCT 
Participants 181 healthy US English-speaking women between 13 and 25 weeks' pregnant, smoking >= 5 
cigarettes daily, and aged >= 18 years. Must have smoked > 100 cigarettes in lifetime. 
Interventions Control group: 5 face-to-face and 1 telephone behavioural counselling sessions with booklet and 
support materials. 
Intervention group: counselling as above but with additional focus on use of NRT. Women permitted 
choice of NRT from patch, gum, or lozenge. Patch dose depended on CPD: < 10 CPD, 7 mg/16 h; 10 
to 14 CPD, 14 mg/16 h; >= 15 CPD, 21 mg/16 h. Where gum or lozenge was used, one 2 mg piece 
was used for each cigarette smoked daily. Maximum of 6 weeks' NRT provided, and no NRT provided 
when women returned to smoking. 
Outcomes Self-reported 7-day point prevalence abstinence at 38 weeks. 
Also follow-up at 7 weeks after randomisation and 3 months' postpartum using self-report data. 
Saliva samples for cotinine validation were collected at the intervention session that coincided with 
each telephone survey from all women regardless of smoking status. Cut point for primary outcome 
<= 10 ng/mL. Validation data were collected at all 3 time points, but are only reported for the 2 
data collection points within pregnancy. 
Notes Choices of NRT: 72/122 patch = 59%, 32/122 gum = 26.2% and 12/122 lozenge = 9.8%. 19 women 
chose another formulation as they could not quit with initial selection (changes not recorded). 
Dates of study: May 2003 to August 2005 
Funding sources: "This work was supported by the National Cancer Institute (grant R01CA089053 
and operated under IND #67,259)." NRT donated by GlaxoSmithKline. 





Methods Parallel-design RCT with active and placebo patches and clinicians/researchers and participants 
unaware of allocation 
Participants 250 healthy Danish women < 22 weeks' pregnant and smoking >= 10 cigarettes daily 
Interventions 11-week course of NRT or identical placebo patches: 15 mg/16 h for 8 weeks then 10 mg/16 h for 3 
weeks plus behavioural counselling and information pamphlet. 
Intervention = active patch, control = placebo 
Outcomes Self-reported abstinence of >= 7 days at 2nd, 3rd, and 4th prenatal visits (4 weeks prior to 
delivery).  
Follow-ups at times above and also by telephone at 3 months and 1 year after delivery. 
Notes Saliva cotinine level < 26 ng/mL at the 4th visit (4 weeks prior to expected delivery date) used to 
validate reported smoking cessation. The test used could not detect lower than 20 ng/mL (data 
verified by communication with author). Only self-report data were collected after childbirth. 
Dates of study: October 1995 to October 1997 
Funding sources: "This study was supported by the Danish Cancer Society and the Ministry of Health 
(The National Health Fund supported this study for Research and Development). Pharmacia & Upjohn 
provided nicotine patches." 







Systematic review: Table of adherence with NRT regimens 
Study 
Adherence with offered regimen as a percentage of complete 
course Adherence with offered regimen in terms of period of use 
Wisborg 
2000 
Complete adherence with 11-week course: nicotine group = 
11%, placebo = 7%. Partial adherence (up to 8 weeks' use): 
nicotine group = 17%, placebo = 8%. 
Median number patches (ranges): nicotine group = 14 (0 to 
77), median = approximately 2 weeks; placebo = 7 (0 to 77), 
median = approximately 1 week. 
Kapur 
2001 
In the nicotine group, 4/17 (23.5%) completed the 14-week 
programme. In the placebo group, no participants completed 
the programme. 
In the nicotine group, 4/17 (23.5%) completed the 14-week 
programme; 3/17 (17.6%) used the patch for at least 3 weeks; 
and 10/17 (58.8%) used the patch for less than 1 week. 
In the placebo group, no participants completed the 
programme; 3/13 (23%) used the patch for between 4 and 5 
weeks; and 10/13 (76.9%) used the patch for < 1 week. 
Hotham 
2006 
25% (5) participants complied fully with protocol: "continuous 
patch use till 12 weeks or confident that abstinence achieved 
or adverse reaction experienced". 
50% (10) of participants used NRT for 6 weeks or less. 
Pollak 
2007 
Difficult to ascertain from manuscript. A secondary publication 
reported that 29% of participants used NRT as directed for 
intended 6-week programme. 
Means of reported periods of use: 
Patch = 23.4 patches = 3.3 weeks 
Gum = 8 days 
Lozenge = 4 days 
Oncken 
2008 
Not clearly reported. The nicotine group used gum for a mean (SD) of 37.8 (3.8) days 
(i.e. just > 5 weeks). The placebo group used gum for a mean 





Limited compliance with the intervention. Only 7.2% of women 
(35 of 485) assigned to receive NRT and 2.8% (14 of 496) 
assigned to receive placebo reported using trial medications for 
more than 1 month (2 months represented a complete course); 
rates of use of non-study NRT were very low. Most participants 
had no additional contact, either face-to-face or by text 
message, with smoking cessation advisors; amongst those who 
did, the frequency of contact was similar in the 2 groups. 
Most participants discontinued patches after using them for only 
a short period: in the nicotine group 60.1% of participants used 
patches for no longer than 2 weeks, whilst in the placebo patch 
group this figure was 76.8%. 
Berlin 
2014 
In contrast to other studies, women were issued with a much 
longer course of transdermal patches, i.e. from women's quit 
dates to their delivery. 
Compliance was measured using self-reported data on patches 
used between study visits and was obtained at 1016 study visits 
from 307 (76%) participants: 164 (84%) in the NRT group and 
143 (72%) in the placebo group. 
Median (IQR) reported patch use was 85% (56% to 99%) in 
the NRT group and 83% (56% to 95%) in the placebo group. 
However, it is not clear how these figures relate to the rate with 
which participants discontinued the intervention. Overall, 225 
(60.0%) of participants stopped using trial treatments: 105 
(51.7%) in the NRT group and 60.3% in the placebo group. 
This was not reported, but it has less meaning for this RCT, as 
women started using patches at different points in pregnancy 
and continued until childbirth. 
Oncken 
2019 
Not clearly reported. The nicotine group used the inhaler for a mean (SD) of 36.39 
(23.92) days (i.e. just > 5 weeks) and used a mean (SD) of 
1.70 (1.19) cartridges per day. The placebo group used the 
inhaler for a mean (SD) of 34.11 (20.54) days (i.e. just < 5 
weeks) and used a mean (SD) of 1.81 (1.62) cartridges per day. 
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Neither of these were statistically significant differences 
between groups (number of days, P = 0.587; number of 
cartridges, P = 0.701). Compliance with the inhaler during 




Forest plots  
 
Figure S1 Forest plot of nicotine replacement therapy versus control, 
outcome: Low birthweight (< 2500 g) 
 
 
Figure S2 Forest plot of nicotine replacement therapy versus control, 





Figure S3 Forest plot of nicotine replacement therapy versus control, 
outcome: Neonatal intensive care unit admissions. 
 
 
Figure S4 Forest plot of nicotine replacement therapy versus control, 
outcome: Neonatal death. 
 
 
Figure S5 Forest plot of nicotine replacement therapy versus control, 
outcome: Caesarean section. 
 
 
Figure S6 Forest plot of nicotine replacement therapy versus control, 






Saliva cotinine concentrations in pregnant women who smoke and 





















Pharmacological interventions for promoting smoking cessation 

































Pharmacological interventions for promoting smoking cessation 














Fetal safety of nicotine replacement therapy in pregnancy: 



















































































Using Trial Sequential Analysis for estimating the sample sizes of 





























Advanced Statistical Methods (9 training units) 
Research Methods in Epidemiology with Basic Statistics (19 training units) 
Tobacco control interventions (9 training units) 
Graduate school short courses 
Microsoft Word:  Creating and Managing Long Documents (2 training units) 
Thinking Ahead - Career options and planning for PhDs (1 training unit) 
Preparing for your confirmation review (0 training units) 
Problems with academic writing (0.5 training units) 
Structuring Your Thesis (1 training unit) 
Faculty postgraduate Research Forum (Medicine and Health Sciences 
Faculty) (4 training units) 
Advanced presentation skills for researchers (moderated online learning 
course) (2 training units) 
Structuring Your Thesis (1 training unit) 
Drafting a Chapter of your Thesis (1 training unit) 
Applying for academic jobs - PhD students (1 training unit) 
Applying for jobs outside academia - PhD students (1 training unit) 
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Editing Academic Writing (0.5 training units) 
Preparing for the viva (1 training unit) 
Creating a strong argument for your thesis (0.5 training units) 
External courses 
Joanna Briggs Institute (JBI) Comprehensive Systematic Review Training 
Program (10 training units)  
NIHR CLAHRC EM skills session: Preparing your data for analysis with STATA 
NIHR CLAHRC EM skills session: Writing for publication 
Conferences and seminars 
University of Nottingham Medicine & Health Sciences Faculty Postgraduate 
Research Forum 2017 – ‘2 minutes of impact’ pitch and printed poster: 
Nicotine replacement therapy for smoking cessation during pregnancy. (4 
training units) 
Society for Research on Nicotine and Tobacco (SRNT); Florence, Italy 2017 
– Poster presentation: Nicotine Replacement Therapy for Smoking Cessation 
during Pregnancy: A Trial Sequential Analysis. 
SRNT-Europe; Munich, Germany 2018 – Poster presentation:  Saliva 
cotinine concentrations in pregnant women who smoke whilst using nicotine 
replacement therapy 
11th Congrès national de la Société Francophone de Tabacologie (CSFT; 
National meeting of the Francophone Society of Tobacco); Paris, France 
2017 – Attendance only. 
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12th CSFT; Montpellier, France 2018 – Oral presentation: Mobile phone 
interventions for smoking cessation in pregnant women that smoke. This 
presentation incorporated some of the findings in Chapter 4. 
NIHR ARC EM 3-Minute Thesis Presentation Day; Nottingham, UK 2018 – 
Oral presentation: NRT for smoking cessation during pregnancy. 
University of Nottingham Sue Watson Oral Presentation Event; Derby, UK 
2019 – Oral presentation: Saliva cotinine levels in pregnant women who 
smoke and use nicotine patches. (2 training units) 
I have performed oral presentations describing TSA at research seminars 
for the Division of Primary Care, and Epidemiology and Public Health at the 
University of Nottingham; as well as at research seminars for biostatistics 
and pharmacology at the Pitié-Salpêtrière hospital in Paris, France. 
Prizes and awards 
Awarded £470.17 from the School of Medicine Doctoral Programmes 







Trial Sequential Analysis software 
Figure S7 Meta-analysis summary page. Here you can change the effect 






Figure S8 Included trials. Here you include all trials to be included in the 
TSA, and their results. 
 
Figure S9 Setting the parameters to calculate the information size and 
monitoring boundaries. Here you input a priori assumptions for the TSA. 
Once all relevant information is input the TSA will calculate the information 
size and monitoring boundaries, and create the TSA graph.
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